 
 
 
  
 
   
 
  
A Randomized, Double-Blind Study  to Compare the Efficacy, 
Safety and Long-Term Safety of  Topical Administration of 
FMX-101 for 1 Year in the Treatme nt of Moderate-to-Severe Acne 
Vulgaris, Study FX2014-05  
 
Study Registry ID: [REMOVED] 
 
  
Date of Protocol: 14 October 2016 
  Privileged and Confidential 
 
Clinical Study Report FX2014-05   
   
16.1.1 Protocol an d Amendments 
 
Protocol version 4, 14 October 2016 
Protocol version 3, 06 April 2016  
  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 1 of 67 
 
 CONFIDENTIAL     
 
CLINICAL STUDY PROTOCOL   
Title: A Randomized, Double -Blind Study to Compare the Efficacy, 
Safety and Long-Term Safety of Topical Administration of 
FMX-101 for 1 Year in the Treatment of Moderate- to-Severe Acne 
Vulgaris, Study FX2014 -05 
Development Phas e: 3 
Project Number: FMX-101 
Study drug(s): FMX-101, minocycline foam 4%; matching vehicle foam 
Indication: Acne vulgaris  
Authors:  
Protocol Number: FX2014-05 
Version  4 
Date of Protocol : October 14, 2016 
Supersedes Version 3 of April 6, 2016  
  
This Protocol is the property of Foamix Pharmaceuticals, Inc.  This Protocol must be kept in a 
confidential manner, and may only be used in connection with the clinical study.  It must be 
returned on request.  No part of this Protocol may be reproduced or transmitted in any form 
without written permission of Foamix Pharmaceuticals, Inc.  If you are not authorized to receive 
this document, please return it immediately to:  
Foamix Pharmaceuticals, Inc.  520 U.S. Hwy 22, Suite 305  Bridgewater, NJ 08807 
 
 
PPD
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 3 of 67 
 
 CONFIDENTIAL   1.  SYNOPSIS 
This is a Phase 3 study to evaluate the efficacy, safety and long -term safety of the topical 
administration of FMX -101, 4% minocycline foam for the treatment of moderate -to-severe acne 
vulgaris.  The first 12 weeks of the study involves randomized, double- blind treatment with 
active FMX-101, 4% or matching vehicle.  Subjects who successfully complete the 12 -week 
double blind portion of the study may  be offered the opportunity to continue in the trial for up to 
an additional 40 weeks (for a total of 1 year) and receive open -label treatment wi th 
FMX-101, 4%. 
1.1.  Investigational Product , Dosage, and Mode of Administration  
The investigational product is FMX -101, minocycline foam 4%.  FMX-101 4% will be  applied 
topically daily for the 12 -week treatment duration of the study. 
1.2.  Active Ingredient  
The active ingredient is minocycline HCl. 
1.3.  Reference Product, Dosage, and Mode of Administration  
The reference product is vehicle foam .  Vehicle foam  will be applied topically daily for the  
12-week treatment duration of the study. 
1.4.  Study Centers  
Approximately 30 study centers will participate in this study.  
1.5.  Study Period 
Estimated date first subject enrolled: April 2016 
Estimated date last subject completed: August 2017 
1.6.  Study Objective s 
The objectives of this study are:  
• To evaluate the efficacy in the treatment of acne compared to vehicle of topical FMX -
101, 4% administered daily for 12 weeks 
• To evaluate the safety compared to vehicle of topical FMX -101, 4% administered 
daily for 12 weeks 
• To evaluate the long -term safety of topical FMX -101, 4% administered daily for up to 
40 additional weeks 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 4 of 67 
 
 CONFIDENTIAL   1.7.  Methodology 
The study will h ave 2 parts.  The first will involve 12 weeks of double- blind treatment with 
FMX-101, 4% or vehicle foam.  The second will involve up to 40 additional weeks of open- label 
treatment with FMX -101, 4% of subjects who complete the first part of the study. 
1.7.1. Part 1 – Double-blind Period  
This is a randomized, multicenter, double-blind, vehicle-controlled, 2- arm study to evaluate the 
safety and efficacy over 12 weeks of FMX -101 minocycline foam, 4%, compared to vehicle, in 
the treatment of subjects with moderate to severe facial acne vulgaris.  
Qualified subjects will be randomized to receive 1 of the following 2 treatments: 
• FMX-101, 4%  minocycline foam 
• Vehicle foam 
Subjects with qualifying lesion counts ( Section 8.1.2) an d Investigator’s Global Assessments 
(IGA, Section 8.1.1)  of acne severity scores and will be assigned to 1 of 2 treatments according 
to the randomization schedule.  Subjects will apply the assigned study drug topically once daily 
for 12 weeks as directed.  Subjects will be advised to apply the study drug at approximately the same time each day, preferably in the evening at bedtime.  Both the Investigator and subject will 
be blinded to the study drug identity. 
Subjects will return for visits at Weeks 1, 3, 6, 9, and 12. At the discretion of the clinic staff, for 
the convenience of subjects or clinic staff, visits can be scheduled to occur 3 days before or after 
the nominal schedule date for the Weeks 1, 3 and 6 visits and 7 days before or after for the 
Weeks 9 and 12 visits.  Efficacy e valuations (acne lesion counts and IGAs will be performed at 
Weeks 3, 6, 9, and 12 during the study.  Other assessments will be performed as described in  
Section 9.  
1.7.2. Part 2 – Open -label  
At the Week 12 Visit, subjects whose IGA score has not worsened may be invited to continue into the open- label part of this study  for an additional 9 months of treatment.  Subjects will be 
enrolled in this phase of the study until a total of approximately 400 subjects from Studies FX2014-04 and FX2014-05 have elected to continue in the open- label portion of their respective 
study.  Subjects who elect to continue into the open- label part of this study will receive supplies 
of active FMX -101, 4% minocycline foam.   
Treatment during this part of the study will be guided by each subject’s clinical response.  The Investigator may elect to suspend treatment of some or all areas if there is clinical improvement 
or resolution of the a cne in those areas.  Even if the treatment is partially or completely 
temporarily suspended, the subject will be continued in the study and will make all scheduled 
clinic visits.  If at any time the acne recurs or worsens, treatment of the affected areas m ay be 
resumed.  
Subjects may be discontinued from the study after 12 weeks if their disease becomes refractory 
or they become intolerant of the product.   
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 5 of 67 
 
 CONFIDENTIAL   1.8.  Number of Subjects  
The planned enrollment is 450 subjects.  Subjects will be randomized to active or vehicle in a 2:1 
ratio.  Approximately 300 and 150 subjects will be assigned to the FMX -101, 4% or vehicle 
treatment groups, respectively. 
1.9.  Diagnosis and Main Criteria for Inclusion  
Subjects are to be at least 9 years of age. 
Eligible subjects are to have a  diagnosis of facial acne vulgaris characterized by (subjects are 
permitted to also have acne on other parts of the body): 
• 20 to 50 inflammatory lesions (papules, pustules, and nodules) 
• 25 to 100 noninflammatory lesions (open and closed comedones) 
• No more than 2 nodules on the face  
• Investigator’s Global Assessment (IGA) score of moderate (3) to severe (4)  
1.10.  Criteria for Evaluation  
1.10.1. Efficacy 
The efficacy assessments will include the IGA and lesion counts at Baseline and Weeks 3, 6, 9 and 12.  
1.10.2. Safety 
The safety assessments in this study are physical examinations, vital signs, assessment of the 
skin at application site(s), adverse events (volunteered, observed, and elicited by general 
questioning in a non- suggestive manner), and clinical laboratory test results.  
1.11.  Statistical Methods  
Efficacy analyses will be conducted on the Intent- to-Treat (ITT) population, using the last-
observation-carried-forward (LOCF) approach to impute missing values.  Supportive efficacy 
analyses will also be conducted on the Per Protocol (PP) population, with no imputation for missing values.  The co- primary efficacy endpoints are the absolute change from Baseline in the 
inflammatory lesion count at Week 12 IGA Treatment Success (dichotomized as Yes/No) at 
Week 12, where success is defined as an IGA score of 0 or 1, and at least a 2 -grade decrease 
from Baseline .  FMX-101 4% will be tested against vehicle at the two -sided 0.05 level of 
significance without adjustment for multiplicity.  The absolute change from Baseline in inflammatory lesions  at Week 12 will be analyzed using an Analysis of Covariance (ANCOVA) 
model with main effect treatment and investigational site as a covariate.  The IGA Treatment 
Success rates will be compared between the treatment groups  using a Cochran–Mantel –Haenszel 
(CMH) test stratified  for investigational site.  
No statistical tests will be performed for any of the safety assessments.  
 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 6 of 67 
 
 CONFIDENTIAL   TABLE OF CONTENTS, LIST OF TABLES, AN D LIST OF FIGURES  
 
1.  SYNOPSIS ...................................................................................................................3  
1.1.  Investigational Product, Dosage, and Mode of Administration ...................................3  
1.2.  Active Ingredient  ..........................................................................................................3  
1.3.  Reference Product, Dosage, and Mode of Administration ...........................................3  
1.4.  Study Centers  ................................................................................................................3  
1.5.  Study Period..................................................................................................................3  
1.6.  Study Objectives  ...........................................................................................................3  
1.7.  Methodology .................................................................................................................4  
1.7.1.  Part 1 – Double-blind Period  ........................................................................................4  
1.7.2.  Part 2 – Open -label .......................................................................................................4  
1.8.  Number of Subjects ......................................................................................................5  
1.9.  Diagnosis and Main Criteria for Inclusion ...................................................................5  
1.10.  Criteria for Evaluation  ..................................................................................................5  
1.10.1.  Efficacy .........................................................................................................................5  
1.10.2.  Safety ............................................................................................................................5  
1.11.  Statistical Methods  ........................................................................................................5  
TABLE OF CONTENTS, L IST OF TABLES, AND LIST OF  FIGURES ....................................6  
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS ................................................12  
STUDY ADMINISTRATIVE  STRUCTURE  ...............................................................................13  
2.  INTRODUCTION  ......................................................................................................14  
3.  STUDY OBJECTIVES  ..............................................................................................14  
4.  INVESTIGATIONAL PLAN  .....................................................................................14  
4.1.  Overall Study Design  ..................................................................................................14  
4.1.1.  Part 1 – Double-blind ..................................................................................................15  
4.1.2.  Part 2 – Open -label .....................................................................................................15  
4.2.  Rationale for Study Design and Dose Selection .........................................................15  
5.  STUDY POPULATION  .............................................................................................16  
5.1.  Inclusion Criteria  ........................................................................................................16  
5.2.  Exclusion Criteria  .......................................................................................................16  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 7 of 67 
 
 CONFIDENTIAL   6.  STUDY PROCEDURES  ............................................................................................18  
6.1.  Part 1 – Double- Blind .................................................................................................20  
6.1.1.  Screening Visit  ............................................................................................................20  
6.1.2.  Baseline Visit, Visit 1  .................................................................................................20  
6.1.3.  Visit 2, Week 1 ...........................................................................................................21  
6.1.4.  Visit 3, Week 3 ...........................................................................................................21  
6.1.5.  Visit 4, Week 6 ...........................................................................................................22  
6.1.6.  Visit 5, Week 9 ...........................................................................................................22  
6.1.7.  Visit 6, Week 12 End of Double-Blind or Continuation in Open Label / 
Early Termination  .......................................................................................................23  
6.2.  Part 2 – Open -label .....................................................................................................24  
6.2.1.  Visit 7 - Week 16  ........................................................................................................25  
6.2.2.  Visits 8, 9, 10, 11 and 12 – Weeks 22, 28, 34, 40 and 46...........................................25  
6.2.3.  Visit 13, Final Visit – Week 52  ..................................................................................26  
7.  STUDY TREATMENTS ............................................................................................26  
7.1.  Treatments Administered  ............................................................................................26  
7.1.1.  Part 1 (double-blind) – Weeks 1 to 12 ........................................................................26  
7.1.2.  Part 2 (open-label) – Weeks 13 to 52 .........................................................................27  
7.1.3.  Dosing Instructions  .....................................................................................................27  
7.1.3.1.  Part 1 – Double-blind ..................................................................................................27  
7.1.3.2.  Part 2 – Open -label .....................................................................................................27  
7.1.4.  Manufacturer  ...............................................................................................................28  
7.1.5.  Labeling of Study Drug ..............................................................................................28  
7.1.6.  Storage of Study Drug  ................................................................................................28  
7.2.  Study Drug Accountability .........................................................................................29  
7.3.  Handling and Disposal of Study Drug ........................................................................29  
7.4.  Method of Assignment of Study Drug ........................................................................29  
7.4.1.  Part 1 – Double- blind .................................................................................................29  
7.4.2.  Part 2 – Open -label .....................................................................................................29  
7.5.  Selection and Timing of Doses in the Study ..............................................................29  
7.6.  Blinding ......................................................................................................................30  
7.7.  Prior and Concomitant Therapy ..................................................................................30  
7.8.  Use of Contraception ..................................................................................................31  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 8 of 67 
 
 CONFIDENTIAL   7.9.  Treatment Compliance  ................................................................................................31  
8.  EFFICACY ASSESSMENTS  ....................................................................................32  
8.1.  Primary Efficacy Asse ssments ...................................................................................32  
8.1.1.  Investigator Global Assessment Score (IGA) .............................................................32  
8.1.2.  Lesion Counts .............................................................................................................32  
8.2.  Photography ................................................................................................................33  
8.3.  Subject Satisfaction Questionnaire  .............................................................................33  
9.  SAFETY ASSESSMENTS  ........................................................................................33  
9.1.  Medical/Surgical History  ............................................................................................33  
9.2.  Medication History  .....................................................................................................34  
9.3.  Concomitant Medications  ...........................................................................................34  
9.4.  Vital Signs ..................................................................................................................34  
9.5.  Physical Examination  .................................................................................................34  
9.6.  Clinical Laboratory Tests  ...........................................................................................34  
9.6.1.  Urine Pregnancy Test  .................................................................................................35  
9.6.2.  Sample Collection, Storage, and Shipping .................................................................35  
9.7.  Other Safety Measurements  ........................................................................................35  
9.7.1.  Tolerability .................................................................................................................35  
9.8.  Adverse Events  ...........................................................................................................36  
9.8.1.  Method of Determining Adverse Events ....................................................................36  
9.8.2.  Adverse Event Definitions ..........................................................................................36  
9.8.2.1.  Adverse Events  ...........................................................................................................36  
9.8.2.2.  Serious Adverse Events ..............................................................................................37  
9.8.2.3.  Severity of Adverse Events ........................................................................................37  
9.8.2.4.  Relationship of Adverse Events to Study Treatments ................................................38  
9.8.2.5.  Adverse Events Expectedness  ....................................................................................38  
9.8.3.  Reporting Adverse Events ..........................................................................................38  
9.8.4.  Adverse Event Follow- up ...........................................................................................38  
9.8.4.1.  Pregnancy reportin g ....................................................................................................39  
9.8.5.  Clinically Significantly Abnormal Laboratory Results  ..............................................39  
9.9.  Appropriateness of Safety Measurement  ....................................................................39  
10.  STATISTICAL DESIGN AND ANALYSIS  .............................................................40  
10.1.  Statistical Analysis Plan  .............................................................................................40  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 9 of 67 
 
 CONFIDENTIAL   10.2.  Determination of Sample Size  ....................................................................................40  
10.3.  Analysis Populations ..................................................................................................41  
10.4.  Efficacy Endpoints ......................................................................................................42  
10.4.1.  Primary Efficacy Endpoints ........................................................................................42  
10.4.2.  Secondary Efficacy Endpoints ....................................................................................43  
10.4.3.  Tertiary efficacy endpoints .........................................................................................43  
10.5.  Safety endpoints  ..........................................................................................................43  
10.5.1.  Adverse Events  ...........................................................................................................43  
10.5.2.  Vital Signs ..................................................................................................................44  
10.5.3.  Physical Examinations  ................................................................................................44  
10.5.4.  Clinical Laboratory Results  ........................................................................................44  
10.6.  Statistical Analysis  ......................................................................................................44  
10.6.1.  Interim Analysis  ..........................................................................................................44  
10.6.2.  Subject Accounting, Demogr aphic, and Baseline Characteristics  ..............................44  
10.6.3.  Efficacy Analysis  ........................................................................................................44  
10.6.4.  Safety Analysis  ...........................................................................................................45  
11.  STUDY MANAGEMENT  .........................................................................................46  
11.1.  Monitoring ..................................................................................................................46  
11.2.  Protocol Amendments ................................................................................................46  
11.3.  Protocol Deviations ....................................................................................................47  
11.4.  Withdrawal of Subjects ...............................................................................................47  
11.5.  Termination of the Study ............................................................................................48  
11.6.  Publication Policy  .......................................................................................................48  
12.  ETHICS ......................................................................................................................48  
12.1.  Conduct of the Study ..................................................................................................48  
12.2.  Institutional Review Boards (IRB) .............................................................................48  
12.3.  Written Informed Consent ..........................................................................................48  
12.4.  Subject Confidentiality  ...............................................................................................49  
12.5.  Records Retention  .......................................................................................................49  
12.6.  Financing ....................................................................................................................50  
13.  QUALITY CONTROL AND QUALITY ASSURANCE  .........................................50  
14.  DATA HANDLING AND RECORD KEEPING  ......................................................50  
15.  REFERENCE LIST  ....................................................................................................51  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 10 of 67 
 
 CONFIDENTIAL   16.  APPENDICES  ............................................................................................................52  
16.1.  Appendix 1 – Subjects Satisfaction Questionnaire  .....................................................52  
16.2.  Appendix 2 – Protocol Amendments ..........................................................................53  
16.2.1.  Amendment 1, effective February 26, 2016 ...............................................................53  
16.2.2.  Amendment 2, effective April 6, 2016 .......................................................................61  
16.2.3.  Amendment 3, effective September 12, 2016 ............................................................66  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 11 of 67 
 
 CONFIDENTIAL   List of Tables  
Table 1: Schedule of Procedures - Study FX2014-05 – Part 1  ......................................................19  
Table 2: Schedule of Procedures - Study FX2014-05 – Part 2  ......................................................24  
Table 3: IGA Scale for Acne Vulgaris  ...........................................................................................32  
 
 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 12 of 67 
 
 CONFIDENTIAL   LIST OF ABBREVIATION S AND DEFINITIONS OF TERMS 
 
Abbreviation  Definition 
AE Adverse event  
CFR Code of Federal Regulations  
CRF Case report form  
eCRF Electronic case repor t form 
EKG Electrocardiogram  
FDA Food & Drug Administration  
GCP Good Clinical Practice  
HEENT Head, eyes, ears, nose, and throat  
ICF Informed consent form  
ICH International Conference on Harmonization  
IGA Investigator’s Global Assessment  
IRB Institutional Review Board  
IWRS Interactive Web Response System (IWRS)  
LOCF Last-observation-carried-forward 
ITT Intent-to-treat 
MedDRA Medical Dictionary for Regulatory Activities  
OC Observed-Cases 
P. acnes Propionibacterium acnes  
PP Per protocol 
TEAE Treatment-emergent adverse event  
SAE Serious adverse event  
SOC System organ class  
 
 
  
 
  
 
 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 13 of 67 
 
 CONFIDENTIAL   STUDY ADMINISTRATIVE  STRUCTURE  
Name Affiliation / Address /  
Telephone Number Responsibility  
Foamix Pharmaceuticals, Inc 520 U.S. Highway  22, Suite 305 
Bridgewater, NJ 08807 Sponsor 
TKL Research, Inc.  
 365 West Passaic Street, Suite 550  
Rochelle Park, NJ 07662 CRO 
 TKL R esearch, Inc.  
 TKL R esearch, Inc.  
 
PPD
PPD
PPD
PPD
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 14 of 67 
 
 CONFIDENTIAL   2.  INTRODUCTION 
Acne vulgaris is a common disease of both males and females , usually manifesting initially 
during adolescence.  The primary pathologic events are initiated in the pilo -sebaceous units, 
especially of sebaceous -gland-bearing areas of the face, chest, and back as a result of increased  
androgen stimulation initiated at adrenarche or puberty.  As a result of both abnormal 
keratinization of the infra-infundibular portion of the pilo- sebaceous follicle and increased 
sebum produced in the gland, a blockage of the duct results in the inappar ent clinical lesion of 
the microcomedone.  Continued blockage, colonization of the follicle by Propionibacterium acnes (P. acnes), and generation of multiple chemoattractant and proinflammatory moieties may 
result in non-inflammatory clinical lesions, come dones, and inflammatory lesions: papules, 
pustules, nodules, and cysts.
1 
FMX-101, 4% is a minocycline containing topical foam being developed as a treatment for acne 
vulgaris.  Antibiotics, especially erythromycin, minocycline, and doxycycline, have been prescribed as acne treatments for many years.  These antibiotics effectively control the signs of inflammatory acne while patients continue to use them.   Nonclinical studies have demonstrated 
that FMX-101, 4% exhibits favorable characteristics.   
Foamix has conducted 2 Phase 1 and 1 Phase 2 study of FMX-101, 4% to assess its safety and 
tolerability.  FMX-101, 4% has been shown to be effective and well tolerated  at the 4% dose that 
is being utilized in this study.  The Investigator’s Brochure should be consulted for summaries of 
the results of these studies.  
This Phase 3 study (Study FX2014-05) will assess the efficacy, safety and long- term safety of 
FMX-101, 4% for the treatment of moderate to s evere facial acne vul garis. 
3.   STUDY OBJECTIVE S  
The objectives of this study are: 
• To evaluate the efficacy in the treatment of acne compared to vehicle of topical FMX -
101, 4% administered daily for 12 weeks 
• To evaluate the safety compared to vehicle of topical FMX -101, 4% admin istered 
daily for 12 weeks 
• To evaluate the long -term safety of topical FMX -101, 4% administered daily for up to 
an additional 40 weeks  
4.  INVESTIGATIONAL PLAN  
4.1.  Overall Study D esign 
The one-year study will have 2 parts.  The first 12 weeks will be double-blind treatment with 
FMX-101, 4% or vehicle foam.  The remaining 40 weeks  will involve open- label treatment with 
FMX-101, 4% by any subjects who complete the first part of the study . 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 15 of 67 
 
 CONFIDENTIAL   4.1.1. Part 1 – Double -blind  
This is a randomized, multicenter, double-blind, vehicle-controlled, 2- arm study to evaluate the 
safety and efficacy over 12 weeks of FMX -101 minocycline foam, 4%, compared to vehicle, in 
the treatment of subjects with moderate to severe facial acne vulgaris.  
Qualified subjects will be randomized to receive 1 of the following 2 treatments: 
• FMX-101, 4%  minocycline foam 
• Vehicle foam 
Subjects with qualifying lesion counts ( Section 8.1.2) and Investigator’s Global Assessments 
(IGA, Section 8.1.1)  of acne severity scores and will be assigned to 1 of 2 treatments according 
to the randomization schedule.  Subjects will apply the assigned study drug topically once daily 
for 12 weeks as directed.  Subjects will be advised to apply the study drug at approximately the same time each day, preferably in the evening before bedtime.  Both the Investigator and subject 
will be blinded to the study drug identity.  
Subjects will return for visits at Weeks 1, 3, 6, 9, and 12.  Efficacy e valuations (acne lesion 
counts and IGAs  will be performed at Weeks 3, 6, 9, and 12 during the study.  Other assessments 
will be performed as described in  Sections 8.2 and 9. 
4.1.2. Part 2 – Open-label  
At the Week 12 Visit, subjects whose IGA score has not worsened may be invited to continue 
into the open- label part of this study for an additional 9 months of treatment .  Subjects will be 
enrolled in this phase of the stud y until a total of approximately 400 subjects from  Studies 
FX2014-04 and FX2014-05 have elected to continue in the open- label portion of their respective 
study.  Subjects who elect to continue into the open- label part of this study will receive supplies 
of active FMX -101, 4% minocycline foam.   
Treatment during this part of the study will be guided by each subject’s clinical response.  The Investigator may elect to suspend treatment of some or all areas if there is clinical improvement 
or resolution of the acne in those areas.  Even if the treatment is partially or completely 
temporarily suspended, the subject will continue  in the study and make all scheduled clinic visits.  
If at any time the acne recurs or worsens, treatment of the affected areas may be resumed.   
Subjects may be discontinued from the study after 12 weeks  if their disease becomes refractory 
or they become intolerant of the product.   
4.2.  Rationale for Study Design and Dose Selection  
A randomized, multicenter, double-blind, vehicle-controlled study design has been selected in 
order to assess the efficacy of the study drug  in accordance with the FDA Guidance.2  The 
subjects will be selected according to predefined entry criteria.  The study will have a 12- week 
treatment duration.    
FMX-101 foam, 4% is a novel minocycline formulation  that has been  shown to have efficacy in 
once daily use in a Phase 2 study.  The once daily dosing regimen is appropriate given the 
pharmacokinetic characteristics of FMX -101, 4%. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 16 of 67 
 
 CONFIDENTIAL   Because of the mode of action of tetracycline drugs, the primary efficacy endpoints will be the 
effect on inflammatory lesion count and IGA (Section 8.1.1) .  The effect on noninflammatory 
lesions will be the most important secondary endpoint.  
The extension of the study for an additional 40 weeks is necessary to obtain safety information 
about the long- term use of FMX -101, 4% to treat acne, which is a chronic condition.  The design 
of the study is expected to provide suffic ient safety information to fulfill the ICH E1 guideline.  
5.  STUDY POPULATION  
The planned enrollment is 450 subjects.  Subjects will be randomized to active or vehicle in a 2:1 ratio.  Approximately 300 and 150 subjects will be assigned to the FMX-101, 4% or vehicle 
treatment groups, respectively.  
5.1.  Inclusion Criteria 
A male or female subject will be considered eligible for participation in the study if all of the 
following inclusion criteria are satisfied prior to randomization:  
1. Has completed and signed an appropriately administered Informed Consent Form (ICF) 
prior to any study-related procedures.  Subjects less than 18 years of age (or as required 
by state law) must sign an Assent Form for the study and a parent or legal guardian must 
sign the ICF.  
2. Is 9 years of age or greater,  
3. Has facial acne vulgaris with:  
• 20 to 50 inflammatory lesions (papules, pustules, and  nodules) 
• 25 to 100 noninflammatory lesions (open and closed comedones) 
• No more than 2 nodules on the face 
• IGA score of moderate (3) to severe (4) 
4. If women of child-bearing potential, ha ve a negative urine pregnancy test  
5. For women of child-bearing potential at risk of becoming pregnant, agree to an effective method of contraception (Sections 7.7 and 7.8) 
6. Willing to use only the supplied non- medicated cleanser  
and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study 
5.2.  Exclusion Criteria  
Subjects who have any of the following will be excluded from the study: 
1. Female who is pregnant or lactating, or is planning a pregnancy during the study 
2. Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne) or a ny 
dermatological condition of the face or facial hair (eg, beard, sideburns, mustache) that could interfere with the clinical evaluations  
CCI
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 17 of 67 
 
 CONFIDENTIAL   3. Sunburn on the face  
4. Severe systemic disease, which might interfere with the conduct of the study or the 
interpretation of the results. 
5. Abnormal baseline laboratory values that are considered clinically significant.  
6. Currently participating, or has participated within 30 days prior to this study, in an investigational drug or device study 
7. Inability to fully comply with th e study requirements 
Subjects who have a history of any of the following will be excluded: 
8. Allergy to tetracycline -class antibiotics or to any ingredient in the study drug 
9. Pseudomembranous colitis or antibiotic- associated colitis  
10. Hepatitis or liver damage or renal impairment  
11. Known or suspected premalignant or malignant disease (excluding successfully treated 
skin cancers)  
12. Subjects who have used the following medications (topical refers only to the facial area) 
will not be eligible: 
Within 1 week prior to randomization:  
• Medicated facial cleansers  
• Topical acne treatments (other than those listed below)  
Within 4 weeks prior to randomization: 
• Topical retinoids 
• Topical anti-inflammatories and corticosteroids  
• Systemic antibiotics  
• Systemic acne treatments  
Within 12 weeks prior to randomization:  
• Systemic retinoids  
• Systemic cortico steroids 
13. Drug addiction or alcohol abuse (within the last 2 years). 
14. Current or significant past history of depression.  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 18 of 67 
 
 CONFIDENTIAL   6.  STUDY PROCEDURES  
Potential subjects will be assessed for eligibility at Screening.  During this visit, the purpose, 
timing, procedures, and risks of the study will be explained to the subject, including requirements for enrollment and participation in the study, medication restrictions during the study, and requirements f or washout of certain medications that the subject may already be 
taking.  
The eligible subject who is willing to participate in the study will then sign  an appropriately 
administered Informed Consent Form (ICF) prior to any study-related procedures.  Subj ects less 
than 18 years of age (or per state law)  must sign an Assent Form for the study and a parent or 
legal guardian must sign the ICF . 
Procedures at the Screening Visit will include obtaining blood and urine samples for clinical 
laboratory tests.  Thes e results must be no more than 30 days old at the time of Baseline Visit  
randomization.   
If a subject, who has agreed to participate in the study and signed the ICF or Assent Form , is 
currently undergoing acne therapy identified in Exclusion Criterion 12, they must first enter a 
washout period, before beginning the Screening procedures.   
A summary of study assessments and the time point at which they will be performed during the 
study is presented in Table 1.  If a subject prematurely withdraws from the study  before the 
Week 12 Visit, the subject should return to the study site for a withdrawal visit, during which all evaluations described under Visit 6/Week 12 must be performed. 
See  
Table 2 and Section 6.2 for descriptions of the procedures required during the open- label part of 
the study. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 19 of 67 
 
 CONFIDENTIAL   Table 1: Schedule of Procedures  - Study FX2014-05 – Part 1  
 
Assessment  
Screening 1  
Baseline 1  
Visits “Final” 
Visit 2 
Visit  1 2 3 4 5 6 
Week   1 3 6 9 12 
Informed Consent/Assent  X       
Demographic Data  X       
Assign identification number  X       
Medical/Surgical/Me dication 
(prior/concomitant) History  X       
Inclusion/Exclusion criteria  X X      
Physical Exam, height, weight 3,4  X      X 
Blood Pressure/heart rate 5  X X X X X X 
Blood and urine samples for clinical 
laboratory tests  X   X   X 
Urine pregnancy te st (females of 
childbearing potentia l only)6  X  X X X X 
Investigator’s Global Assessment  X X  X X X X 
Lesion Count X X  X X X X 
Photography  X   X  X 
Subject Satisfaction Questionnaire        X 
Randomization   X      
Concomitant Medication   X X X X X X 
Adverse Events  X X X X X X X 
Tolerability Assessments    X X X X X 
Perform drug accountability    X X X X X 
Collect empty canisters    X X X X X 
Dispense Study Drug   X X X X X X7 
Schedule/Confirm Next Visit  X X X X X X X 
                                                 
1 The duration of Screening is variable but if there are medications to be discontinued it can not be less than the time indicated in 
Exclusion Criterion 12. The procedures required at these visits can be combined.  However, drug should not be dispensed until 
all inclusion and exclusion criteria are met.  
2 Subject may continue into open -label phase of study. If a subject is not continuing into open-label phase for any reason 
(see Section 4.1.2 , all evaluations described under Visit 6/Week 12 must be performed.   
3 Height to be measured only at Baseline  
4 Including 12-lead EKG at Screening in subjects over 39 years of age  
5 Measure blood pressure and heart rate after the subject has been sitting for at least 5  minutes at rest 
6 Perform urine pregnancy test at indicated visits.  Also dis pense home urine pregnancy test at Week 12 if subject is 
continuing into open -label treatment  
7 If subject is continuing into open -label treatment phase, dispense appropriate Study Drug Kit  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 20 of 67 
 
 CONFIDENTIAL   6.1.  Part 1 – Double-Blind 
6.1.1. Screening Visit  
• Obtain a signed and dated, written Informed Consent Form (ICF)  prior to any study-
related procedures ; subjects less than 18 years of age (or as required by state law) 
must sign an Assent Form for the study and a parent or legal guardian must sign the 
ICF.  (Subject s must be at least 9 years of age at the time of assent/ consent) 
• Obtain demographic data 
• Assign the subject a unique subject identification number  
• Obtain medical history  
• Obtain surgical history 
• Obtain history of prior and concomitant medication usage (including previous use of 
acne medications) ; record start and stop dates of any medications used in the last 
3 months  
• Perform IGA (Section 8.1.1)  
• Perform facial lesion count of inflammatory, n oninflammatory, and nodular lesions 
(Section 8.1.2)  
• Record regions beyond face affected by acne  
• Collect blood and urine samples for clinical laboratory tests and send to the central laboratory (Section 9.6)  
• If subject wears make-up, remind the subject not to wear any make- up at future visits.  
• Record AEs 
• Schedule/confirm the next study visit and remind subject to avoid overexposure to natural or artificial s unlight 
6.1.2. Baseline Visit, Visit 1  
The procedures required at this  visit can be combined with Screening.  However, drug should not 
be dispensed until all inclusion and exclusion criteria are met.   
• Confirm/reconfirm  eligibility according to the inclusion/exclusion criteria  and 
o Perform IGA  
o Perform facial lesion count of inflammatory, noninflammatory, and nodular lesions  
• Perform photography ( Section 8.2) 
• Measure blood pressure and heart rate (Section 9.4)   
• Perform physical examination including height and weight (Section 9.5) 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 21 of 67 
 
 CONFIDENTIAL   • Perform 12-lead EKG if subject is over 39 years of age 
• Perform urine pregnancy test  in females of childbearing potential  
• Randomize the subject using the IWRS system, when all criteria have been met   
• Record concomitant medications  
• Record AEs 
• Dispense 1 kit (2 canisters) of study drug   
• Dispense cleanser      
• Schedule/confirm the next study vis it and remind subject to avoid overexposure to 
sunlight 
6.1.3. Visit 2, Week 1 
• Measure blood pressure and heart rate 
• Record concomitant medications  
• Record AEs and Tolerability Assessment  
• Assess product use to confirm that subject continues to use properly; confir m that 
only provided cleanser is being used. 
• Collect previously dispensed study drug canister(s) if applicable  
• Dispense 1 kit (2 canisters) of study drug  
• Schedule/confirm the next study visit and remind subject to avoid overexposure to 
natural or artificial s unlight 
6.1.4. Visit 3, Week 3  
• Measure blood pressure and heart rate 
• Perform urine pregnancy test  in females of childbearing potential  
• Perform IGA 
• Perform facial lesion count  of inflammatory, noninflammatory, and nodular lesions 
• Collect blood and urine sample s for clinical laboratory tests and send to the central 
laboratory (Section 9.6)  
• Record concomitant medications  
• Record AEs and Tolerability Assessment  
• Assess product use to confirm that subject continues to use properly; confirm that 
only provided cleanser is being used. 
• Collect previously dispensed study drug canister(s) if applicable  
• Dispense 1 kit (2 canisters) of study drug  
CCI
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 22 of 67 
 
 CONFIDENTIAL   • Determine if additional drug or cleanser needs to be dispensed.   
• Schedule/confirm the next study visit and remind su bject to avoid overexposure to 
natural or artificial s unlight 
6.1.5.  Visit 4, Week 6  
• Measure blood pressure and heart rate 
• Perform urine pregnancy test  in females of childbearing potential  
• Perform IGA 
• Perform facial lesion count o f inflammatory, noninflammatory, and nodular lesions 
• Perform photography 
• Record concomitant medications  
• Record AEs and Tolerability Assessment  
• Assess product use to confirm that subject continues to use properly; confirm that 
only provided cleanser is being used. 
• Collect previously dispensed study drug canister(s) if applicable  
• Dispense 1 kit (2 canisters) of study drug  
• Determine if additional drug or cleanser needs to be dispensed.   
• Schedule/confirm the next study visit and remind subject to avoid overexposure to natural or artificial s unlight 
6.1.6. Visit 5, Week 9  
• Measure blood pressure and heart rate 
• Perform urine pregnancy test  in females of childbearing potential  
• Perform IGA 
• Perform facial lesion count of inflammatory, noninflammatory, and nodular lesions 
• Record concomitant medications  
• Record AEs and Tolerability Assessment  
• Assess product use to confirm that subject continues to use properly; confirm that 
only provided cleanser is being used. 
• Collect previously dispensed study drug canister(s) if applicable  
• Dispense 1 kit (2 canisters) of study drug  
• Determine if additional drug or cleanser needs to be dispensed.   
• Schedule/confirm the next study visit and remind subject to avoid overexposure to 
natural or artificial s unlight 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 23 of 67 
 
 CONFIDENTIAL   6.1.7. Visit 6, Week 12  End of Double -Blind or Continuation in Open Label / Early 
Termination   
• Perform physical examination including weight 
• Measure blood pressure and heart rate 
• Collect blood and urine samples for clinical laboratory tests and send to the central 
laboratory 
• Perform urine pregnancy test in females of childbearing potential 
• Perform IGA 
• Perform facial lesion count of inflammatory , noninflammatory, and nodular lesions 
• Perform photography 
• Administer Subject Satisfaction Questionnaire  
• Record concomitant medications  
• Record AEs and Tolerability Assessment  
• Assess product use to confirm that subject continues to use properly; confirm that only provided cleanser is being used. 
• Collect previously dispensed study drug canister(s)  
• If subject is continuing into the open- label phase of the stu dy (see Section 4.1.2), 
dispense 2 kit ( 4 canisters) of FMX -101, 4% minocycline foam 
o If subjects facial acne is “clear” or “almost clear,” consider withholding 
treatment with FMX -101, 4% at this time but continue subject in study and 
schedule next visit. 
• Schedule/confirm the next study visit and remind subject to avoid overexposure to 
natural or artificial s unlight 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 24 of 67 
 
 CONFIDENTIAL    
6.2.  Part 2 – Open-label 
A summary of study assessments and the time point at which they will be perfo rmed during the 
Part 2 of this study is presented in 
Table 2.  If a subject prematurely withdraws from the study, the subject should return to the 
study site at which time all evaluations described under Final Visit 13/Week 52 must be 
performed. 
 
Table 2: Schedule of Procedures - Study FX2014-05 – Part 2  
 
Assessment  
 Visits Final 
Visit 1 
Visit 7 8 9 10 11 12 13 
Week 16 22 28 34 40 46 52 
Physical Exam,  weight,       X 
Blood Pressure/hea rt rate 2 X X X X X X X 
Blood and urine samples for clinical 
laboratory tests    X    X 
Urine pregnancy test (females of 
childbearing potential only)3 X X X X X X X 
Investigator’s Global Assessment  X X X X X X X 
Lesion Count X X X X X X X 
Concomitant Medication  X X X X X X X 
Adverse Events  X X X X X X X 
Tolerability Assessment  X X X X X X X 
Subject Satisfaction Questionnaire        X 
Perform drug accountability  X X X X X X X 
Collect empty canisters  X X X X X X X 
Dispense Study Drug  X X X X X X  
Schedule/Confirm Next Visit  X X X X X X  
 
                                                 
1 If a subject prematurely withdraws from the study, all evaluations described under F inal Visit 13/Week 5 2 must be performed.   
2 Measure blood pressure and heart rate after the subject has been sitting for at least 5  minutes at rest 
3 Home pregnancy t ests will be dispensed at each visit  to all female subjects of a childbearing potential  and will be performed at 
least monthly and whenever there is a suspicion of pregnancy (e.g., a missed period). Perform urine pregnancy test at F inal visit. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 25 of 67 
 
 CONFIDENTIAL   6.2.1. Visit 7 - Week 16  
• Measure blood pressure and heart rate 
• Perform IGA 
• Perform facial lesion count of inflammatory, noninflammatory, and nodular lesions 
• Record concomitant medications  
• Record AEs and Tolerability Ass essment 
• Assess product use to confirm that subject continues to use study drug properly 
• Collect empty study drug canister(s)  
• Dispense 2 kits (4 canisters) of FMX -101, 4% minocycline foam if required 
• Dispense Home pregnancy kit to all female subjects of chi ldbearing potential 
• Schedule/confirm the next study visit and remind subject to avoid overexposure to 
natural or artificial s unlight 
o If subjects facial acne is “clear” or “almost clear,” consider withholding 
treatment with FMX -101, 4% at this time but continue subject in study and 
schedule next visit.  
o If treatment has been interrupted, consider restarting treatment if clinically indicated 
6.2.2. Visits 8, 9, 10, 11 and 12 – Weeks 22, 28, 34, 40 and 46 
• Measure blood pressure and heart rate 
• Perform IGA 
• Perform facial lesion count of inflammatory, noninflammatory, and nodular lesions 
• Record concomitant medications  
• Record AEs and Tolerability Assessment  
• At Visit 9 (Week 28) only - Collect blood and urine samples for clinical laboratory tests and send to the central laboratory (Section 9.6)  
• Assess product use to confirm that subject continues to use study drug properly 
• Collect empty study drug canister(s)  
• Dispense 2 kit s (4 canisters) of FMX -101, 4% minocycline foam if requir ed 
• Dispense Home pregnancy kit to all female subjects of childbearing potential 
• Schedule/confirm the next study visit and remind subject to avoid overexposure to 
natural or artificial s unlight 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 26 of 67 
 
 CONFIDENTIAL   o If subjects facial acne is “clear” or “almost clear,” consider withholding 
treatment with FMX -101, 4% at this time but continue subject in study and 
schedule next visit.  
o If treatment has been interrupted, consider restarting treatment if clinically indicated 
6.2.3. Visit 13, Final Visit – Week 52  
• Measure blood pressure and heart rate  
• Perform physical examination including weight 
• Collect blood and urine samples for clinical laboratory tests and send to the central 
laboratory 
• Perform urine pregnancy test in females of childbearing potential  
• Perform IGA 
• Perform facial lesion co unt of inflammatory, noninflammatory, and nodular lesions 
• Record concomitant medications  
• Record AEs and Tolerability Assessment  
• Administer Subject Satisfaction Questionnaire  
• Collect previously dispensed study drug canister(s)  
7.  STUDY TREATMENTS  
FMX-101, 4% and vehicle will be supplied as identical canisters .  All study drug will be stored, 
inventoried, reconciled, and destroyed according to US regulations. 
7.1.  Treatments Administered  
The description of study drug kits and treatments is shown below.  
7.1.1. Part 1 (double-blind) – Weeks 1 to 12 
Dosage form description  Active kit: FMX-101 minocycline foam, 4% ;  
Vehicle kit: Matching vehicle foam 
Package description  Active kit: 2 canisters of FMX-101, 4% dispensed as foam when actuator is depressed  
Vehicle kit: 2 canisters  dispensing vehicle foam when actuator is depressed  
Daily dose Approximately 0.5 gm of FMX -101, 4% (containing 40 mg minocycline per gram of foam; 0 mg 
for vehicle subjects); applied to face topically each day.  Additional drug product may be applied 
to other acne-affected areas  
Cumulative maximal 
dose Approximately 1,680 mg of minocycline ( 0 mg for vehicle subjects) assuming application of 0.5 
gm of foam daily  to the face for 84 days. Maximum total amount of drug dispensed contains 14 
gm of minocycline.   
Dispensing 1 Kit (2 canisters) dispensed at Baseline  and Weeks 1, 3, 6, and 9.   Total of 5 kits (10 canisters) 
dispensed to the subject for the study.  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 27 of 67 
 
 CONFIDENTIAL   7.1.2. Part 2 (open-label) – Weeks 13 to 52 
Dosage form description  FMX-101 minocycline foam, 4%;  
Package description Active kit: 2 canisters of FMX -101, 4% dispensed as foam when actuator is depressed  
Daily dose Approximately 0.5 gm of FMX -101, 4% (containing 40 mg minocycline per gram of foam)  
applied to face topically each day.  Additional drug product may be applied to other acne- affected 
areas 
Cumulative maximal 
dose Up to approximately 5,600 mg of minocycline assuming application of 0.5 gm of FMX -101 foam 
daily to the face for 280 days. Maximum total amount of drug dispensed contains 39.2 gm of 
minocycline. 
Dispensing Up to 2 Kits (4 canisters) dispensed at Weeks 12,  16, 22, 28, 34, 40 and 46  depending on rate of 
usage. Up to a total of 14 kits (28 canisters) dispensed to the subject for the study.  
7.1.3. Dosing Instructions  
7.1.3.1. Part 1 – Double -blind 
The dosing regimen will be the same for both treatm ent groups.  
After shaking the canister well , a small amount of foam (about 1/2 gram or a cherry -sized 
amount) should be expressed from the canister onto the fingertips of the hand and then rubbed 
into acne-affected parts of the face .  This should be repeated as needed until all acne- affected 
parts of the face are treated.  If acne is present on other parts of the subject’s body (neck, shoulders, arms, back or chest) additional amounts (up to a total of 4g) of foam should also be applied to these areas. The foam should be applied  at approximately the same time each day  
preferably in the evening at bedtime . The subject should not bathe, shower or swim for at least 1 
hour after application of the product. 
Study kits of blinded drug supplies will be dispensed at Baseline and Weeks 1, 3, 6 and 9 to 
ensure continuous dosing in case the subject is late for subsequent visits.  
Dose adjustments are not permitted in this  part of the study.   Subjects who require a dose 
adjustment or discontinuation of study drug  must be withdrawn from the study (Section 11.4) . 
7.1.3.2. Part 2 – Open -label 
At the Week 12 Visit, subjects who elect to continue into the open- label part of this study will 
receive supplies of active FMX -101, 4% minocycline foam.   
Treatment during this part of the study will be guided by each subject’s clinical response.  The 
Investigator may elect to suspend treatment of some or all areas if there is clinical improvement 
or resolution of the acne in those areas.  Even if  the treatment is partially or completely 
temporarily suspended, the subject will be continued in the study and make all scheduled clinic 
visits.  If at any time the acne recurs or worsens, retreatment of the affected areas may be 
resumed. At each visit, the changes in treatment will be documented.  
Sufficient product will be dispensed at each visit to allow continuation of treatment as required. 
Subjects may be discontinued from the study at any time if their disease becomes refractory or 
they become intolerant of the product.   
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 28 of 67 
 
 CONFIDENTIAL   
7.1.4. 
 
Manufacturer 
 
The manufacturer of the investigational product is 
 
 
7.1.5. 
 
Labeling of 
Study 
Drug
  
The Sponsor, or designee will label 
study 
drug
 
supplies accordin
g to the requirements of the 
Code of Federal Regulations (21CFR§ 210, Subpart G- Packaging & Labeling Control).  
The labels of the investigational (test) product will contain appropriate information as required 
by regional regulatory authorities and include, 
as needed, 
the following information: 
• 
 
Name and address of the Sponsor 
• 
 
Protocol number 
• 
 
Product name / dosage form / mode of administration 
• 
 
Kit Number 
/ 
Canister
 Number 
• 
 
Site number 
/ 
Subject number  
• 
 
Name and address of manufacturer  
• 
 
Date of manufacture  
• 
 
Lot/batch number 
• 
 
Canister contents  
• 
 
Storage conditions  
• 
 
Caution Statements:  
o 
 
“New Drug 
– 
Limited by Federal Law to Investigational Use”  
o 
 
“Flammable” 
o 
 
“Shake well before use”  
o 
 
“Keep out of the reach of children” 
The composition, pharmaceutical quality, batch number, and expiration date of the 
investigational (test) product will be traceable via the 
kit number. 
7.1.6. 
 
Storage of 
Study 
Drug
 
FMX-101, 4% and vehicle canisters must be stored at 2°C – 8°C until being dispensed to the 
subjects.  Subsequently, they must be stored at 20°C – 25°C 
(refer to US
P Controlled Room 
Temperature) .  
The investigator will be responsible for the suitable storage of the investigational 
product in compliance with the storage instructions and must restrict access to the study 
personnel only. 
CCI
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 29 of 67 
 
 CONFIDENTIAL   7.2.  Study Drug Accountability  
The Investigator will have overall responsibility for the use of the study drug.  The Investigator 
or designee will verify the contents of the drug shipment and confirm receipt of the study drug in 
the Interactive Web  Response System  (IWRS) system.  In addition, an accurate study drug 
dispensing record that specifies the date and amount dispensed to each subject must be kept.  
This inventory record must be available for inspection by representatives of the Sponsor and is 
subject to regional regulatory authority inspection at any time.  At the conclusion of the study, 
the Investigator must provide a copy of this record to the Sponsor.  In addition, the weight of 
each canister will be determined prior to being dispensed to the subjects and e ach canister that 
has been retrieved from the subject wil l be returned to the vendor to be weighed. 
Under no circumstances will the Investigator allow the investigational drugs to be used other than as directed by this protocol.  Qualified study personnel must use the IWRS to assign and 
dispense kits to the subjects.  Reasons for digression from the expected dispensing regimen must also be recorded . 
7.3.  Handling and Disposal of Study Drug 
The study drug  must be protected from unauthorized access (eg, in a locke d storage facility).  
Any unused, partially used, or empty bottles of study drug  will be returned to the Sponsor or 
designee by the time of the site’s close -out visit.  Receipt, distribution, and return of the study 
drug must be properly documented on forms provided by the Sponsor or designee. 
7.4.  Method of Assignment of Study Drug 
7.4.1. Part 1 – Double - blind 
After pretreatment clinical evaluations and all other screening procedures have been completed, 
authorized site personnel will acknowledge that the applicable s ubject met all the specified 
inclusion criteria and none of the exclusion criteria.  Assignment to a treatment group will then 
follow a predetermined list of randomization numbers, with each successive number receiving 
1 of the 2 treatments in random order.  Authorized site personnel will use the IWRS system to 
assign a kit number that corresponds to the randomization schedule.  The kit box with the 
assigned kit number will be dispensed to the subject.  
The randomization code will be provided by TKL.  
7.4.2. Part 2 – Open -label 
All subjects who elect to continue into the second part of the study will receive FMX-101, 4% 
minocycline foam as described in Section 7.1.3.2.        
7.5.  Selection and Timing of Doses in the Study  
The 4% minocycline  concentration of FMX-101 was shown to be more effective than 1 % in a 
Phase 2 study.  The once -daily dosing regimen is appropriate given the pharmacokinetic 
characteristics of minocycline . 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 30 of 67 
 
 CONFIDENTIAL   7.6.  Blinding 
The first part of this study is double-blind with limited access to the randomization code.  The 
randomization code will be held in confidence until after the study database is locked and a 
memo documenting the database lock has been issued.  Every effort will be made to retain the 
integrity of the blind.  When issued to the sites, the study drug will be identical in appearance for all subjects, regardless of treatment assignment.  
The treatment each subject receives will not be disclosed to the Investigator, study site personnel, subjects, monitors, or the Sponsor staff except as required for the purposes of conducting this study. 
In the event that emergency identification of study drug is required (eg, if the Investigator believes that the information is necessary to properly treat a subject with an AE), the study drug identity can be obtained by the Investigator through the IRT system. 
Before breaking the blind for a subject, the Investigator should determine that the information is 
necessary (ie, that it will alter the subject’s immediate course of treatment and will contribute to the management of the AE).  In many cases, particularly when the emergency is clearly not 
related to study drug, the problem may be effectively managed by assuming that the subject is 
receiving active study drug without the need for unblinding.  Every effort should be made to alert the Medical Monitor before requesting that the blind be broken.  If this is not possible, the 
Medical Monitor should be immediately notified of the breaking of the blind.  The Investigator 
will record the unblinding procedures in the subject’s source documents. 
If unblinding is necessary, the subject will be withdrawn from the study and Week 12  Visit 
assessments will be completed.  
7.7.  Prior and Concomitant Therapy   
Subjects should use the cleanser,  (provided by the Sponsor).  An 
alternative, non-medicated, cleanser may be used if agreed to by the Sponsor. The use of or change in the dose of any and all concomitant medication, either prescription or 
over-the-counter, during the study will be recorded. The reason for use or change of dose of a 
concomitant therapy may need to be reported as an AE .  Therapies (medication and non-
medication therapies) not restricted by the protocol may be used.  Non-prohibited chronic 
therapies being used at Baseline may be continued. If a subject is using an oral contraceptive 
product, she should have been on the same product for at least 3 months and she should continue 
using the same or equivalent product for the duration of the double-blind portion of the study.  
If a subject is taking anticoagulant therapy, the subject should be advised that they may require a downward adjustment of their anticoagulant dosage. 
All topical or systemic medications listed in the exclusion criteria are prohibited  during the 
double-blind part of this study (through Week 12).  Similarly, n o other topical medications are 
permitted to be used on the face during this period .  Subjects requiring systemic antibiotics not 
known to affect acne will be considered on a case- by-case basis.   
During the open- label part of the study, concomitant acne medications are permitted; their use 
should be properly recorded. Benzoyl peroxide (e.g., Pro- Activ, Clearasil) can inactivate 
CCI
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 31 of 67 
 
 CONFIDENTIAL   minocycline and may thus decrease the effectiveness of FMX -101 if the two products are applied 
at the same time. Treated areas should be washed between applications of FMX -101 and 
products containing benzoyl peroxide.  Preferably, the products should be applied no less than 8 
hours apart. 
See the Investigators’ Brochure for  information about tetracyclines and possible drug- drug 
interactions 
7.8.  Use of Contraception  
Tetracycline-class antibiotics can cause fetal harm when administered to a pregnant woman.  
Tetracycline-class antibiotics used during tooth development (last half of pregnancy, infancy, 
and childhood to the age of 8 years) may cause permanent discoloration of teeth (yellow- gray-
brown). Prior to study enrollment, females of childbearing potential must be advised of the importance of 
avoiding pregnancy during study participation and the potential risk factors for an unintentional 
pregnancy. Females of childbearing potential include any female who has experienced menarche 
and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal 
ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea > 12 
consecutive months).  Females of childbearing potential must have a negative urine pregnancy 
test and, if they are sexually active or become sexually active during the study, mu st use an 
effective method of birth control such as those listed below during the course of the study.  The following is not an all- inclusive list; the subject must discuss with the Investigator the most 
appropriate form of birth control: 
• Hormonal methods 
o Oral contraceptives – ( Topical antibiotics may lessen the effectiveness of oral  
contraceptives. Therefore, a second form of birth control must be utilized in subjects using oral  contraceptives)  
o Implant 
o Injection 
o Transdermal patch  
o Intravaginal Ring  
• Intrauterine Device (hormonal or non-hormonal) 
• Barrier methods  
o Condom (male or female) with spermicide  
o Diaphragm with spermicide  
• Abstinence 
7.9.  Treatment Compliance  
Each subject is to be instructed on the importance of following the dosing schedule and returning all kits (empty/used/unused) at the appropriate visits.  The study personnel will question the 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 32 of 67 
 
 CONFIDENTIAL   subject on the history of study drug use since the last visit. A subject who deviates significantly 
from the prescribed dosage will be counseled.  
8.  EFFICACY ASSESSMENT S 
8.1.  Primary Efficacy Assessments 
The primary efficacy assessments will be the IGA and lesion counts. 
8.1.1. Investigator Global Assessment Score (IGA) 
Table 3 displays the IGA scale for acne vulgaris , which will be used by t he investigators to 
assess the severity of a subject’s acne vulgaris.  The Case Report Forms (CRFs) will allow for 
Investigators to report lesions worsening beyond Grade 4 with treatment.    The IGA must be 
performed prior to the lesion count. 
The same evaluator should perform all evaluations for a subject; when this is not possible, 
another approved evaluator may perform the evaluations. 
Table 3: IGA Scale for Acne Vulgaris  
Score Grade   Description 
0 Clear Normal, clear skin with no evidence of acne vulgaris 
 
1  
Almost clear Rare noninflammatory  lesions may be present, with rare non-inflamed papules 
(papules must be resolving and may be hyperpigmented,  though not pink- red) 
2 Mild Some noninflammatory lesions are present, with few inflammatory lesions 
(papules/pustules  only; no nodulocystic lesions) 
 
3   
Moderate Many noninflammatory  lesions.  Multiple  inflammatory lesions evident with several  
to many papules/pustules,  and there may be one small nodulocystic lesion 
4 Severe Inflammatory lesions are more apparent, many comedones and papules/pustules,  there 
may be a few nodulocystic lesions 
5  Very Severe Highly inflammatory  lesions predominate,  variable number of comedones, many 
papules/pustules  and many nodulocystic lesions 
8.1.2. Lesion Counts  
Subjects are eligible for enrollment if they have:  
• 20 to 50 inflammatory lesions (papules, pustules, and nodules) 
• 25 to 100 noninflammatory lesions (open and closed comedones) 
• No more than 2 nodules can be present on the face at Screening 
Lesions will be characterized as inflammatory or non -inflammatory using the following criteria:  
• Inflammatory  lesions: 
Papule – a solid, elevated lesion less than 0.5 cm in diameter 
Pustule – an elevated lesion containing pus less than 0.5 cm in dia meter 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 33 of 67 
 
 CONFIDENTIAL   Nodule – palpable solid lesion greater than 0.5 cm in diameter; has depth, not 
necessarily elevated  
 
 
• Noninflammatory  lesions: 
Open comedones  (blackhead) – non- infected plugged hair follicle with 
dilated/open orifice; black in color  
Closed comedones  (whitehead) – non- infected plugged hair follicle: small 
(microscopic) opening at skin surface 
Facial lesion counts will be made for the forehead, left and right cheeks, nose and chin at each 
visit.  Total in flammatory lesions (pustules, papules, and nodular lesions) and noninflammatory 
lesions (open and closed comedones) will be counted  and recorded separately .  Lesion counts 
will be repeated at Weeks 3, 6, 9 and 12. 
8.2.  Photography  
Photography of the face will be performed at Baseline and at Weeks 6  and 12 using recognized 
methods.  The equipment and techniques for this photography and for archiving the images are 
described in the Study Manual.  Photographs will be reviewed at the site and by the sponsor for 
quality.  Photographs will not be used to assess the lesion counts or the Investigator’s assessment 
of global severity but will be archived to be available for subsequent review, if required, by the sponsor, auditors or the FDA. 
8.3.  Subject Satisfaction Questionnaire  
A satisfaction questionnaire will be administered at Visit 6, Week 12 and Visit 13, Week 52 (see Section 16.1, Appendix 1 ). 
9.  SAFETY ASSESSMENTS  
The safety assessments in this study are standard safety measures in clinical studies, including physical examinations, the monitoring of vital signs, AEs  (volunteered, observed, and elicited by 
general questioning in a non-suggestive manner), and clinical laboratory test results.  In addition, 
skin assessments at the drug application site(s) will be performed. 
9.1.  Medical/Surgical History 
A complete medical and surgical history will be obtained at Screening, which will include 
diseases of the head, ears, eyes, nose and throat; respiratory diseases; cardiovascular diseases; 
gastrointestinal diseases, hepatic diseases, genitourinary diseases, musculoskeletal diseases, endocrine diseases, neurological diseases, psychiatric diseases, skin diseases, allergies, 
hematological diseases, and other abnormalities. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 34 of 67 
 
 CONFIDENTIAL   9.2.  Medication History  
A history of medication usage (including previous use of acne medications  and non-medication 
therapies) will be recorded at Screening .  The start and stop dates of previous use of medications 
in the last 3 months will be recorded. 
9.3.  Concomitant Medications  
All medication that the subject is currently taking  or any change in medication or dos age since 
the last visit will be documented throughout the study. 
9.4.  Vital Signs 
Heart rate and  blood pressure will be measured at all post- Baseline visits.  All blood pressure 
measurements will be made using a sphygmomanome ter with an appropriate cuff size for the 
individual subject.  Measurements will be administered  while the subject is seated after at least 
5 minutes at rest.  
9.5.  Physical Examination  
A complete physical examination will include an evaluation of general appearance, skin, 
HEENT, neck, lymph nodes, lungs, heart, abdomen, musculoskeletal system, and neurologic 
system. A standard 12- lead EKG (after at least 5 minutes rest) will be performed at Baseline  in 
subjects over 39 years of age. 
Weight will be recorded at th e Baseline Visit , Visit 6 (Week 12) and Final Visit (Week 5 2).  
Height will be measured at Baseline, only . 
9.6.  Clinical Laboratory Tests  
Serum chemistry, hematology and urinalysis will be evaluated at Baseline, Week 12/ Final Visit 
of the double-blind phase of the Study, and at Week 28 and Week 52/Final Visit of the open-
label phase of the Study. Serum chemistry , hematology, and urinalysis tests will be performed at 
a central laboratory.  
Refer to the manual from the central laboratory for detailed instructions on collecting, 
processing, and shipping of samples.  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 35 of 67 
 
 CONFIDENTIAL   Hematology Urinalysis Serum chemistry  
Hematocrit 
Hemoglobin 
MCH 
MCHC 
MCV 
MPV 
Platelet count  
RBC 
RDW 
WBC 
Reticulocyte count  
WBC differential  (% & 
absolute) : 
Basophils 
Eosinophils 
Lymphocytes  
Monocytes 
Neutrophils 
 
 Bilirubin 
Blood 
Glucose 
Ketones 
Leukocytes esterase  
pH 
Protein 
Specific gravity  
 Urine pregnancy performed at the site  
  
 Alanine aminotransferase (ALT)  
Albumin 
Alkaline phosphatase  
Aspartic acid transaminase (AST)  
Blood urea nitrogen (BUN)  
Calcium 
Chloride 
Cholesterol 
Creatinine 
Creatinine kinase 
Gamma glutamyl transferase (GGT)  
Globulin 
Glucose 
Phosphorus 
Potassium 
Sodium 
Total bilirubin (if elevated obtain direct bilirubin)  
Total protein 
Triglycerides 
Uric acid
 
9.6.1. Urine Pregnancy Test  
A urine pregnancy test will be performed on all females of childbearing potential at Baseline, 
Week 3, Week 6, Week 9 and Week 12 of the double-blind phase of the Study and Final Visit or 
when a subject prematurely withdraws from the study. 
Home pregnancy kits will be provided at each visit to all female subjects  of childbearing 
potential in the open-label phase of the Study and are to be used at least monthly and if a 
pregnancy is suspected between visits (e.g., if a subject misses a period). A urine pregnancy t est 
will be performed at  Week 52/ Final Visit. 
9.6.2. Sample Collection, Storage, and Shipping  
Sample collection kits, requisition slips, and shipping boxes will be supplied by the central laboratory. Sample collection procedures and shipping instructions will be detailed in the 
laboratory manual. Study centers must be equipped to store the samples according to the 
laboratory manual procedures before shipping samples to the central laboratory. 
9.7.  Other Safety Measurements  
9.7.1. Tolerability  
Erythema, dryness, hyper pigmentation and skin peeling at the sites of study drug application will 
be assessed by the investigator at each study visit on a scale of 0 to 3 (0=none; 1=mild; 2=moderate; 3=severe). Itching will be assessed using the same scale based on the subjects’ subjective assessment.  The intensity and location of each finding will be recorded.  These signs 
and symptoms should not be recorded as AEs unless they require concomitant treatment or lead to the subject’s discontinuation from the study. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 36 of 67 
 
 CONFIDENTIAL   9.8.  Adverse Events  
9.8.1. Method of Determining Adverse Events  
Safety assessments will include recording AEs  reported spontaneously by the subject or observed 
by the Investigator.  AEs  will be recorded at each visit throughout the study on the appropriate 
CRF. Every attempt should be made to describe the AE in terms of a diagnosis.  If a clear 
diagnosis has been made, individual signs and symptoms will not be recorded unless they 
represent atypical or extreme manifestations of the diagnosis, in which case they should be 
reported as separate events.  If a clear diagnosis cannot be established, each sign and symptom 
must be recorded individually. 
Subjects should be asked whether, since the time of the last observation or visit, they had any of 
the following: 
• Experienced any changes in well -being 
• Used any new medications  
• Changed medication regimens (both prescription and over-the-counter) 
• Were admitted to a hospital or had any accidents  
• Developed unusual headaches or changes in vision 
With the exception of the last item above, all questions should be of a general nature and should 
not suggest symptoms. 
When an AE is suspected, all relevant evaluations will be carried out and appropriate treatment 
provided.  Additional follow- up will be done as necessary (Section 9.8.4) and recorded in the 
subject’s source documents, and the results will be provided to the Sponsor. 
For AE definitions and reporting requirements, refer to Section  9.8.2 and Section 9.8.3, 
respectively. 
9.8.2. Adverse Event Definitions  
9.8.2.1. Adverse Events  
An adverse event (AE) is any unfavorable or unintended sign, symptom, or disease that appears 
or worsens in a subject after the subject signs the ICF  (and/or Assent Form)  for a clinical study . 
Examples of what may be considered an AE include any of the following: 
• A new illness  
• An exacerbation of a sign or symptom of an underlying condition or of a concomitant illness unrelated to participation in the clinical study or a n effect of the study drug  or 
comparator drug  
No causal relationship with the study drug  is implied by the use of the term “adverse event.”  An 
exacerbation of a pre -existing condition/illness is defined as a more frequent occurrence or as an 
increase in the severity of the pre-existing condition/illness during the study.  Planned or elective 
surgical procedures for pre -existing conditions that have not worsened are not AEs .  However, 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 37 of 67 
 
 CONFIDENTIAL   any complication that occurs during a planned or elective surgery is an A E.  (If the event meets 
the criteria for a serious adverse event [S AE], such as an extended hospitalization, it will be 
considered an SAE).  Conditions leading to unplanned surgical procedures may also be AEs . 
9.8.2.2. Serious Adverse Events  
A “serious adverse event” (SAE) is any AE that:  
• Results in death  
• Is life-threatening 
(Note: The term “life -threatening” refers to any AE that, as it occurs, puts the subject 
at immediate risk of death.  It does not refer to an AE that hypothetically might have 
caused death if it  were more severe.)  
• Results in hospitalization or prolongation of current hospitalization (not including hospitalization for a pre-existing condition that has not increased in severity or 
frequency from the subject’s underlying medical condition prior to entry into the 
study) 
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect in the offspring of a subject 
• Is another serious (important medical events)  events 
 
(Note: Important medical events may not be immediately life -threatening or result in 
death or hospitalization but may be considered serious when, based upon appropriate 
medical judgment, they may jeopardize the subject or require medical or surgical intervention to prevent one of the outcomes listed above.  Ex amples of such medical 
events include allergic bronchospasm requiring intensive treatment in an emergency room or at home; blood dyscrasias or convulsions that do not result in inpatient hospitalization; or development of drug dependency or drug abuse.) 
SAEs will be reported by the Sponsor to the regulatory authorities as required. 
9.8.2.3. Severity of Adverse Events  
“Severity” of the AE refers to the extent to which an AE affects the subject’s daily activities and differs from “Serious ,” which is a regulatory class ification.  Severity will be categorized 
according to the following criteria:  
• Mild:  The symptom has a negligible effect or no impairing effect on the subject’ s 
normal function. 
• Moderate:  The symptom impairs the subject’s normal function to some extent. 
• Severe:  The symptom has an obvious, significantly impairing effect on the subject’ s 
normal function. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 38 of 67 
 
 CONFIDENTIAL   9.8.2.4. Relationship of Adverse Events to Study Treatments  
“Causality” refers to the relationship of the AE to study drug and will be categorized according 
to the following criteria: 
• Unlikely:  There is no medical evidence to suggest that the AE may be related to 
study drug usage, or there is another more probable medical explanation. 
• Possible:  There is medical evidence to suggest that there is a reasonable possibi lity 
that the AE may be related to study drug  usage. However, other medical explanations 
cannot be excluded as a possible cause.  
• Probable:  There is strong medical evidence to suggest that the AE is related to study 
drug usage. 
9.8.2.5. Adverse Events Expectedness  
Expected AEs  are defined as those described in the Investigator’s Brochure.  If an event 
increases in intensity or severity from that described in the IB, it will be considered unexpected. 
9.8.3. Reporting Adverse Events  
AEs that occur from the time of informed consent /assent through completion of the last study 
visit should be reported.  Any AE that the Investigator becomes aware of that occurs within 30 
days of study completion or withdrawal should also be reported. 
Every attempt should be made to describe the AE in terms of a diagnosis.  If a clear diagnosis 
has been made, individual signs and symptoms will not be recorded unless they represent 
atypical or extreme manifestations of the diagnosis, in which case they should be reported as separate events.  If a clear diagnosis cannot be established, each sign and symptom must be 
recorded individually. 
Any serious AEs  occurring in a subject receiving study drug  must be reported to the Sponsor or 
designee within 24 hours of the site being informed of the event, even if the event does not 
appear to be drug -related.  The report must be made by sending a completed Serious Adverse 
Event (SAE) Report form to the Sponsor or designee.  Any pertinent follow-up information 
should be provided in a similar manner.  Contact information is provided below:  
TKL Clinical Pharmacovigilance 
 
9.8.4. Adverse Event Follow -up 
Adverse events , and tolerability signs and symptoms greater than zero (0), that are ongoing when  
a subject withdraws from or completes the study will be followed until resolution or stabilization (in the opinion of the Investigator), or for 30 days, whichever is shorter.  Investigators and the Sponsor will decide if longer follow-up is appropriate on a case- by-case basis.  Subjects who 
experience any cl inically significant AE will remain under medical supervision until the 
Investigator or the Sponsor’s Medical Monitor deems the AE to be resolved, stabilized, or no longer serious enough to warrant follow-up. 
CCI
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 39 of 67 
 
 CONFIDENTIAL   Laboratory values that are abnormal and not assessed as AEs  may be followed at the discretion 
of the Investigator or the Sponsor’s Medical Monitor until resolved or stabilized. 
9.8.4.1. Pregnancy reporting  
Prior to study enrollment, females of childbearing potential must be advised of the importance of 
avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy.  The Informed Consent or Assent Form that the subject signs must document this 
discussion.  
If a subject or Investigator suspects that the subject may be p regnant prior to study drug 
administration, the study drug must be withheld until the results of laboratory pregnancy testing 
are available.  If pregnancy is confirmed, the subject must not receive study drug and must not be 
enrolled in the study. 
A urine pregnancy test will be performed on all females of childbearing potential at Baseline, 
Week 3, Week 6, Week 9 and Week 12 of the double-blind phase of the Study and Final Visit or 
when a subject prematurely withdraws from the study. 
Home pregnancy kits wil l be provided at each visit to all female subjects of childbearing 
potential in the open-label phase of the Study and are to be used at least  monthly and if a 
pregnancy is suspected between visits (e.g., if a subject misses a period). A urine pregnancy tes t 
will be performed at Week 52/F inal Visit. 
During the study, all females of childbearing potential should be instructed to contact the 
Investigator immediately if they suspect they might be pregnant (eg, missed or late menstrual period).  If a subject or Investigator suspects that the subject may be pregnant at any time before 
or during the study, the study drug must be withheld until the results of laboratory pregnancy testing are available.  The Sponsor and Site Monitor must be notified and available information captured on a “Suspected Pregnancy” form.   If pregnancy is confirmed, the subject must be 
withdrawn from the study and the Sponsor and Site Monitor notified.  Additional relevant information about the confirmed pregnancy will be recorded on the appropriate form (s) but the 
pregnancy will not be captured as an AE . 
The subject should be followed until the outcome of the pregnancy is known. 
9.8.5. Clinically Significantly Abnormal Laboratory Results  
All laboratory values that are outside of the normal range for that parameter will be so flagged 
when reported to the site.  The Investigator will determine which out-of- range laboratory test 
results should be characterized as clinically significant and will so annotate the laboratory report.  If a clinically significant laboratory abnormality requires treatment or is the reason for a subject being discontinued from the study, the abnormal result must also be classified as an AE.  
9.9.  Appropriateness of Safety Measurement  
The safety assessments in this study are standar d safety measures in clinical trials.  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 40 of 67 
 
 CONFIDENTIAL   10.  STATISTICAL DESIGN AND ANALYSIS  
10.1.  Statistical Analysis Plan  
A detailed statistical analysis plan will be finalized prior to breaking of the study blind.  
Descriptive statistics for qualitative variables (eg, race) will in clude the number and percentage 
of subjects with the qualitative response.  Missing responses will be enumerated, but the 
calculation of percentages will exclude missing responses.  For quantitative variables (eg, age), 
descriptive statistics will include the number of subjects with non-missing data, mean, standard deviation, median, minimum value and maximum value.  All hypothesis testing will be 
conducted using two- sided tests with  α=0.05 level of significance  unless otherwise specified . 
All study data will be presented in listings.  
10.2.  Determination of Sample Size  
In a phase 2 study, the proportion of subjects with an IGA score of 0 or 1 after 12 weeks of treatment was  in the minocycline 4% foam  group compared to 2% in the vehicle group. The 
following table provides a few alternate assumptions and corresponding sample sizes. Power was 
set to  and type-1 error to two-sided 0.05. Sample size was calculated based on Fisher’s Exact test. 
Vehicle IGA (0,1) Minocycline 4% 
foam IGA (0,1) Sample sizes (vehicle, active) 
   
   
   
Assuming 12% dropout rate, 300 subjects on active, and 150 subjects on vehicle will provide at least  power for a statistically significant difference on IGA 0 or 1. In the same phase 2 study, the change from baseline in inflammatory lesions was  in the minocycline 4% foam 
versus  in the vehicle group. The standard deviation in change from baseline was 
approximately  The following table shows alternate assumptions and corresponding sample sizes, for 90% power and a two-sided type 1 error of 0.05. The sample sizes were calculated 
using a t-test. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 41 of 67 
 
 CONFIDENTIAL   Vehicle mean 
inflammatory 
lesion reduction Minocycline 4% foam 
mean inflammatory 
lesion reduction Sample sizes 
(vehicle, active)  
   
   
   
To summarize, using some conservative estimates of the effect on minocycline 4% foam versus 
the vehicle for both IGA and change in inflammatory lesions at week  subjects on active, 
and 150 on vehicle will provide > 90% power for s statistically significant difference.  
Another consideration for the sample size must be given to the secondary endpoint of 
noninflammatory lesions which will be compared to the vehicle for non-inferiority. The margin 
for non-inferiority will be f the change from baseline to week 12. In a phase 2 study, 
change from baseline in noninflammatory lesions at week 9 was  for the vehicle group with 
a standard deviation of 18. Assuming approximately the same reduction at week 12, a  non-
inferiority margin is about  lesions. The following table provides approximate sample sizes for alternate assumptions for 90% power to show non- inferiority. 
Vehicle mean 
noninflammatory 
lesion reduction Minocycline 4% foam 
mean noninflammatory 
lesion reduction Sample sizes 
(vehicle, active)  
   
   
   
 
If Minocyclin e 4% foam has the same effect on noninflammatory lesions as vehicle,  subjects 
on vehicle and  on 4% foam will be needed for 90% power to show non- inferiority. If 
Minocycline 4% foam has a slightly less effect on noninflammatory lesions (  lesion 
reduction versus  in vehicle), there will be about 90% power to show non- inferiority. 
10.3.   Analysis Populations  
The Intent-to-Treat (ITT) population will include all randomized subjects. The ITT population 
will be the primary population for all efficacy analyses.  
The Safety population will include all randomized subjects who took at least one dose of study 
drug.  Subjects who have no post- Baseline assessments will be included in the Safety population 
unless all dispensed study drug is returned unused. 
The Per Protocol (PP) population is defined as the subset of the ITT population without any 
protocol deviations that may have an impact on the efficacy assessments.  The subjects to be 
CCI
CCI
CCI
CCI
CCI
CCI
C
CCI
CCI
CCI
CCI
CCI
CCI
CC
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 42 of 67 
 
 CONFIDENTIAL   included in the PP population will be determined by the Sponsor/CRO prior to the unblinding of 
the study.  The PP population will be secondary for the co-primary endpoints only. 
Subjects may be excluded from the PP populati on if any of the following are met:  
• Did not meet inclusion/exclusion criteria  
• Have administered  any interfering concomitant medications  
• Have not, in the opinion of the investigator, been compliant with the treatment 
regimen (e.g. reported frequent missed doses) 
Prior to breaking the blind, additional criteria for exclusion from the PP population may be included to accommodate for unforeseen events that occurred during the conduct of the study.  
10.4.  Efficacy Endpoints  
The primary population for all efficacy analyses will be the ITT population.  Subjects will be 
analyzed according to their randomized treatment.   The primary method of handling missing data 
will be the last observation carried forward (LOCF) approach.   Sensitivity analyses using 
multiple imputatio ns and baseline observation carried forward (BOCF) will be performed on the 
co-primary endpoints only. 
Supportive efficacy analyses will also be performed on the PP population.  All analyses using the PP population will use the Observed- Cases (OC) approach .  i.e., there will be no imputation for 
missing data at any time point.  
Changes from Baseline lesion count will be calculated as the Baseline value minus the post -
Baseline value.  Thus, a positive change will reflect a reduction in lesion count.  The perc ent 
change from Baseline lesion count will be calculated as the Baseline value minus the post -
Baseline value divided by the Baseline value, expressed as a percentage.  Thus, a positive percent change will reflect a reduction in lesion count.  
10.4.1. Primary Effica cy Endpoints  
The co-primary efficacy endpoints are: 
• The absolute change from Baseline in the inflammatory lesion count at Week 12  
• Treatment Success (dichotomized as Yes/No) at Week 12, where success is defined 
as an IGA score of 0 or 1, and at least a 2 -grade improvement (decrease) from 
Baseline 
The null hypotheses of the equality of the FMX-101 4% and vehicle means for absolute change 
from Baseline to Week 12 in the inflammatory lesion count and the equality of IGA success rates 
at Week 12 will each be tested at a two -sided 0.05 level of significance. Change from baseline in 
inflammatory lesion count will be analyzed using an Analysis of Covariance (ANCOVA), with 
Treatment as a main effect, baseline inflammatory lesion count as a covariate, and 
investigational site a blocking factor. Investigational site by Treatment interaction will be tested at 0.1 level, and if significant, it will further be explored. The dichotomized IGA will be 
analyzed using a Cochran -Mantel-Haenszel (CMH) test, stratified by investigational site.  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 43 of 67 
 
 CONFIDENTIAL   10.4.2. Secondary Efficacy Endpoints 
• The absolute change from Baseline in the noninflammatory lesion count at Week 12 
• The absolute change from Baseline in the inflammatory lesion count and IGA 
Treatment Success at the interim visit at Week 9  
• The absolute change from Baseline in the inflammatory lesion count and IGA 
Treatment Success at the interim visit at Week 6  
10.4.3. Tertiary efficacy endpoints  
• The percent change from Baseline in the inflammatory lesion count at Weeks 3, 6, 9 and 12 
• The absolute change f rom Baseline in the inflammatory and noninflammatory lesions, 
and the IGA Treatment Success at Week 3  
• The absolute change from Baseline in the noninflammatory lesion count at Weeks 3, 
6, 9 and 12 
• The percent change from Baseline in the noninflammatory lesi on count at Weeks 3, 6, 
9 and 12 
Secondary efficacy endpoint will be tested sequentially in the order listed above, at 0.05 level of significance, only if the co -primary efficacy endpoints are significant.  
10.5.  Safety endpoints   
Treatment-emergent adverse even ts (TEAEs), vital signs , physical examinations , and clinical 
laboratory measurements  will be reported  on the Safety population.  Subjects will be reported  
according to the treatment they actually received.  No statistical tests will be performed for any of the safety assessments.  
Baseline for vital signs, physical examinations, and clinical laboratory measurements is defined as the last non -missing value prior to the first dose of study drug. 
10.5.1. Adverse Events  
The Medical Dictionary for Regulatory Activities ( MedDRA) terminology will be used to 
classify all AEs with respect to system organ class (SOC) and preferred term.  
TEAEs will be defined as events that emerge during treatment having been absent pre- treatment, 
or worsen relative to the pre- treatment state.  Summaries of AE s will be limited to TEAEs.  The 
number and percentage of subjects reporting each SOC and preferred term will be summarized for each treatment group and by the Study Period.  At each level of summarization, a subject will be counted once if he/she reported one or more events.  The severity of TEAEs and relationship 
to study drug will be summarized in a similar manner.  For summaries of relationship to study 
drug, a subject will be classified according to the closest relationship.  For summar ies of TEAE 
severity, a subject will be classified according to the highest severity.  
Summaries of SAE s and subjects who prematurely withdraw from the study due to AEs  will be 
presented. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 44 of 67 
 
 CONFIDENTIAL   10.5.2. Vital Signs  
Vital sign parameters will be summarized using descriptive statistics at B aseline and at each 
post-baseline time point.  Changes from B aseline will also be summarized.  Baseline is defined 
as the last non -missing value prior to the first dose of study drug. 
10.5.3. Physical Examinations 
Physical examinations will be summarized using descriptive statistics at Baseline and at each 
post-baseline time point.  Shifts from Baseline will also be summarized.  Baseline is defined as 
the last non-missing value prior to the first dose of study drug. 
10.5.4. Clinical Laboratory Results  
Baseline is defined as the last non-missing value prior to the first dose of study drug. 
Shift tables for each clinical laboratory test will cross -tabulate the number of subjects with values 
below the laboratory reference range (low), values within the labor atory reference range 
(normal) or above the laboratory range (high) at baseline with the number of subjects with low, 
normal or high values at each post-baseline time point.  
A listing of subjects with pre -treatment and treatment- emergent clinically signif icant abnormal 
laboratory values will be presented for each treatment group. Clinical significance is based on the Investigator’s judgment.   
10.6.  Statistical Analysis 
10.6.1. Interim Analysis   
No interim analysis is planned. 
10.6.2. Subject Accounting, Demographic, and Baselin e Characteristics  
Demographic, baseline characteristics, and prior and concomitant medications will be 
summarized by treatment.  Study completion status and reasons for discontinuation will also be 
displayed by treatment.   
Medical and surgical history will only be presented in the listings. 
10.6.3. Efficacy Analysis 
The co-primary endpoint of absolute change from Baseline in inflammatory lesions at Week 12 
will be analyzed using an Analysis of Covariance (ANCOVA) model with main effect treatment 
and investigationa l site as a covariate.  The treatment by investigational site interaction will be 
tested separately at 0.1 level of significance, and if significant, will be further be explored.  A 
95% confidence interval will be calculated on the difference in mean changes from baseline 
between FMX -101 4% and vehicle. 
The co-primary endpoint of IGA Treatment Success rate at Week 12 will be analyzed using a 
Cochran–Mantel–Haenszel (CMH) test with investigational site as the stratification factor.  If the 
overall IGA Treatment Success  rate is less than 10%, a Fisher’s Exact test will be used to 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 45 of 67 
 
 CONFIDENTIAL   corroborate the CMH test.  A 95% confidence interval will be constructed on the difference in 
IGA Treatment Success rates between FMX -101 4% and vehicle. 
If FMX-101, 4% is found superior to vehicle (one-sided p<=0.025) for both co- primary 
endpoints, the secondary endpoints will be tested sequentially. The first secondary endpoint of noninflammatory lesions at Week  12 will be tested initially as a non -inferiority comparison of 
FMX-101, 4% to vehicle. Non-inferiority margin is defined as 30% of the noninflamm atory 
lesion reduction in the vehicle group at Week  12. A lower 97.5% confidence limit will be 
calculated for µ
a-0.6×µv, where µa and µv are the mean reduction of no ninflamatory lesio ns of 
FMX-101, 4% and vehicle respectively. If the confidence limit is above 0, non- inferiority will be 
concluded. If non-inferiority is concluded, the superiority of FMX-101, 4% to vehicle for noninflammatory lesions at Week  12 will be tested. The sequent ial testing will proceed 
according to the order in Section 10.4.2.1.  Testing of secondary efficacy endpoints at an earlier 
timepoint for each type of lesion and IGA Treatment Success  will be performed only if 
superiority (one -sided p<=0.025) is seen at the later timepoint.  
Secondary efficacy parameters will be analyzed similar to the appropriate co -primary efficacy 
parameter. 
Absolute change from baseline in inflammatory lesion count and the IGA assessments in the 
open-label phase of the study will be summarized. No statistical testing will be performed for the 
open label efficacy data.  
10.6.4. Safety Analysis 
The Medical Dictionary for Regulatory Activities (MedDRA) terminology will be used to classify all AEs with respect to system organ class (SOC) and preferred term.  
TEAEs will be defined as events that emerge during treatment having been absent pre- treatment, 
or worsen relative to the pre- treatment state.  Summaries of AEs  will be limited to TEAEs.  The 
number and percentage of subjects reporting each SOC and preferred term will be summarized 
for each treatment group.  At each level of summarization, a subject will be counted once if he/she reported one or more events.  The severity of TEAEs and relationship to study drug will 
be summarized in a similar manner.  For summaries of relationship to study drug, a subject will 
be classified according to the closest relationship.  For summaries of TEAE severity, a subject will be classified according to the highest severity.  
Summaries of SAEs and subjects who prematurely withdraw from the study due to AEs  will be 
presented. 
Vital sign parameters will be summarized using descriptive statistics at Baseline and at each 
post-baseline time point.  Changes from Baseline will also b e summarized.  
Physical examinations will be summarized using descriptive statistics at Baseline and for the 
final visit.  Shifts from Baseline will also be summarized.  
Shift tables for each clinical laboratory test will cross -tabulate the number of subjects with values 
below the laboratory reference range (low), values within the laboratory reference range (normal) or above the laboratory range (high) at baseline with the number of subjects with low, 
normal or high values at the Final Visit.  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 46 of 67 
 
 CONFIDENTIAL   A listing of subjects with pre -treatment and treatment- emergent clinically significant abnormal 
laboratory values will be presented for each treatment group. Clinical significance is based on 
the Investigator’s judgment.  
11.  STUDY MANAGEMENT  
11.1.  Monitoring 
The Investigator will be responsible for preparing and maintaining adequate and accurate source 
documents (medical records, raw data collection forms, etc.) designed to record all observations and other pertinent data for each subje ct treated with the study drug .  The Investigator will allow 
representatives of the Sponsor, contract designees, authorized regulatory authority inspectors, and the IRB to have direct access to all documents pertaining to the study.  The Investigator is to immediately notify the Sponsor or the Sponsor ’s representative of any regulatory authority  
inspections.  The Investigator will be informed about the outcome of any Sponsor audit. 
This study will be monitored regularly, by or under supervision of a monitor from the Sponsor.  
The frequency of monitoring visits will be agreed upon by the Sponsor’s representative and the 
study site.  
Monitoring visits will take place on a regular basis according to the enrollment rate and number 
of subjects enrolled at each investigational site.  During these visits, the monitor will check the 
completion of the CRF entries, compliance with the study protocol and with GCP-ICH, and the 
agreement of key entries with the source data.  The monitor will also verify the corre ct use of the 
study drug.  At the Final Visit or at an agreed to time prior to the Final Visit, the monitor will 
check all remaining material including the remaining quantities of the study drug and will 
organize their return to the Sponsor or designee.  At each visit, the Investigator and staff will be expected to cooperate with the Sponsor’s representative(s) for the purposes of review and 
verification of protocol compliance, AE reporting, CRFs, source documents, clinical supplies and inventory records, and any additional records as may have been previously a rranged between 
the Investigator and the Sponsor’s representative(s). 
The Investigator and/or other designated study personnel are expected to contact the Sponsor’s 
or the Sponsor’s representative’s clinical research associate, as needed, regarding study concerns and/or questions.  Contact information is provided in the Study Binder for the site.  
11.2.  Protocol Amendments 
The Sponsor may propose to amend this protocol at any time. 
No change to the protocol will be implemented until the Sponsor and the IRB have reviewed and 
approved the amendment. 
In the event of an emergency, the Investigator shall implement any medical procedures deemed 
appropriate for subject safety.  All such procedures must have written documentation and be promptly reported to the Sponsor. 
Amendments to the protocol, if any, are included in Section 16.2, page 53.  This protocol version 
includes Amendment 1, effective February 26 , 2016 and Amendment 2, effective April 6 , 2016.   
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 47 of 67 
 
 CONFIDENTIAL   11.3.  Protocol Deviations 
A protocol deviation is any change, divergence or departure from the IRB-approved protocol by 
the study staff (intentional or unintentional).  All deviations are to be documented at the site and 
reported to the IRB according to the IRB’s guidelines. 
In the event of an emergency, the Investigator shall implement any medical procedures deemed 
appropriate for subject safety.  All such procedures must have written documentation and be 
promptly reported to the Sponsor. 
11.4.  Withdrawal of Subjects  
Withdrawn subjects are those who do not complete all evaluations and procedures outlined in the 
protocol.  Subjects who discontinue taking study drug  for any reason must also be withdrawn 
from the study.  Subjects may be withdrawn from the study because of one of the following: 
• Adverse Event:   An AE that, in the opinion of the Investigator or Sponsor, suggests 
that continued participation in the study is not in the subject’s best interest for safety reasons.  All AEs that are present when the subject withdraws from the study will be 
followed as described in Section 9.8.4. 
• Abnormal Laboratory Result:   Any clinically significant laboratory abnormality 
that requires w ithdrawal of the subject from the study should be considered an AE 
leading to withdrawal.  If possible, laboratory tests will be repeated for any results that were clinically significantly abnormal until the abnormality is resolved or stabilized to the satisfaction of the Investigator in consultation with the Medical 
Monitor. 
• Lost to Follow- up:  Confirmed at minimum by 2 phone calls and a traceable letter 
without response. 
• Subject Request:  Subject requests , for any reason (eg, AE) , to be withdrawn or 
withdraws his/her consent . 
• Poor protocol adherence:  A subject may be withdrawn from the study at the discretion of the Investigator or Sponsor due to poor compliance with protocol requirements that may compromise the study results or subject safety.  
• Other:  Other reasons include but are not limited to: Investigator decision that it is in 
the subject’s best interest to be withdrawn, administrative reasons, relocation of 
subject, etc.  If a subject becomes pregnant during the study, the subject will be 
withdrawn from the study and followed through conclusion of the pregnancy. 
If a subject is withdrawn from the study following the start of study drug  during Period 1 of the 
study, all Week 12 assessments should be completed.  If a subject is withdrawn from the study 
following the start of study drug  during Period 2 of the study , all Final Visit assessments should 
be completed.  Subjects withdrawn from the study will not be replaced. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 48 of 67 
 
 CONFIDENTIAL   11.5.  Termination of the Study  
The study may be terminated at any time at the request of th e Sponsor or a regulatory authority, 
with proper and timely notification of all parties concerned.  The IRB will be informed promptly 
and the Sponsor or the Investigator will supply reason(s) for the termination or suspension, as 
specified by the applicabl e regulatory requirements.  Otherwise, the study is considered 
terminated upon completion of all subject treatments and evaluations. 
11.6.  Publication Policy  
The data obtained in this study are the property of the Sponsor, which will make reasonable 
efforts to assure that the results are published in a peer-reviewed journal.  As some of the 
information concerning the investigational product and development activities at the Sponsor may be of strictly confidential nature, any manuscript or other presentation of da ta must first be 
reviewed by the Sponsor before its submission. 
12.  ETHICS 
12.1.  Conduct of the Study  
This study will be conducted in accordance with the ICH Harmonized Tripartite Guideline for 
GCP, 1997; the US Title 21 CFR parts 50, 56, and 312; and the ethical pr inciples that have their 
origin in the Declaration of Helsinki.  The study will not begin until all of the requirements of the appropriate regulatory authorities have been fulfilled. 
12.2.  Institutional Review Boards (IRB)  
This protocol (and any changes), all consent /assent forms, and subject consent procedures must 
be reviewed and approved by a properly constituted IRB.  The i nformation presented to the IRB 
at the time initial approval is sought must include any plans for subject recruitment that involve advertising or other direct contact with potential subjects outside of the doctor- subject 
relationship.  A letter of approval issued by the IRB must be sent to the Sponsor prior to initiation of the study.   Any changes made to the protocol must be approved by the IRB prior to 
implementation, except where needed to eliminate a potential imminent safety hazard to the 
subjects.  In this case, immediate implementation may apply place followed by IRB approval. 
Review and approval by the IRB for continuation of the stud y must apply place at least once a 
year. 
12.3.  Written Informed Consent  
The Investigator or designee will explain the nature of the study, its purpose and associated procedures, the expected duration and the potential benefits and risks of participation to each 
subject prior to his/her entry into the study (ie, before examinations and procedures associated with selection for the study are initiated).  Each subject will have ample opportunity to ask 
questions and will be informed about the right to withdraw from t he study at any time without 
any disadvantage and without having to provide reasons for this decision. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 49 of 67 
 
 CONFIDENTIAL   Following this informative discussion, the subject will be asked if he/she is willing to sign a 
statement of informed consent.  Only subjects who voluntarily sign the Informed Consent Forms 
(ICF) may enter the study.  Subjects less than 18 years of age (or as required by state law)  must 
sign an Assent Form for the study and a parent or legal guardian must sign the ICF. 
The ICF and Assent Form must be review ed and approved by the Sponsor and the IRB prior to 
their use. 
The original signed ICF and Assent Form will remain in the Investigator ’s files.  The 
Investigator or designee will indicate in each subject’s source documents that he / she has 
informed the subject about the study and its procedures, the subject has signed and dated the 
ICF/Assent Form , and the subject has been given a copy of the documents .  The Investigator or 
designee will inform subjects of any new information that may be relevant to the su bjects’ 
willingness to continue in the study. 
12.4.  Subject Confidentiality  
The Sponsor ensures that the following have permission to review all study- related documents: 
monitor, auditor, IRB and regulatory authorities.  The subject’s identity and study- related records 
will remain confidential throughout the duration of the study data collection and reporting process. 
A unique subject identification code is assigned to each potential study subject.  The  
identification code protects the subject’s identity and is used in lieu of the subject’s name when reporting subject data.  The data will always maintain the confidentiality of the subject.  
The investigator or designee will review the subject data, which will be referenced using the 
subject identifier.  At the conclusion of the study, the data obtained may be presented to regional 
regulatory authorities but the subject’s identity will not be revealed.  In addition, if any clinical data obtained from the study is published in scientific journals or presented at scientific meetings 
the subject’s identity will not be revealed. 
12.5.  Records Retention  
The Investigator must maintain essential study documents (protocol and amendments, source 
documentation corresponding to all information contained in the CRFs, signed informed consent and assent forms, relevant correspondence, and all other supporting documentation) until at least 
2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region, or at least 2 years after the 
formal discontinuation of clinical development of the investigational product.  These documents 
should be retained for a longer period if required by the applicable regulatory requirements or the 
hospital, institut ion, or private practice in which the study is being conducted.  Subject 
identification codes (subject names and corresponding study numbers) will be retained for this 
same time period. Custody of the records may be transferred to another responsible party, 
acceptable to the Sponsor, who agrees to abide by the retention policies.  Written notice of 
transfer must be submitted to the Sponsor.  The Investigator must contact the Sponsor prior to 
disposing of any study records. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 50 of 67 
 
 CONFIDENTIAL   12.6.  Financing 
Funding for this study will be agreed between the Investigator and the Sponsor and will be 
confirmed in writing before the study starts.  
Completion of Financial Disclosure Forms will be required before the study starts.  Any additions to the primary site personnel will necessitate the completion of new Financial Disclosure Forms.  This information will also be collected at site closure and one year after the 
completion of the study. 
Disclosure Forms.  Investigators will be informed that they must report any new information to 
the sponsor or designate at site closure and one year after the completion of the study. 
13.  QUALITY CONTROL AND QUALITY ASSURANCE  
The Sponsor and Investigator will apply all steps possible to ensure the accuracy, consistency, 
completeness, and reliability of the data, including participating in an Investigator meeting 
and/or site initiation visit, routine site monitoring, review of CRFs against source documents, and quality control checks.  
In addition, a representative from the Sponsor’s Clinical Quality Assuranc e (CQA) Department 
or designee may conduct periodic audits of the study processes, including, but not limited to, 
auditing the clinical site, laboratories, vendors and CROs, the clinical database, and the final 
study report. 
14.  DATA HANDLING AND RE CORD KEEPIN G 
This study will use web -based, electronic case report forms (eCRFs) developed through a 
validated, Electronic Records / Electronic Signatures -compliant platform (US Title 21  CFR Part 
11).  Foamix Clinical Data Management  department or designee will create the electronic CRFs 
and corresponding clinical database based on the final protocol. 
All site personnel who will be using this system will receive formal training on the system, after 
which each person will be issued a unique user name and password.  Only the person who owns 
the user name and password will enter the system using that user name and password.  For data 
security reasons and to be in compliance with regulatory guidelines, usernames and passwords 
are not transferable.  
The Investigator is responsible for all data entered via the eCRFs and must confirm the accuracy 
of the data by electronically approving (signing) the eCRFs.  This responsibility includes the 
timely completion and accuracy of the data entered into the eCRFs by their site personnel as well 
as the review of some  data entered directly into the database (eg, clinical laboratory results) by 
an external vendor.  The Sponsor will review the database to identify data errors or 
inconsistencies, which will be posted in the RDC system as queries for resolution. In addition, 
the Sponsor may make obvious corrections to the data in the database (eg, obvious errors in dates) and so inform the Investigator without issuing a query to the site. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 51 of 67 
 
 CONFIDENTIAL   15.  REFERENCE LIST  
1. Brown SK, Shalita A R; Acne Vulgaris, Fol licutitis, and Acne Rosacea. Lancet 
351:1871-76, 1998 
2. Guidance for Industry: “Acne Vulgaris: developing Drugs for Treatment ” Se ptember 
2005 FDA Draft Guidance 
 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 52 of 67 
 
 CONFIDENTIAL   16.  APPENDICES  
16.1.  Appendix 1 – Subjects Satisfaction Questionnaire  
 
The following 8 questions will be asked of the subject at Visit 6, Week12 and Visit 13, Week 52: 
1. How satisfied are you with this product in  treating your acne? 
2. How satisfied are you with how easy this product is to use? 
3. How satisfied  are you with this product compared to other products you have previously 
used for acne, such as gels and creams ? 
4. How satisfied are you with how this product feels on your skin after treatment? 
5. How satisfied are you with  the odor of this product after treatment ? 
6. How satisfied are you with  the color of this produ ct after treatment ? 
7. Overall, how satisfied  are you with this product? 
8. Overall, how likely are  you to recommend this product to a friend? 
 
Answers to Questions 1-7 will be selected from the following:  
1=Very Satisfied  
2=Satisfied 
3=Somewhat Satisfied  
4=Dissatisfied 
5=Very Dissatisfied  
 
Answer to Question 8 will be selected from the following: 1=Very Likely 
2=Likely 
3=Somewhat Likely 
4=Unlikely 
5=Very Unlikely 
 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 54 of 67 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
6.  Study 
Procedures Inserted Procedures at the 
Screening Visit will include 
obtaining blood and urine 
samples for clinical 
laboratory tests.  These 
results must be no more 
than 30 days old at the time of Baseline Visit  
randomization. Clarification of timing of 
laboratory tests during 
Screening 
6.  Study 
Procedures – 
Table 1 Inserted “X” for Tolerability 
Assessment at all post -
Baseline visits  Added at request of FDA  
“X” for Blood and urine 
samples at Baseline  “X” for Blood and urine 
samples at Screening  Sampling moved to earlier 
timepoint 
Inserted “X” for Blood and urine 
samples at Week 3  Added at request of FDA  
Inserted  “X” for Dispense study drug 
at Week 1 Correction  
Inserted “X” to Confirm next visit  Correction 
Footnote inserted  Footnote 6  -  Home 
pregnancy tests will be 
dispensed to all  female 
subjects at risk of becoming pregnant and 
will be performed 
whenever there is a suspicion of pregnancy 
(e.g., a missed period)  Added at request of FDA  
6.  Study 
Procedures – Table 1 
Footnote 2 If a subject prematurely 
withdraws from the study, all evaluations described 
under Visit 6/Week 12 must be performed.   Subject may continue into 
open-label phase of study. 
If a subject is not 
continuing into open -label 
phase for any reason (see 
Section 4.1.2), all 
evaluations described under 
Visit 6/Week 12 must be 
performed.   Clarification of process at 
Visit 6 
6.1 – 6.2   Study 
Procedures 
at Visits 3 – 14 Record AEs  Record AEs and 
Tolerability Assessments  Changed at all post -Baseline 
Visits at request of FDA  
6.1.1  Screening 
Visit Using the Interactiv e Web 
Response system (IWRS),  
assign the subject a . . .  Assign the subject a  . . .  Screening number will not 
be assigned by IWRS  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 55 of 67 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
Inserted  •   Collect blood and urine 
samples for clinical 
laboratory tests . . .  Lab tests moved from 
Baseline to Screening Visit 
6.1.2  Baseline 
Visit, Visit 1 • Confirm eligibility  none Deleted repetition  
• Collect blood and urine 
samples for clinical 
laboratory tests . . . deleted Lab tests moved from 
Baseline to Screening Visit  
6.1.3    Visit 2, 
Week 1  Inserted  • Dispense 1 kit (2 
canisters) of study drug  Correction 
6.1.4. Visit 3, 
Week 3 inserted • Collect blood and urine 
samples for clinical . . .  Added per FDA request  
• Confirm that subject 
continues to use the drug product and only provided 
cleanser correctly  Deleted Redundant 
6.1.7. Visit 6, 
Week 12  End of Double -Blind or 
Early Termination   End of Double -Blind or 
Continuation in Open 
Label / Early Termination   Title changed for clarity  
6.2   Part 2 – 
Open-label  Table 
2 Footnote inserted  Footnote 3  -  Home 
pregnancy tests will be 
dispensed to all female 
subjects at risk of becoming pregnant and 
will be performed 
whenever there is a 
suspicion of pregnancy 
(e.g., a missed period)  Added at request of FDA  
Inserted “X” for Tolerability 
Assessment at all pos t-
Baseline visits  Added at request of FDA  
Inserted “X” for Blood and urine 
samples at Week 28  Added at request of FDA  
6.2.1   Visit 7 – 
Week 16 Dispense 1 kits (2 canisters) 
of FMX-101, 4% 
minocycline foam if required  Dispense 2 kits (4 canisters) 
of FMX-101, 4% 
minocycline foam if required  Correction 
6.2.2  Visit 9, 
Week 28 inserted • At Visit 9 (Week 28) only 
– Collect blood and urine . 
. . Added per FDA request  
7.1.3.1  Part 1 – 
Double-blind none After shaking the canister 
well . . . Added text to include 
instruction to shake  
 . . .supplies will be 
dispensed at Baseline and 
Weeks 3, 6 and 9 . . . . . . supplies will be 
dispensed at Baseline and 
Weeks 1, 3, 6 and 9 . . . Correction 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 56 of 67 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
7.1.5  Labeling of 
Study Drug none “Shake well before using”  Added text to label about 
shaking  
7.1.6  Storage of 
Drug FMX-101, 4% and vehicle 
canisters must be stored at 
20°C – 25°C  . . . FMX-101, 4% and vehicle 
canisters must be stored at 
2°C – 8°C until being 
dispensed to the subjects.  
Subsequently, they must be 
stored at 20°C – 25°C . . . Inclusion of instruction that 
site must keep drug refrigerated until it is 
dispensed 
7.2   Study Drug 
Accountability Inserted 
 In addition, the weight of 
each canister will be 
determined prior to being 
dispensed to the subjects 
and each canister that has been retrieved from the 
subject will be returned to 
the vendor to be weighed  Added per FDA request  
7.7  Prior and 
Concomitant 
Therapy  Inserted 
 If a subject is taking 
anticoagulant therapy, the 
subject should be advised that they may require a 
downward adjustment of 
their anticoagulant dosage.  Tetracyclines may decrease 
plasma prothrombin activity 
7.8  Use of 
Contraception • Hormonal methods  
o Oral contraceptives  
. . . birth control must be 
utilized in subjects using 
topical contraceptives) • Hormonal methods  
o Oral contraceptives  
. . . birth control must be utilized in subjects using 
oral contraceptives)  Correction 
8.1.1  IGA 
Table 3 See a) below See b) below Removal of quantitative 
description of non-
inflammatory lesions  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 57 of 67 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
8.1.2  Lesion 
counts Facial lesion counts . . . 
Inflammatory lesions 
(pustules, papules, and nodular lesions) and 
noninflammatory lesions 
(open and closed comedones) will be counted 
for each area and recorded 
separately.  The totals of 
inflammatory and non-
inflammatory lesions will 
be calculated from these 
regional lesion counts .   
Lesion counts will be repeated at Weeks 3, 6, 9 and 12. Totals do not need 
to be calculated at these 
visits. Facial lesion counts  . . .  
Total inflammatory lesions 
(pustules, papules, and 
nodular lesions) and 
noninflammatory lesions 
(open and closed comedones) will be counted 
and recorded separately.   
Lesion counts will be 
repeated at Weeks 3, 6, 9 
and 12.  Counting method modified 
and addressed in Data 
Management Plan  
9.2  Medication 
History A history of medication 
usage . . . medications in the 
last 3 months (6 months for 
acne medications)  will be 
recorded. A history of medication 
usage . . . medications in the last 3 months w ill be 
recorded. Consistency with Section 
6.1.1. 
9.4  Vital Signs Heart rate and blood 
pressure will be measured at 
all visits.   Heart rate and blood 
pressure will be measured at 
all post-Baseline visits.   Correction 
9.8.1   Method of 
Determining 
Adverse Events  inserted •  Developed unusual 
headaches or changes in 
vision Queried at each visit as per 
FDA request 
9.8.3.  Reporting 
Adverse Events  Any serious AEs . . . must be 
reported to the Sponsor 
within . . . Any serious AEs . . . must be 
reported to the Sponsor or 
designee within . . . Correction of omi ssion 
10.2  
Determination of 
Sample Size  None See text at c) below  Modified as per FDA 
suggestion 
10.4.1  Primary 
Efficacy 
Endpoints  IGA score at Week 12 
(where success is defined as 
at least a 2-grade decrease 
from Baseline) . Treatment Success 
(dichotomized as Yes/No) 
at Week 12, where success 
is defined as an IGA score 
of 0 or 1, and at least a 2-
grade improvement 
(decrease) from Baseline.    Modified as per FDA 
suggestion 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 58 of 67 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
10.4.2. Secondary 
Efficacy 
Endpoints 
 • The absolute change 
from Baseline in t he 
noninflammatory lesion 
count at Week 12  
• The absolute change 
from Baseline in the 
inflammatory lesion count and IGA at the interim visit 
at Week 9 
• The absolute change 
from Baseline in the 
noninflammatory lesion count at Week 9  
• The absolute change 
from Baseline in the 
inflammatory lesion count and IGA Treatment Success 
at the interim visit at Week 6  
• The absolute change 
from Baseline in the noninflammatory lesion 
count at Week 6  • The absolute change 
from Baseline in the 
noninflammatory lesion 
count at Week 12 
• The absolute change 
from Baseline in the 
inflammatory lesion count and IGA Treatment 
Success at the interim visit 
at Week 9 
• The absolute change 
from Baseline in the inflammatory lesion count 
and IGA Treatment 
Success at the interim visit 
at Week 6 Modified as per FDA 
suggestion 
10.4.3. Tertiary 
Efficacy Endpoints 
 • The percent change from 
Baseline in the inflammatory lesion count at Weeks 3, 6, 9 
and 12 
• The percent change 
from Baseline in the noninflammatory lesion 
count at Weeks 3, 6, 9 and 
12 
• The absolute change 
from Baseline in the 
inflammatory and 
noninflammatory lesions, 
and the dichotomized IGA 
score, (where success is 
defined as at least a 2-
grade decrease from 
Baseline), at Week 3 
• The percent change from 
Baseline in the 
noninflammatory lesion 
count at Weeks 3, 6, 9 and 
12 • The percent change from 
Baseline in the inflammatory lesion count at Weeks 3, 6, 9 
and 12 
• The absolute change 
from Baseline in the inflammatory and 
noninflammatory lesions, 
and the IGA Treatment Success at Week 3 
• The absolute change 
from Baseline in the 
noninflammatory lesion 
count at Weeks 3, 6, and 9 
• The percent change from 
Baseline in the 
noninflammatory lesion 
count at Weeks 3, 6, 9 and 
12 Modified as per FDA 
suggestion 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 59 of 67 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
10.6.3 Efficacy 
Analysis The co-primary endpoint of 
at least a 2-grade 
improvement (decrease) 
from Baseline in the IGA 
score at Week 12 will be 
analyzed . . . overall IGA 
response rates  are less than 
10% . . . on the difference in 
IGA success rates between 
FMX-101 4% and vehicle.  The co-primary endpoint of 
IGA Treatment Success 
rate at Week 12 will be 
analyzed . . . overall IGA 
Treatment Success rate is 
less than 10%  . . . on the 
difference in IGA 
Treatment Success rates 
between FMX -101 4% and 
vehicle. Modified as per FDA 
suggestion 
. . .Testing of secondary 
efficacy endpoints at an 
earlier timepoint for each 
type of lesion and IGA w ill 
be performed only if 
superiority (one-sided 
p<=0.025) is seen at the later 
timepoint. .  Testing of secondary 
efficacy endpoints at an 
earlier timepo int for each 
type of lesion and IGA 
Treatment Success will be 
performed only if superiority 
(one-sided p<=0.025) is seen 
at the later timepoint.  Modified as per FDA 
suggestion 
11.1  Monitoring  Monitoring visits will apply 
place . . . Monitoring visits wil l take 
place Correction  
 . . . Sponsor . . .  . . . Sponsor or Sponsor’s 
representative . . . Multiple corrections  
 
  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 60 of 67 
 
 CONFIDENTIAL   a)  Old Table 3 – IGA Scale 
 
Table 3: IGA Scale for Acne Vulgaris  
Score Grade Description 
0 Clear Normal, clear skin with no evidence of acne vulgaris 
 
1  
Almost clear Rare noninflammatory  lesions present; rare (eg, <5) non-inflamed papules 
(papules must be resolving and may be hyperpigmented,  though not pink-
red) 
2 Mild Some noninflammatory lesions are present; few (eg, <10) inflammatory  
lesions (papules/pustules  only; no nodulocystic  lesions) 
 
3  
Moderate Many noninflammatory  lesions; multiple (eg, between 25 and 40) 
inflammatory lesions present; many papules/pustules;  there may or may not 
be a few nodulocystic lesions 
4  Severe Inflammatory lesions predominate,  many papules/pustules  (eg, between 40 and 75); 
there may be a few nodulocystic lesions 
5 Very Severe Highly inflammatory  lesions predominate,  variable number of comedones, many 
papules/pustules  and many nodulocystic lesions 
 
b)  New Table 3 – IGA Scale 
 
Table 3: IGA Scale for Acne Vulgaris  
Score Grade   Description 
0 Clear Normal, clear skin with no evidence of acne vulgaris 
 
1  
Almost clear Rare noninflammatory  lesions may be present, with rare non-inflamed papules 
(papules must be resolving and may be hyperpigmented,  though not pink- red) 
2 Mild Some noninflammatory lesions are present, with few inflammatory lesions 
(papules/pustules  only; no nodulocystic lesions) 
 
3   
Moderate Many noninflammatory  lesions.  Multiple inflammatory lesions evident with 
several to many papules/pustules,  and there may be one small nodulocystic lesion 
4 Severe Inflammatory lesions are more apparent, many comedones and papules/pustules,  
there may be a few nodulocystic lesions 
5  Very Severe Highly inflammatory lesions predominate,  variable number of comedones, many 
papules/pustules  and many nodulocystic lesions 
 
 
c)  Inserted in Section 10.2 
Another consideration for the sample size must be given to the secondary endpoint of 
noninflammatory lesions which will be compared to the vehicle for non-inferiority. The margin 
for non-inferiority will be 30% of the change from baseline to week 12. In a phase 2 study, 
change from baseline in noninflammatory lesions at week 9 was 22.8 for the vehicle group with a standard deviation of 18. Assuming approximately the same reduction at week 12, a 30% non-
inferiority margin is about 6.8 lesions. The following table provides approximate sample sizes 
for alternate assumptions for 90% power to show non- inferiority. 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 61 of 67 
 
 CONFIDENTIAL   Vehicle mean 
noninflammatory 
lesion reduction Minocycline 4% foam 
mean noninflammatory 
lesion reduction Sample sizes 
(vehicle, active)  
   
   
   
 
If Minocyclin e 4% foam has the same effect on noninflammatory lesions as vehicle,  subjects 
on vehicle and  on 4% foam will be needed for 90% power to show non- inferiority. If 
Minocycline 4% foam has a slightly less effect on noninflammatory lesions (  lesion 
reduction versus  in vehicle), there will be about 90% power to show non- inferiority. 
16.2.2. Amendment 2 , effective April 6, 2016 
The following is the summary of the changes that were made to Protocol FX2014-05 Version 2 
issued February 26, 2016. 
 
Section Revision Rationale 
Old Text New Text  
5.2 Exclusion Criteri a 2. Dermatological condition 
of the face or facial hair 
(eg, beard, sideburns, 
mustache) that could 
interfere with the clinical evaluations  2. Acne conglobata, acne 
fulminans, secondary acne (chloracne, drug 
induced acne) or any 
dermatological condition .  Specific exclusions added 
for clarity 
6. Study Procedures  
Table 1: Schedule of 
Procedures 
 
 
  
 
 
 
 Footnote 3 
 
 Urine pregnancy test 
(females, only) Urine pregnancy test 
(females of childbearing 
potential only)  Clarification  
Inserted “X” for pregnancy tests to 
be performed at Week 3, 6 
and 9 Modified per FDA  
Inserted New line and “X” for 
Subject Satisfaction 
Questionnaire for Week 12  Procedure added  
. . . This visit and  the 
procedures required at this 
visit can be combined with 
Screening. . . . . . The procedures required 
at these visits can be 
combined . . . Clarification  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 62 of 67 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
 
Footnote 6 Home pregnancy tests will 
be dispensed to all female 
subjects at risk of becoming 
pregnant and will be 
performed whenever there 
is a suspicion of pregnancy 
(e.g., a missed period)  Perform urine pregnancy 
test at indicated visits.  Also dispense home urine 
pregnancy test at Week 12 
if subject is continuing 
into open-label treatment  Modified per FDA  
6.1.2. Baseline Visit, 
Visit 1 
 . . . This visit and  the 
procedures required at this 
visit can be combined with 
Screening. . . . . . The procedures required 
at this visit can be 
combined with Screening . . 
. Clarification 
Perform urine pregnancy 
test Perform urine pregnancy 
test in females of 
childbearing potential  Clarification 
6.1.4. Visit 3, Week 3;  
6.1.5. Visit 4, Week 6; 6.1.6. Visit 5, Week 9 Inserted 
 Perform urine pregnancy 
test in females of childbearing potential  Modified per FDA  
6.1.7. Visit 6, Week 12  Collect a urine sample from 
female subjects for a urine 
pregnancy test  Perform urine pregnancy 
test in females of 
childbearing potential  Clarification 
Inserted • Administer Subject 
Satisfaction 
Questionnaire  Procedure added  
• If subject is continuing  
. . . dispense 1 kit ( 2 
canisters) of FMX -101 . . . • If subject is continuing 
. . . dispense 2 kits (4 canisters) of FMX-101 . Correction 
6.2 Part 2 – Open-label 
Table 4: Schedule of 
Procedures  
 
  
Footnote 3  
 
 
 Inserted “X” for pregnancy tests to 
be dispensed at Weeks 16, 
22, 28, 34, 40 and 46.  Modified per FDA  
Inserted New line and “X” for 
Subject Satisfaction 
Questionnaire for Week 52  Procedure added  
Home pregnancy tests will 
be dispensed to all female 
subjects at risk of becoming 
pregnant whenever . . . Home pregnancy tests will 
be dispensed at each visit  
to all female subjects of 
childbearing potential  and 
will be performed at least 
monthly and whenever . . . 
Perform urine pregnancy 
test at Final Visit.  Modified per FDA  
 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 63 of 67 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
6.2.1. Visit 7, Week 16  Inserted 
 Dispense Home 
pregnancy kit to all 
female subjects of 
childbearing potential  Modified per FDA  
 
6.2.2. Visits 8 – 12, 
Weeks 22 – 46 Inserted 
 Dispense Home 
pregnancy kit to all 
female subjects of 
childbearing potential  Modified per FDA  
 
6.2.3. Visit 13, Final 
Visit – Week 52 Collect a urine sample from 
female subjects for a urine 
pregnancy test  Perform urine pregnancy 
test in females of childbearing potential  Clarification 
Inserted • Administer Subject 
Satisfaction Questionnaire  Procedure added  
7.1.3.1. Part 1 – 
Double-blind 
 After shaking . . . , a small 
amount of foam should be 
expressed . . . . additional 
amounts of foam should 
also be applied . . 
.approximately the same time each day preferably in 
the evening. After shaking . . .a small 
amount of foam  (about 1/2 
gram or a cherry-sized 
amount) should be expressed . . .  additional 
amounts (up to a total of 
4g) of foam should also be 
applied . . .the same time each day preferably in the 
evening at bedtime. Clarification of amounts 
and timing 
8.3. Subject 
Satisfaction Questionnaire  
 Inserted A satisfaction 
questionnaire will be administered at Visit 6, Week 12 and Visit 13, 
Week 52 (see Section 16.1, 
Appendix 1).  Procedure added  
9.6. Clinical 
Laboratory Tests  Serum chemistry, 
hematology and 
urinalysis will be evaluated at Baseline , 
Week 12 and Final Visit.
 Serum chemistry, 
hematology and urinalysis will be evaluated at Baseline, Week 12/ Final Visit of 
the double-blind phase 
of the Study, and at Week 28 and Week 52/Final Visit of the open-label phase of the 
Study. Modified per FDA 
 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 64 of 67 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
9.6.1. Urine Pregnancy 
Test A urine sample will be 
collected from all female 
subjects for a urine 
pregnancy test at Baseline, 
Week 12 and Final Visit or 
when a subject prematurely 
withdraws from the study. A urine pregnancy test 
will be performed on all females of childbearing 
potential at Baseline, 
Week 3, Week 6, Week 9 
and Week 12 of the 
double-blind phase of the 
Study and Final Visit or 
when a subject prematurely withdraws from the study. 
Home pregnancy kits will be provided at each visit to all female subjects of 
childbearing potential  in 
the open-label phase of 
the Study and are to be used at least monthly and 
if a pregnancy is 
suspected between visits 
(e.g., if a subject misses a 
period). A urine 
pregnancy test will be 
performed at Week 52/ 
Final Visit. Modified per FDA  
 
9.7.1. Tolerability  . . pigmentation . . .  . . .hyperpigmentation . . .  Correction 
9.8.4. Adverse Event 
Follow-up Adverse events that are 
ongoing when a subject withdraws from or 
completes the study will be 
followed until reso lution or 
stabilization (in the opinion 
of the Investigator), or for 
30 days, whichever is 
shorter.   Adverse events, and 
tolerability signs and 
symptoms greater than 
zero (0), that are ongoing 
when a subject withdraws 
from or completes the study will be followed until 
resolution or stabilization (in the opinion of the 
Investigator), or for 30 
days, whichever is shorter.   Modified as per FDA 
suggestion 
9.8.4.1. Pregnancy 
reporting A urine pregnancy test will 
be performed . . . at 
Baseline and 
Week 12/Final Visit of the 
double-blind phase of the Study or when a subject 
prematurely withdraws . . . A urine pregnancy test will 
be performed . . .at Baseline, Week 3, Week 6,  
Week 9 and Week 12/Final 
Visit of the double-blind 
phase of the Study or when 
a subject prematurely 
withdraws . . .  Modified as per FDA 
suggestion 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 65 of 67 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
Home pregnancy kits will 
be provided to all female 
subjects at risk of becoming 
pregnant and are to be used 
if a pregnancy is suspected 
between visits (e.g., if a 
subject misses a period).  
 Home pregnancy kits will 
be provided to all female subjects of childbearing 
potential in the open- label 
phase of the Study and are 
to be used at least monthly 
and if a pregnancy is 
suspected between visits 
(e.g., if a subject misses a 
period). A urine pregn ancy 
test will be performed at 
Final Visit. 
10.3 Analysis 
Populations • Have not been 
compliant with the dosing regimen (ie, subjects 
missed more than 5 
consecutive days of dosing 
and took less than 80% of 
expected doses)  • Have not, in the 
opinion of the investigator, been 
compliant with the 
treatment regimen (e.g. 
reported frequent missed 
doses) Modify definition of Per 
Protocol Population 
10.6.3  Efficacy 
Analysis Non-inferiority margin is 
defined as 40% of the 
noninflammatory lesion reduction in the vehicle 
group at Week 12  Non-inferiority margin is 
defined as 30%  of the 
noninflammatory lesion reduction in the vehicle 
group at Week 12  Correction 
16.1.  Appendix 1 – 
Subjects Satisfaction 
Questionnaire  Inserted See Appendix 1 (p.52) Procedure added  
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 66 of 67 
 
 CONFIDENTIAL    
16.2.3. Amendment 3 , effective October 14 , 2016 
The following is the summary of the changes that were made to Protocol FX2014-05 Version 3 
issued April 6, 2016. 
Section Revision Rationale 
Old Text New Text  
1. Synopsis Subjects who suc cessfully 
complete the 12 -week 
double blind portion of the 
study will be offered . . .  Subjects who successfully 
complete the 12 -week 
double blind portion of the study may be offered . . . Not all subjects will be 
eligible to continue  
1.7.2. Part 2 – Open-
label  At the Week 12 Visit, 
subjects may be invited to 
continue into the open- label 
part of this study . . .   At the Week 12 Visit, 
subjects whose IGA score 
has not worsened may be 
invited to continue into the open-label part of this study 
. . . Minimize risk of 
prolonging ineffective treatment 
4.1.2. Part 2 – Open-
label 
1.7.2. Part 2 – Open-
label  
 Subjects may be 
discontinued from the study at any time if their disease 
becomes refractory  . . . Subjects may be 
discontinued from the study 
after 12 weeks if their 
disease becomes refractory  
. . . Avoid prolongation of 
ineffective therapy  
4.1.2. Part 2 – Open-
label 
6.1.2.Baseline Visit 1  
6.1.3 Visit 2, Week 1 6.1.4 Visit 3, Week 3  
6.1.5 Visit 4, Week 6  
6.1.6 Visit 5, Week 9  
6.1.7 Visit 6, Week 12 
End of Double-Blind 
or Continuation in 
Open Label / Early 
Termination ·  Schedule/confirm the 
next study visit and remind 
subject to avoid 
overexposure to sunlight  ·  Schedule/confirm the 
next study visit and remind 
subject to avoid 
overexposure to natural or 
artificial sunlight  Remind subjects in 
double-blind phase of 
study to avoid exposure 
overexposure to natural and artificial sunlight  
6.2.1  Visit 7 
 · Schedule/confirm the next 
study visit  ·  Schedule/confirm the 
next study visit  and 
remind subject to  avoid 
overexposure to natural or artificial sunlight  Remind subjects in open -
label phase of study to 
continue to avoid overexposure to natural 
and artificial sunlight. 6.2.2  Visits 8 - 12 
FO AMI X          FMX-101, 4%     Protocol FX2014-05 Version 4   Page 67 of 67 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
7.7  Prior and 
Concomitant Therapy   Inserted Benzoyl peroxid e (e.g., 
Pro-Activ, Clearasil) can 
inactivate minocycline 
and may thus decrease the effectiveness of FMX -101 
if the two products are applied at the same time. 
Treated areas should be 
washed between applications of FMX -101 
and products containing benzoyl peroxide.  
Preferably, the products should be applied no less 
than 8 hours apart.  Minimize potential for 
drug interaction 
9.8.1  Method of 
Determining Adverse 
Events All questions should be of a 
general nature and should not suggest symptoms. With the excep tion of the 
last item above,  all 
questions should be of a general nature and should 
not suggest symptoms. Reminder that these AEs 
should be actively 
questioned. 
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 1 of 65 
 
 CONFIDENTIAL     
 
CLINICAL STUDY PROTOCOL   
Title: A Randomized, Double -Blind Study to Compare the Efficacy, 
Safety and Long-Term Safety of Topical Administration of 
FMX-101 for 1 Year in the Treatment of Moderate -to-Severe Acne 
Vulgaris, Study FX2014-05  
Development Phas e: 3 
Project Number:  FMX-101 
Study drug(s): FMX-101, minocycline foam 4%; matching vehicle foam  
Indication: Acne vulgaris  
Authors:  
Protocol Number:  FX2014-05  
Version  3 
Date of Protocol: April 6, 2016 
Supersedes Version 2 of February 26, 2016  
 
 
This Protocol is the property of Foamix Pharmaceuticals, Inc.  This Protocol must be kept in a 
confidential manner, and may only be used in connection with the clinical study.  It must be 
returned on request.  No part of this Protocol may  be reproduced or transmitted in any form 
without written permission of Foamix Pharmaceuticals, Inc.  If you are not authorized to receive 
this document, please return it immediately to: 
Foamix Pharmaceuticals, Inc. 520 U.S. Hwy 22, Suite 305  Bridgewater,  NJ 08807 
 
 
PPD
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 3 of 65 
 
 CONFIDENTIAL   1.  SYNOPSIS 
This is a Phase 3 study to evaluate the efficacy, safety and long -term safety of the topical 
administration of FMX -101, 4% minocycline foam for the treatment of moderate -to-severe acne 
vulgaris.  The f irst 12 weeks of the study involves  randomized, double -blind treatment with 
active FMX-101, 4% or matching vehicle.  Subjects who successfully complete the 12 -week 
double blind portion of the study will be offered the opportunity to continue in the trial for up to 
an additional 40 weeks (for a total of 1 year) and receive open -label treatment wi th 
FMX-101, 4%. 
1.1.  Investigational Product , Dosage, and  Mode of Administration  
The investigational product is FMX-101, minocycline foam 4% .  FMX-101 4% will be applied 
topically daily for the 12-week treatment duration of the study.  
1.2.  Active Ingredient  
The active ingredient is minocycline HCl . 
1.3.  Reference Product,  Dosage, and Mode of Administration  
The reference product is vehicle foam.  Vehicle foam  will be applied topically daily f or the  
12-week treatment duration of the study.  
1.4.  Study Centers  
Approximately 30 study centers will participate in this study.  
1.5.  Study Period 
Estimated date first subject enrolled: April 2016 
Estimated date last subject completed: August 2017 
1.6.  Study Objective s 
The objective s of this study are: 
  To evaluate the efficacy in the treatment of acne compared to vehicle of topical FMX -
101, 4% admini stered daily for 12 weeks  
  To evaluate the safety compared to vehicle of topical FMX -101, 4% administered 
daily for 12 weeks  
  To evaluate the long -term safety of topical FMX -101, 4% administered daily for up to 
40 additional weeks  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 4 of 65 
 
 CONFIDENTIAL   1.7.  Methodology  
The study will have 2 parts.  The first will involve 12 weeks of double-blind treatment with 
FMX-101, 4% or vehicle foam.  The second will involve up to 40 additional weeks of open-label 
treatment with FMX -101, 4% of subjects who complete the first part of the study.  
1.7.1.  Part 1 – Double-blind Period  
This is a randomized, multicenter, double -blind, vehicle -controlled, 2-arm study to evaluate the 
safety and efficacy over 12 weeks of FMX -101 minocycline foam, 4%, compared to vehicle, in 
the treatment of subjects with moderate to  severe facial acne vulgaris.  
Qualified subjects will be randomized to receive 1 of the following 2 treatments:  
  FMX-101, 4%  minocycline foam  
  Vehicle foam 
Subjects with qualifying lesion counts (Section 8.1.2) and Investigator’s Global Assessments  
(IGA, Section 8.1.1) of acne severity scores and will be assigned to 1 of 2 treatments according 
to the randomization schedule.  Subjects will apply the assigned study drug to pically once daily 
for 12 weeks as directed.  Subjects will be advised to apply the study drug at approximately the 
same time each day, preferably in the evening at bedtime.  Both the Investigator and subject will 
be blinded to the study drug identity.  
Subjects will return for visits at Weeks 1, 3, 6, 9, and 12 . At the discretion of the clinic staff, for 
the convenience of subjects or clinic staff, visits can be scheduled to occur 3 days before or after 
the nominal schedule date  for the Weeks 1, 3 and 6 vis its and 7 days before or after for the 
Weeks 9 and 12 visits .  Efficacy evaluations (acne lesion counts and IGAs will be performed at 
Weeks 3, 6, 9, and 12 during the study.  Other assessments will be performed as described in  
Section 9.  
1.7.2.  Part 2 – Open-label  
At the Week 12 Visit, subjects  may be invited to continue into the open -label part of this study 
for an additional 9 months of treatment.  Subjects will be enrolled in this phase of the study until 
a total of approximately 400 subjects from  Studies FX2014 -04 and FX2014-05 have elected to 
continue in the open -label portion of their respective study.  Subjects  who elect to continue into 
the open-label part of this study will receive supplies of active FMX -101, 4% minocycline f oam.   
Treatment during this part of the study will be guided by each subject’s clinical response.  The 
Investigator may elect to suspend treatment of some or all areas if there is clinical improvement 
or resolution of the acne in those areas.  Even if the  treatment is partially or completely 
temporarily suspended, the subject will be continued in the study and will make all scheduled 
clinic visits.  If at any time the acne recurs or worsens, treatment of the affected areas may be 
resumed.  
Subjects may be discontinued from the study at any time if their disease becomes refractory or 
they become intolerant of the product.   
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 5 of 65 
 
 CONFIDENTIAL   1.8.  Number of Subjects  
The planned enrollment is 450 subjects.  Subjects will be randomized to active or vehicle in a 2:1 
ratio.  Approximately 300 and 150 subjects will be assigned to the FMX-101, 4% or vehicle 
treatment groups, respectively.  
1.9.  Diagnosis and Main Criteria for Inclusion  
Subjects are to be at least 9 years of age. 
Eligible subjects are to have a diagnosis of facial acne vulgaris characterized by (subjects are 
permitted to also have acne on other parts of the body) : 
  20 to 50 inflammatory lesions (papules, pustules, and nodules)  
  25 to 100 noninflammatory lesions (open and closed comedones)  
  No more than 2 nodules on the face  
  Investi gator’s Global Assessment (IGA) score of moderate (3) to severe (4)  
1.10.  Criteria for Evaluation  
1.10.1.  Efficacy 
The efficacy assessments will include  the IGA and lesion counts at Baseline and Weeks 3, 6, 9 
and 12.  
1.10.2.  Safety 
The safety assessments in this study are phys ical examinations, vital signs, assessment of the 
skin at application site(s), adverse events (volunteered, observed, and elicited by general 
questioning in a non -suggestive manner), and clinical laboratory test results.  
1.11.  Statistical Methods  
Efficacy analys es will be conducted on the Intent -to-Treat (ITT) population, using the last -
observation-carried-forward (LOCF) approach to impute missing values.  Supportive efficacy 
analyses will also be conducted on the Per Protocol (PP) population, with no imputation for 
missing values.  The co -primary efficacy endpoints are the absolute change from Baseline in the 
inflammatory lesion count at Week 12 IGA Treatment Success (dichotomized as Yes/No) at 
Week 12, where success is defined as an IGA score of 0 or 1, and at l east a 2-grade decrease 
from Baseline .  FMX-101 4% will be tested against vehicle at the two-sided 0.05 level of 
significance without adjustment for multiplicity.  The absolute change from Baseline in 
inflammatory lesions at Week 12 will be analyzed using an Analysis of Covariance (ANCOVA) 
model with main effect treatment and investigational site as a covariate.  The IGA Treatment 
Success rates will be compared between the treatment groups  using a Cochran –Mantel –Haenszel 
(CMH) test stratified for investigational site. 
No statistical tests will be performed for any of the safety assessments.  
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 6 of 65 
 
 CONFIDENTIAL   TABLE OF CONTENTS , LIST OF TABLES, AN D LIST OF FIGURES  
 
1.  SYNOPSIS ................................ ................................ ................................ ...................3  
1.1.  Investigational Product, Dosage, and Mode of Administration  ................................ ...3  
1.2.  Active Ingredient  ................................ ................................ ................................ ..........3  
1.3.  Reference Product, Dosage, and Mode of Administration  ................................ ...........3  
1.4.  Study Centers  ................................ ................................ ................................ ................3  
1.5.  Study Period................................ ................................ ................................ ..................3  
1.6.  Study Objectives  ................................ ................................ ................................ ...........3  
1.7.  Methodology ................................ ................................ ................................ .................4  
1.7.1.  Part 1 – Double-blind Period ................................ ................................ ........................ 4  
1.7.2.  Part 2 – Open-label ................................ ................................ ................................ .......4  
1.8.  Number of Subjects  ................................ ................................ ................................ ......5  
1.9.  Diagnosis and Main Criteria f or Inclusion ................................ ................................ ...5  
1.10.  Criteria for Evaluation  ................................ ................................ ................................ ..5  
1.10.1.  Efficacy ................................ ................................ ................................ ......................... 5  
1.10.2.  Safety ................................ ................................ ................................ ............................ 5  
1.11.  Statistical Methods  ................................ ................................ ................................ ........5  
TABLE OF CONTENTS, L IST OF TABLES, AND L IST OF FIGURES  ................................ ....6  
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS ................................ ................12  
STUDY ADMINISTRATIVE  STRUCTURE  ................................ ................................ ...............13  
2.  INTRODUCTION  ................................ ................................ ................................ ......14  
3.  STUDY OBJECTIVES  ................................ ................................ .............................. 14  
4.  INVESTIGATIONAL PLAN  ................................ ................................ .....................14  
4.1.  Overall Study Design  ................................ ................................ ................................ ..14  
4.1.1.  Part 1 – Double-blind ................................ ................................ ................................ ..15  
4.1.2.  Part 2 – Open-label ................................ ................................ ................................ .....15  
4.2.  Rationale for Study Design and Dose Selection  ................................ ......................... 15  
5.  STUDY POPULATION  ................................ ................................ ............................. 16  
5.1.  Inclusion Criteria  ................................ ................................ ................................ ........16  
5.2.  Exclusion Criteria  ................................ ................................ ................................ .......16  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 7 of 65 
 
 CONFIDENTIAL   6.  STUDY PROCEDURES  ................................ ................................ ............................ 18  
6.1.  Part 1 – Double-Blind ................................ ................................ ................................ .20  
6.1.1.  Screening Visit  ................................ ................................ ................................ ............20  
6.1.2.  Baseline Visit, Visit 1  ................................ ................................ ................................ .20  
6.1.3.  Visit 2, Week 1  ................................ ................................ ................................ ...........21  
6.1.4.  Visit 3, Week 3  ................................ ................................ ................................ ...........21  
6.1.5.  Visit 4, Week 6  ................................ ................................ ................................ ...........22  
6.1.6.  Visit 5, Week 9  ................................ ................................ ................................ ...........22  
6.1.7.  Visit 6, Week 12 End of Double -Blind or Continuation in Open Label / 
Early Termination  ................................ ................................ ................................ .......23  
6.2.  Part 2 – Open-label ................................ ................................ ................................ .....24  
6.2.1.  Visit 7 - Week 16 ................................ ................................ ................................ ........25  
6.2.2.  Visits 8, 9, 10, 11 and 12 – Weeks 22, 28, 34, 40 and 46 ................................ ...........25  
6.2.3.  Visit 13, Final Visit – Week 52 ................................ ................................ ..................26  
7.  STUDY TREATMENTS ................................ ................................ ............................ 26  
7.1.  Treatments Administered  ................................ ................................ ............................ 26  
7.1.1.  Part 1 (double -blind) – Weeks 1 to 12  ................................ ................................ ........26  
7.1.2.  Part 2 (open-label) – Weeks 13 to 52  ................................ ................................ .........27  
7.1.3.  Dosing Instructions  ................................ ................................ ................................ .....27  
7.1.3.1.  Part 1 – Double-blind ................................ ................................ ................................ ..27  
7.1.3.2.  Part 2 – Open-label ................................ ................................ ................................ .....27  
7.1.4.  Manufacturer  ................................ ................................ ................................ ...............28  
7.1.5.  Labeling of Study Drug  ................................ ................................ .............................. 28  
7.1.6.  Storage of Study Drug  ................................ ................................ ................................ 28  
7.2.  Study Drug Accountability  ................................ ................................ ......................... 29  
7.3.  Handling and Disposal of Study Drug  ................................ ................................ ........29  
7.4.  Method of Assignment of Study Drug  ................................ ................................ ........29  
7.4.1.  Part 1 – Double- blind ................................ ................................ ................................ .29  
7.4.2.  Part 2 – Open-label ................................ ................................ ................................ .....29  
7.5.  Selection and Timing of Doses in the Study  ................................ .............................. 29  
7.6.  Blinding ................................ ................................ ................................ ...................... 30  
7.7.  Prior and Concomitant Therapy  ................................ ................................ ..................30  
7.8.  Use of Contraception  ................................ ................................ ................................ ..31  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 8 of 65 
 
 CONFIDENTIAL   7.9.  Treatment Compliance  ................................ ................................ ................................ 31  
8.  EFFICACY ASSESSMENTS  ................................ ................................ ....................32  
8.1.  Primary Efficacy Assessments  ................................ ................................ ...................32  
8.1.1.  Investigator Global Assessment Score (IGA)  ................................ ............................. 32  
8.1.2.  Lesion Counts  ................................ ................................ ................................ .............32  
8.2.  Photography ................................ ................................ ................................ ................33  
8.3.  Subject Satisfaction Questionnaire  ................................ ................................ .............33  
9.  SAFETY ASSESSMENTS  ................................ ................................ ........................ 33  
9.1.  Medical/Surgical History  ................................ ................................ ............................ 33  
9.2.  Medication History  ................................ ................................ ................................ .....33  
9.3.  Concomitant Medications  ................................ ................................ ........................... 34  
9.4.  Vital Signs ................................ ................................ ................................ ..................34  
9.5.  Physical Examination  ................................ ................................ ................................ .34  
9.6.  Clinical Laboratory Tests  ................................ ................................ ........................... 34  
9.6.1.  Urine Pregnancy Test  ................................ ................................ ................................ .35  
9.6.2.  Sample Collection, Storage, and Shipping  ................................ ................................ .35  
9.7.  Other Safety Measurements  ................................ ................................ ........................ 35  
9.7.1.  Tolerability ................................ ................................ ................................ .................35  
9.8.  Adverse Events  ................................ ................................ ................................ ...........36  
9.8.1.  Method of Determining Adverse Events  ................................ ................................ ....36  
9.8.2.  Adverse Event Definitions  ................................ ................................ .......................... 36  
9.8.2.1.  Adverse Events ................................ ................................ ................................ ...........36  
9.8.2.2.  Serious Adverse Events  ................................ ................................ .............................. 37  
9.8.2.3.  Severity of Adverse Events  ................................ ................................ ........................ 37  
9.8.2.4.  Relationship of Adverse Events to Study Treatments  ................................ ................38  
9.8.2.5.  Adverse Events Expectedness  ................................ ................................ ....................38  
9.8.3.  Reporting Adverse Events  ................................ ................................ .......................... 38  
9.8.4.  Adverse Event Follow -up ................................ ................................ ........................... 38  
9.8.4.1.  Pregnancy reporting  ................................ ................................ ................................ ....39  
9.8.5.  Clinically Significantly Abnormal Laboratory Results  ................................ ..............39  
9.9.  Appropriateness of Safety Measurement  ................................ ................................ ....39  
10.  STATISTICAL DESIGN A ND ANALYSIS  ................................ ............................. 40  
10.1.  Statistical Analysis Plan  ................................ ................................ ............................. 40  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 9 of 65 
 
 CONFIDENTIAL   10.2.  Determination of Sample Size  ................................ ................................ ....................40  
10.3.  Analysis Populations  ................................ ................................ ................................ ..41  
10.4.  Efficacy Endpoints  ................................ ................................ ................................ ......42  
10.4.1.  Primary Efficacy Endpoints  ................................ ................................ ........................ 42  
10.4.2.  Secondary Efficacy Endpoints  ................................ ................................ ....................43  
10.4.3.  Tertiary efficacy endpoints  ................................ ................................ ......................... 43  
10.5.  Safety endpoints  ................................ ................................ ................................ ..........43  
10.5.1.  Adverse Events  ................................ ................................ ................................ ...........43  
10.5.2.  Vital Signs ................................ ................................ ................................ ..................44  
10.5.3.  Physical Examinations  ................................ ................................ ................................ 44  
10.5.4.  Clinical Laboratory Results  ................................ ................................ ........................ 44  
10.6.  Statistical Analysis  ................................ ................................ ................................ ......44  
10.6.1.  Interim Analysis  ................................ ................................ ................................ ..........44  
10.6.2.  Subject Accounting, Demographic, and Baseline Characteristics  .............................. 44  
10.6.3.  Efficacy Analysis  ................................ ................................ ................................ ........44  
10.6.4.  Safety Analysis  ................................ ................................ ................................ ...........45  
11.  STUDY MANAGEMENT  ................................ ................................ ......................... 46  
11.1.  Monitoring ................................ ................................ ................................ ..................46  
11.2.  Protocol Amendments  ................................ ................................ ................................ 46  
11.3.  Protocol Deviations  ................................ ................................ ................................ ....47  
11.4.  Withdrawal of Subjects  ................................ ................................ ............................... 47  
11.5.  Termination of the Study  ................................ ................................ ............................ 48  
11.6.  Publication Policy  ................................ ................................ ................................ .......48  
12.  ETHICS ................................ ................................ ................................ ...................... 48  
12.1.  Conduct of the Study  ................................ ................................ ................................ ..48  
12.2.  Institutional Review Boards (IRB)  ................................ ................................ .............48  
12.3.  Written Informed Consent  ................................ ................................ .......................... 48  
12.4.  Subject Confidentiality  ................................ ................................ ............................... 49  
12.5.  Records Retention  ................................ ................................ ................................ .......49  
12.6.  Financing ................................ ................................ ................................ ....................50  
13.  QUALITY CONTROL AND QUALITY ASSURANCE  ................................ .........50  
14.  DATA HANDLING AND RE CORD KEEPING  ................................ ...................... 50  
15.  REFERENCE LIST  ................................ ................................ ................................ ....51  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 10 of 65 
 
 CONFIDENTIAL   16.  APPENDICES  ................................ ................................ ................................ ............52  
16.1.  Appendix 1 – Subjects Satisfaction Questionnaire  ................................ .....................52  
16.2.  Appendix 2 – Protocol Amendments  ................................ ................................ ..........53  
16.2.1.  Amendment 1  ................................ ................................ ................................ ..............53  
16.2.2.  Amendment 2  ................................ ................................ ................................ ..............61  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 11 of 65 
 
 CONFIDENTIAL   List of Tables 
Table 1: Schedule of Procedures - Study FX2014-05  – Part 1 ................................ .....................19  
Table 2: Schedule of Procedures - Study FX2014-05  – Part 2 ................................ .....................24  
Table 3: IGA Scale for Acne Vulgaris  ................................ ................................ ........................... 32  
 
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 12 of 65 
 
 CONFIDENTIAL   LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS 
 
Abbreviation  Definition 
AE Adverse event  
CFR Code of Federal Regulations  
CRF Case report form  
eCRF Electronic case report form  
EKG Electrocardiogram  
FDA Food & Drug Administration  
GCP Good Clinical Practice  
HEENT Head, eyes, ears, nose, and throat  
ICF Informed consent form  
ICH International Conference on Harmonization  
IGA Investigator’s Global Assessment  
IRB Institutional Review Board  
IWRS Interactive Web Response System (IWRS)  
LOCF Last-observation-carried-forward 
ITT Intent-to-treat 
MedDRA Medical Dictionary for Regulatory Activities  
OC Observed-Cases 
P. acnes Propionibacterium acnes  
PP Per protocol 
TEAE Treatment-emergent adverse event  
SAE Serious adverse event  
SOC System organ class  
 
 
 
 
 
 
 
 
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 13 of 65 
 
 CONFIDENTIAL   STUDY ADMINISTRATIVE  STRUCTURE  
Name Affiliation / Address /  
Telephone Number  Responsibility  
Foamix Pharmaceutica ls, Inc 520 U.S. Highway 22, Suite 305 
Bridgewater, NJ 08807  Sponsor 
TKL Research, Inc.  
 365 West Passaic Street, Suite 550  
Rochelle Park, NJ 07662  CRO 
 TKL Research, Inc.   
 TKL Research, Inc.   
 
PPD
PPD
PPD
PPD
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 14 of 65 
 
 CONFIDENTIAL   2.  INTRODUCTION  
Acne vulgaris is a common disease of both males and females , usually manifesting initially 
during adolescence.  The primary pathologic events are initiated in the pilo -sebaceous units , 
especially of sebaceous -gland-bearing areas of the face, chest, and back as a result of increased 
androgen stimulation initiated at adrenarche or puberty.   As a result of both abnormal 
keratinization of the infra -infundibular portion of the pilo -sebaceous follicle and increased 
sebum produced in the gl and, a blockage of the duct results in the inapparent clinical lesion of 
the microcomedone.  Continued blockage, colonization of the follicle by Propionibacterium 
acnes (P. acnes), and generation of multiple chemoattractant and proinflammatory moieties may  
result in non-inflammatory clinical lesions, comedones, and inflammatory lesions: papules, 
pustules, nodules, and cysts.1 
FMX-101, 4% is a minocycline containing topical foam being developed as a treatment for a cne 
vulgaris.  Antibiotics, especially erythromycin, minocycline, and doxycycline, have been 
prescribed as acne treatments for many years.  These antibiotics effectively control the signs of 
inflammatory acne while patients continue to use them.  Nonclinical studies have demonstrated 
that FMX-101, 4% exhibits favorable characteristics.   
Foamix has conducted 2 Phase 1 and 1 Phase 2 study of FMX-101, 4% to assess its safety and 
tolerability.  FMX-101, 4% has been shown to be effective and well tolerated  at the 4% dose that 
is being utilized in this study.  The Investigator’s Brochure should be consulted for summaries of 
the results of these studies.   
This Phase 3 study (Study FX2014-05 ) will assess the efficacy, safety and long-term safety of 
FMX-101, 4% for the treatment of moderate to s evere facial acne vulgaris . 
3.   STUDY OBJECTIVE S  
The objectives of this study are:  
  To evaluate the efficacy in the treatment of acne compared to vehicle of topical FMX -
101, 4% administered daily for 12 weeks  
  To evaluate the safet y compared to vehicle of topical FMX -101, 4% administered 
daily for 12 weeks  
  To evaluate the long -term safety of topical FMX -101, 4% administered daily for up to 
an additional 40 weeks 
4.  INVESTIGATIONAL PLAN  
4.1.  Overall Study Design 
The one-year study will have 2 parts.  The first 12 weeks will be double-blind treatment with 
FMX-101, 4% or vehicle foam.  The remaining 40 weeks  will involve open -label treatment with 
FMX-101, 4% by any subjects who complete the first part of the study . 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 15 of 65 
 
 CONFIDENTIAL   4.1.1.  Part 1 – Double-blind  
This is a randomized, multicenter, double -blind, vehicle -controlled, 2-arm study to evaluate the 
safety and efficacy over 12 weeks of FMX-101 minocycline foam, 4%, compared to vehicle, in 
the treatment of subjects with moderate to severe facial acne vulgaris.  
Qualified subjects will be randomized to receive 1 of the following 2 treatments:  
  FMX-101, 4%  minocycline foam  
  Vehicle foam 
Subjects with qualifying lesion counts (Section 8.1.2) and Investigator’s Global Assessm ents 
(IGA, Section 8.1.1) of acne severity scores and will be assigned to 1 of 2 treatments according 
to the randomization schedule.  Subjects will apply the assigned study drug topically once daily 
for 12 weeks as directed.  Subjects will be advised to apply the study drug at approximately the 
same time each day, preferably in the evening before bedtime.  Both the Investigator and subject 
will be blinded to the study drug identity.  
Subjects will return for visits  at Weeks 1, 3, 6, 9, and 12 .  Efficacy evaluations (acne lesion 
counts and IGAs will be performed at Weeks 3, 6, 9, and 12 during the study.  Other assessments 
will be performed as described in  Sections 8.2 and 9. 
4.1.2.  Part 2 – Open-label  
At the Week 12 Visit, subjects  may be invited to continue into the open -label part of this study  
for an additional 9 months of treatment .  Subjects will be enrolled in this phase of the s tudy until 
a total of approximately 400 subjects from Studies FX2014 -04 and FX2014 -05 have elected to 
continue in the open -label portion of their respective study.  Subjects  who elect to continue into 
the open-label part of this study will receive supplies  of active FMX -101, 4% minocycline foam.   
Treatment during this part of the study will be guided by each subject’s clinical response.  The 
Investigator may elect to suspend treatment of some or all areas if there is clinical improvement 
or resolution of t he acne in those areas.  Even if the treatment is partially or completely 
temporarily suspended, the subject will continue in the study and make all scheduled clinic visits.  
If at any time the acne recurs or worsens, treatment of the affected areas may be  resumed.  
Subjects may be discontinued from the study at any time if their disease becomes refractory or 
they become intolerant of the product.   
4.2.  Rationale for Study Design and Dose Selection  
A randomized, multicenter, double -blind, vehicle-controlled stu dy design has been selected in 
order to assess the efficacy of the study drug  in accordance with the  FDA Guidance.2  The 
subjects will be selected according to predefined entry criteria.  The study will have a  12-week 
treatment duration.    
FMX-101 foam, 4% is a novel minocycline formulation  that has been shown to have efficacy in 
once daily use in a Phase 2 study.  The once daily dosing regimen is appropriate given the 
pharmacokinetic characteristics of FMX-101, 4%. 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 16 of 65 
 
 CONFIDENTIAL   Because of the mode of action of tetracycline drugs, the primary efficacy endpoints will be the 
effect on inflammatory lesion count and IGA  (Section 8.1.1).  The effect on noninflammatory 
lesions will be the most important  secondary endpoint.   
The extension of the study for an additional 4 0 weeks is necessary to obtain safety information 
about the long -term use of FMX -101, 4% to treat acne, which is a chronic condition.  The design 
of the study is expected to provide sufficient safety information to fulfill the ICH E1 guideline.  
5.  STUDY POPULATION  
The planned enrollment is 450 subjects.  Subjects will be randomized to active or vehicle in a 2:1 
ratio.  Approximately 300 and 150 subjects will be assigned to the FM X-101, 4% or vehicle 
treatment groups, respectively.  
5.1.  Inclusion Criteria  
A male or female subject will be considered eligible for participation in the study if all of the 
following inclusion criteria are satisfied prior to randomization:  
1.  Has completed and s igned an appropriately administered Informed Consent Form (ICF) 
prior to any study -related procedures.  Subjects less than 18 years of age  (or as required 
by state law) must sign an Assent Form for the study and a parent or legal guardian must 
sign the ICF.  
2.  Is 9 years of age or greater,  
3.  Has facial acne vulgaris with:  
  20 to 50 inflammatory lesions (papules, pustules, and nodules) 
  25 to 100 noninflammatory lesions (open and closed comedones)  
  No more than 2 nodules on the face  
  IGA score of moderate (3) to severe (4) 
4.  If women of child-bearing potential , have a negative urine pregnancy test  
5.  For women of child -bearing potential at risk of becoming pregnant, agree to an effective 
method of contraception (Sections 7.7 and 7.8) 
6.  Willing to use only the supplied non-medicated cleanser  
and to refrain from use of any other acne medication, medicated cleanser, excessive sun 
exposure, and tanning booths for the duratio n of the study  
5.2.  Exclusion Criteria  
Subjects who have any of the following will be excluded from the study:  
1.  Female who is pregnant or lactating, or is planning a pregnancy during the study  
2.  Acne conglobata, acne fulminans, secondary acne (chloracne, drug indu ced acne) or any 
dermatological condition of the face or facial hair (eg, beard, sideburns, mustache) that 
could interfere with the clinical evaluations  
CCI
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 17 of 65 
 
 CONFIDENTIAL   3.  Sunburn on the face  
4.  Severe systemic disease, which might interfere with the conduct of the study or th e 
interpretation of the results.  
5.  Abnormal baseline laboratory values that are considered clinically significant.  
6.  Currently participating, or has participated within 30 days prior to this study, in an 
investigational drug or device study  
7.  Inability to fully comply with the study requirements  
Subjects who have a history of any of the following will be excluded:  
8.  Allergy to tetracycline -class antibiotics or to any ingredient in the study drug  
9.  Pseudomembranous colitis or antibiotic -associated colitis  
10.  Hepatitis or liver damage or renal impairment  
11.  Known or suspected premalignant or malignant disease (excluding successfully treated 
skin cancers)  
12.  Subjects who have used the following medications (topical refers only to the facial area) 
will not be eligible:  
Within 1 week prior to randomization:  
  Medicated facial cleansers  
  Topical acne treatments (other than those listed below)  
Within 4 weeks prior to randomization:  
  Topical retinoids  
  Topical anti-inflammatories and corticosteroids  
  Systemic antibiotics  
  Systemic acne trea tments 
Within 12 weeks prior to randomization:  
  Systemic retinoids  
  Systemic cortico steroids 
13.  Drug addiction or alcohol abuse (within the last 2 years).  
14.  Current or significant past history of depression.  
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 18 of 65 
 
 CONFIDENTIAL   6.  STUDY PROCEDURES  
Potential subjects will be assessed for eligibility at Screening.  During this visit, the purpose, 
timing, procedures, and risks of the study will be explained to the subject, including 
requirements for enrollment and participation in the study, medication restrictions during the 
study, and requirements for washout of certain medications that the subject may already be 
taking.  
The eligible subject who is willing to participate in the study will then sign  an appropriately 
administered Informed Consent Form (ICF) prior to any study -related procedures.  Subjects less 
than 18 years of age  (or per state law)  must sign an Assent Form for the study and a parent or 
legal guardian must sign the ICF . 
Procedures at the Screening Visit will include obtaining blood and urine samples for clinical 
laboratory tests.  These results must be no more than 30 days old at the time of Baseline Visit  
randomization.   
If a subject, who has agreed to participate in the study and signed the ICF  or Assent Form , is 
currently undergoing acne therapy identified in Exclusio n Criterion 12, they must first enter a 
washout period, before beginning the Screening procedures.    
A summary of study assessments and the time point at which they will be performed during the 
study is presented in Table 1.  If a subject prematurely withdraws from the study  before the 
Week 12 Visit , the subject should return to the study site for a withdrawal visit, during which all 
evaluations described under Visit 6/Week 12 must be performed.  
See  
Table 2 and Section 6.2 for descriptions of the procedures required during the open -label part of 
the study. 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 19 of 65 
 
 CONFIDENTIAL   Table 1: Schedule of Procedures - Study FX2014-05  – Part 1 
 
Assessment  
Screening 1  
Baseline 1  
Visits “Final ” 
Visit 2 
Visit  1 2 3 4 5 6 
Week   1 3 6 9 12 
Informed Consent/Assent  X       
Demographic Data  X       
Assign identification number  X       
Medical/Surgical/Medication 
(prior/concomitant) History  X       
Inclusion/Exclusion criteria  X X      
Physical Exam, height, weight 3,4  X      X 
Blood Pressure/heart rate 5  X X X X X X 
Blood and urine samples for clinical 
laboratory tests  X   X   X 
Urine pregnancy test ( females of 
childbearing potentia l only)6  X  X X X X 
Investigator’s Global Assessment  X X  X X X X 
Lesion Count X X  X X X X 
Photography  X   X  X 
Subject Satisfaction Questionnaire        X 
Randomization   X      
Concomitant Medicati on   X X X X X X 
Adverse Events  X X X X X X X 
Tolerability Assessments    X X X X X 
Perform drug accountability    X X X X X 
Collect empty canisters    X X X X X 
Dispense Study Drug   X X X X X X7 
Schedule/Confirm Next Visit  X X X X X X X 
                                                 
1 The duration of Screening is variable but if there are medications to be discontinued it can not be less than the time indica ted in 
Exclusion Criterion 12. The procedures required at th ese visits can be combined.  However, drug should not be dispensed until 
all inclusion and exclusion criteria are met.  
2 Subject may continue into open -label phase of study. If a subject is not continuing into open -label phase for any reason 
(see Section 4.1.2, all evaluations described under Visit 6/Week 12 must be performed.   
3 Height to be measured only at Baseline  
4 Including 12-lead EKG at Screening in subjects over 39 years of age  
5 Measure blood pressure and heart rate after th e subject has been sitting for at least 5  minutes at rest 
6 Perform urine pregnancy test at indicated visits.  Also dis pense home urine pregnancy test at Week 12 if subject is 
continuing into open -label treatment  
7 If subject is continuing into open -label treatment phase, dispense appropriate Study Drug Kit  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 20 of 65 
 
 CONFIDENTIAL   6.1.  Part 1 – Double-Blind 
6.1.1.  Screening Visit  
  Obtain a signed and dated, written Informed Consent Form  (ICF) prior to any study -
related procedures ; subjects less than 18 years of age (or as required by state law) 
must sign an Assent Form for the study and a parent or legal gu ardian must sign the 
ICF.  (Subjects must be at least 9 years of age at the time of assent/consent) 
  Obtain demographic data  
  Assign the subject a  unique subject  identification number  
  Obtain medical history  
  Obtain surgical history  
  Obtain history of prior an d concomitant medication usage (including previous use of 
acne medications) ; record start and stop dates of any medications used in the last 
3 months  
  Perform IGA ( Section 8.1.1) 
  Perform facial lesion count of in flammatory, noninflammatory, and nodular lesions 
(Section 8.1.2)  
  Record regions beyond face affected by acne  
  Collect blood and urine samples for clinical laboratory tests and send to the central 
laboratory (Section 9.6)  
  If subject wears make -up, remind the subject not to wear any make -up at future visits.  
  Record AEs 
  Schedule/confirm the next study visit .  Remind subject to avoid sun overexposure. 
6.1.2.  Baseline Visit, Visit 1 
The procedures required at th is visit can be combined with Screening .  However, drug should not 
be dispensed until all inclusion and exclusion criteria are met.   
  Confirm/reconfirm eligibility according to t he inclusion/exclusion criteria  and 
o  Perform IGA  
o  Perform facial lesion count of inflammatory, noninflammatory, and nodular 
lesions  
  Perform photography ( Section 8.2) 
  Measure blood pressure and heart rate (Section 9.4)  
  Perform physical examination including height and weight (Section 9.5) 
  Perform 12-lead EKG if subject is over 39 years of age 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 21 of 65 
 
 CONFIDENTIAL     Perform urine pregnancy test  in females of childbearing potential  
  Randomize the s ubject using the IWRS system, when all criteria have been met   
  Record concomitant medications  
  Record AEs 
  Dispense 1 kit (2 canisters) of study drug  
  Dispense cleanser      
  Schedule/confirm the next study visit  and remind subj ect to avoid overexposure to 
sunlight 
6.1.3.  Visit 2, Week 1 
  Measure blood pressure  and heart rate 
  Record concomitant medications  
  Record AEs and Tolerability Assessment  
  Assess product use to c onfirm that subject continues to use  properly; confirm that 
only provided cleanser is being used.  
  Collect previously dispensed  study drug canister(s) if applicable  
  Dispense 1 kit (2 canisters) of study drug   
  Schedule/confirm the next study visit and remind subject to avoid overexposure to 
sunlight 
6.1.4.  Visit 3, Week 3 
  Measure bloo d pressure and heart rate 
  Perform urine pregnancy test  in females of childbearing potential  
  Perform IGA 
  Perform facial lesion count  of inflammatory, noninflammatory, and nodular lesions  
  Collect blood and urine samples for clinical laboratory tests and send  to the central 
laboratory (Section 9.6)  
  Record concomitant medications  
  Record AEs and Tolerability Assessment  
  Assess product use to confirm that subject continues to use properly; confirm that 
only provided cle anser is being used.  
  Collect previously dispensed study drug canister(s) if applicable  
  Dispense 1 kit (2 canisters) of study drug  
  Determine if additional drug or cleanser needs to be dispensed.   
CCI
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 22 of 65 
 
 CONFIDENTIAL     Schedule/confirm the next study visit and remind subject to  avoid overexposure to 
sunlight 
6.1.5.   Visit 4, Week 6 
  Measure blood pressure and heart rate  
  Perform urine pregnancy test  in females of childbearing potential  
  Perform IGA 
  Perform facial lesion count of inflammatory, noninflammatory, and nodular lesions  
  Perform photography 
  Record concomitant medications  
  Record AEs and Tolerability Assessment  
  Assess product use to confirm that subject continues to use properly; confirm that 
only provided cleanser is being used.  
  Collect previously dispensed  study drug canister(s) if  applicable 
  Dispense 1 kit (2 canisters) of study drug  
  Determine if additional drug or cleanser needs to be dispensed.   
  Schedule/confirm the next study visit and remind subject to avoid overexposure to 
sunlight 
6.1.6.  Visit 5, Week 9  
  Measure blood pressure and  heart rate 
  Perform urine pregnancy test  in females of childbearing potential  
  Perform IGA 
  Perform facial lesion count of inflammatory, noninflammatory, and nodular lesions  
  Record concomitant medications  
  Record AEs and Tolerability Assessment  
  Assess product  use to confirm that subject continues to use properly; confirm that 
only provided cleanser is being used.  
  Collect previously dispensed  study drug canister(s) if applicable  
  Dispense 1 kit (2 canisters) of study drug  
  Determine if additional drug or cleanser needs to be dispensed.   
  Schedule/confirm the next study visit and remind subject to avoid overexposure to 
sunlight 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 23 of 65 
 
 CONFIDENTIAL   6.1.7.  Visit 6, Week 12 End of Double -Blind or Continuation in Open Label / Early 
Termination    
  Perform physical examination including weight  
  Measure blood pressure  and heart rate 
  Collect blood and urine samples for clinical laboratory tests and send to the central 
laboratory 
  Perform urine pregnancy test in females of childbearing potential  
  Perform IGA 
  Perform facial lesion count  of inflammatory , noninflammatory,  and nodular lesions  
  Perform photography  
  Administer Subject Satisfaction Questionnaire  
  Record concomitant medications  
  Record AEs and Tolerability Assessment  
  Assess product use to confirm that subject continues to use properly; confirm that 
only provided cleanser is being used.  
  Collect previously dispensed  study drug canister(s)  
  If subject is continuing into the open -label phase of the study  (see Section 4.1.2), 
dispense 2 kit (4 canisters) of FMX -101, 4% minocycline foam  
o  If subjects facial acne is “clear” or “almost clear,” consider withholding 
treatment with FMX -101, 4% at this time but continue subject in study and  
schedule next visit.  
  Schedule/confirm the next study visit and remind subject to av oid overexposure to 
sunlight 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 24 of 65 
 
 CONFIDENTIAL    
6.2.  Part 2 – Open-label 
A summary of study assessments and the time point at which they will be performed during the 
Part 2 of this study is presented in  
Table 2.  If a subject prematurel y withdraws from the study, the subject should return to the 
study site at which time all evaluations described under Final Visit 13/Week 52 must be 
performed. 
 
Table 2: Schedule of Procedures - Study FX2014-05  – Part 2 
 
Assessment  
 Visits Final 
Visit 1 
Visit 7 8 9 10 11 12 13 
Week 16 22 28 34 40 46 52 
Physical Exam,  weight,       X 
Blood Pressure/heart rate 2 X X X X X X X 
Blood and urine samples for clinical 
laboratory tests    X    X 
Urine pregnancy test (females of 
childbearing potential  only)3 X X X X X X X 
Investigator’s Global Assessment  X X X X X X X 
Lesion Count X X X X X X X 
Concomitant Medication  X X X X X X X 
Adverse Events  X X X X X X X 
Tolerability Assessment  X X X X X X X 
Subject Satisfaction Questionnai re       X 
Perform drug accountability  X X X X X X X 
Collect empty canisters  X X X X X X X 
Dispense Study Drug  X X X X X X  
Schedule/Confirm Next Visit  X X X X X X  
 
                                                 
1 If a subject prematurely withdraws from the study, all evaluations desc ribed under Final Visit 13/Week 5 2 must be performed.   
2 Measure blood pressure and heart rate after the subject has been sitt ing for at least 5  minutes at rest 
3 Home pregnancy t ests will be dispensed at each visit to all female subje cts of a childbearing potential  and will be performed  at 
least monthly and whenever there is a suspicion of pregnancy (e.g., a missed period). P erform urine pregnancy test at F inal visit. 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 25 of 65 
 
 CONFIDENTIAL   6.2.1.  Visit 7 - Week 16 
  Measure blood pressure and heart rate  
  Perform IGA 
  Perform facial l esion count of inflammatory, noninflammatory, and nodular lesions  
  Record concomitant medications  
  Record AEs and Tolerability Assessment  
  Assess product use to confirm that subject continues to use study drug properly  
  Collect empty study drug canister(s)  
  Dispense 2 kits (4 canisters) of FMX -101, 4% minocycline foam if required  
  Dispense Home pregnancy kit  to all female subjects of childbearing potential  
  Schedule/confirm the next study visit  
o  If subjects facial acne is “clear” or “almost clear,” consider withho lding 
treatment with FMX -101, 4% at this time but continue subject in study and 
schedule next visit.  
o  If treatment has been interrupted, consider restarting treatment if clinically 
indicated 
6.2.2.  Visits 8, 9, 10, 11 and 12 – Weeks 22, 28, 34, 40 and 46  
  Measure blood pressure and heart rate  
  Perform IGA 
  Perform facial lesion count of inflammatory, noninflammatory, and nodular lesions  
  Record concomitant medications  
  Record AEs and Tolerability Assessment  
  At Visit 9 (Week 28) only  - Collect blood and urine samples fo r clinical laboratory 
tests and send to the central laboratory (Section 9.6)  
  Assess product use to confirm that subject continues to use study drug properly  
  Collect empty study drug canister(s)  
  Dispense 2 kits (4 canisters) of FMX -101, 4% minocycline foam if required  
  Dispense Home pregnancy kit  to all female subjects of childbearing potential  
  Schedule/confirm the next study visit  
o  If subjects facial acne is “clear” or “almost clear,” consider withholding 
treatment with FMX-101, 4% at this time but continue subject in study and 
schedule next visit.  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 26 of 65 
 
 CONFIDENTIAL   o  If treatment has been interrupted, consider restarting treatment if clinically 
indicated 
6.2.3.  Visit 13, Final Visit – Week 52 
  Measure blood pressure and heart rate  
  Perform physical examination including weight  
  Collect blood and urine samples for clinical laboratory tests and send to the central 
laboratory 
  Perform urine pregnancy test in females of childbearing potential  
  Perform IGA 
  Perform facial lesion count of inflammatory,  noninflammatory, and nodular lesions  
  Record concomitant medications  
  Record AEs and Tolerability Assessment  
  Administer Sub ject Satisfaction Questionnaire  
  Collect previously dispensed  study drug canister(s)  
7.  STUDY TREATMENTS  
FMX-101, 4% and vehicle will be supplied as identical canisters.  All study drug will be stored, 
inventoried, reconciled, and destroyed according to US regulations. 
7.1.  Treatments Administered  
The description of study drug kits and treatments is shown below.  
7.1.1.  Part 1 (double-blind) – Weeks 1 to 12 
Dosage form description  Active kit: FMX-101 minocycline foam, 4% ;  
Vehicle kit: Matching vehicle foam 
Package description  Active kit: 2 canisters of FMX-101, 4% dispensed as foam when actuator is depressed  
Vehicle kit: 2 canisters dispensing  vehicle foam when actuator is depressed  
Daily dose Approximately 0.5 gm of FMX -101, 4% (containing 40 mg minocycline per gram of foam; 0 mg 
for vehicle subjects); applied to face topically each day.  Additional drug product may be applied 
to other acne-affected areas 
Cumulative maximal 
dose Approximately 1,680 mg of minocycline ( 0 mg for vehicle subjects) assuming application of 0.5 
gm of foam daily  to the face for 84 days. Maximum total amount of drug dispensed contains 14 
gm of minocycline.   
Dispensing 1 Kit (2 canisters) dispensed at Baseline  and Weeks 1, 3, 6, and 9.   Total of 5 kits (10 canisters) 
dispensed to the subject for the study.  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 27 of 65 
 
 CONFIDENTIAL   7.1.2.  Part 2 (open-label) – Weeks 13 to 52  
Dosage form description  FMX-101 minocycline foam, 4%;  
Package description  Active kit: 2 canisters of FMX -101, 4% dispensed as foam when actuator is depressed  
Daily dose Approximately 0.5 gm of FMX -101, 4% (containing 40 mg minocycline per gram of foam)  
applied to face topically each day.  Additional drug product may be applied to other acne-affected 
areas 
Cumulative maximal 
dose Up to approximately 5,600 mg of minocycline assuming application of 0.5 gm of FMX -101 foam 
daily to the face for 280 days. Maximum total amount of drug dispensed contains 39.2 gm of 
minocycline. 
Dispensing Up to 2 Kits (4 canisters) dispensed at Weeks 12,  16, 22, 28, 34, 40 and 46  depending on rate of 
usage. Up to a total of 14 kits (28 canisters) dispensed to the subject for the study.  
7.1.3.  Dosing Instructions  
7.1.3.1.  Part 1 – Double-blind 
The dosing regimen will be the sa me for both treatment groups.  
After shaking the canister well , a small amount of foam  (about 1/2 gram or a cherry -sized 
amount) should be expressed from the canister onto the fingertips of the hand and then rubbed 
into acne-affected parts of the face .  This should be repeated as needed until all acne -affected 
parts of the face are treated.  If acne is present on other parts of the subject’s body (neck, 
shoulders, arms, back or chest) additional amounts (up to a total of 4g) of foam should also be 
applied to these areas. The foam should be applied at approximately the same time each day  
preferably in the evening  at bedtime. The subject should not bath e, shower or swim for at least 1 
hour after application of the product.  
Study kits of blinded drug supplies will be dispensed at Baseline and Weeks 1, 3, 6 and 9 to 
ensure continuous dosing in case the subject is late for subsequent visits.  
Dose adjustments are not permitted in this  part of the study.  Subjects who require a dose  
adjustment or discontinu ation of study drug must be withdrawn from the study (Section 11.4). 
7.1.3.2.  Part 2 – Open-label 
At the Week 12 Visit, subjects who elect to continue into the open -label part of this study will 
receive supplies of active FMX -101, 4% minocycline foam.   
Treatment during this part of the study will be guided by each subject’s clinical response.  The 
Investigator may elect to suspend treatment of some or all areas if there is clinical improvement 
or resolution of the acne in those a reas.  Even if the treatment is partially or completely 
temporarily suspended, the subject will be continued in the study and make all scheduled clinic 
visits.  If at any time the acne recurs or worsens, retreatment of the affected areas may be 
resumed. At each visit, the changes in treatment will be documented.   
Sufficient product will be dispensed at each visit to allow continuation of treatment as required.  
Subjects may be discontinued from the study at any time if their disease becomes refractory or 
they become intolerant of the product.   
F OA M I X
 
        
 
FMX
-
101, 4%  
   
Protocol 
FX2014
-
05 
Version 
3
 
 
 
Page 
28
 
of 
65
 
 
 
CONFIDENTIAL
 
 
7.1.4.
 
Manufacturer
 
The manufacturer of the investigational product is 
  
.
 
7.1.5.
 
Labeling of 
Study 
Drug
 
 
The Sponsor, or designee will label 
study 
drug
 
supplies according to the requirement
s of the 
Code of Federal Regulations (21CFR§ 210, Subpart G
-
Packaging & Labeling Control).
 
The labels of the investigational (test) product will contain appropriate information as required 
by regional regula
tory authorities and include, as needed, 
the foll
owing information:
 

 
Name and address of the Sponsor
 

 
Protocol number
 

 
Product name / dosage form / mode of administration
 

 
Kit Number
 
/ 
Canister
 
Number
 

 
Site number
 
/ 
Subject number
 
 

 
Name and address of manufacturer
 

 
Date of manufacture
 

 
Lot/batch number
 

 
Canister
 
contents
 

 
Storage conditions
 

 
Caution Statements: 
 
o
 
“New Drug 
–
 
Limited by Federal Law to Investigational Use”
 
o
 
“Flammable”
 
o
 
“Shake well before use”
 
o
 
“Keep out of the reach of children”
 
The composition, pharmaceutical quality, batch number, and expiration date 
of the 
investigational (test) product will be traceable via the 
kit
 
number.
 
7.1.6.
 
Storage of 
Study 
Drug
 
FMX
-
101, 4% and vehicle canisters must be stored at 2°C 
–
 
8°C until being dispensed to the 
subjects.  Subsequently, they must be stored at 20°C 
–
 
25°C 
(refer 
to US
P Controlled Room 
Temperature)
.
 
 
The investigator will be responsible for the suitable storage of the investigational 
product in compliance with the storage instructions and must restrict access to the study 
personnel only.
 
CCI
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 29 of 65 
 
 CONFIDENTIAL   7.2.  Study Drug Accountability  
The Investigator will have overall responsibility for the use of the study drug.  The Investigator 
or designee will verify the contents of the drug shipment and confirm receipt of the study drug in 
the Interactive Web  Response System (IWRS) system.  In addition, an accurate study drug 
dispensing record that specifies the date and amount dispensed to each subject must be kept.  
This inventory record must be available for inspection by representatives of the Sponsor and is 
subject to regional regulatory author ity inspection at any time.  At the conclusion of the study, 
the Investigator must provide a copy of this record to the Sponsor .  In addition, the weight of 
each canister will be determined prior to being dispensed to the subjects and  each canister that 
has been retrieved from the subject wil l be returned to the vendor to be weighed . 
Under no circumstances will the Investigator allow the investigational drugs to be used other 
than as directed by this protocol.  Qualified study personnel must use the IWRS to assign and 
dispense kits to the subjects.  Reasons for digression from the expected dispensing regimen must  
also be recorded . 
7.3.  Handling and Disposal of Study Drug 
The study drug must be protected from unauthorized access (eg, in a locked storage facility).  
Any unused, partially used, or empty bottles of study drug will be returned to the Sponsor or 
designee by the time of the site’s close -out visit.  Receipt, distribution, and return of the study 
drug must be properly documented on forms provided by the Spo nsor or designee.  
7.4.  Method of Assignment of Study Drug 
7.4.1.  Part 1 – Double- blind 
After pretreatment clinical evaluations and all other screening procedures have been completed, 
authorized site personnel will acknowledge that the applicable subject met all the s pecified 
inclusion criteria and none of the exclusion criteria.  Assignment to a treatment group will then 
follow a predetermined list of randomization numbers, with each successive number receiving 
1 of the 2 treatments in random order.   Authorized site p ersonnel will use the IWRS system to 
assign a kit number that corresponds to the randomization schedule.   The kit box with the 
assigned kit number will be dispensed to the subject.  
The randomization code will be provided by TKL.  
7.4.2.  Part 2 – Open-label 
All subjects who elect to continue into the second part of the study will receive FMX -101, 4% 
minocycline foam as described in Section 7.1.3.2.        
7.5.  Selection and Timing of Doses in the Study  
The 4% minocycline concentration of FM X-101 was shown to be more effective than 1% in a 
Phase 2 study.  The once-daily dosing regimen is appropriate given the pharmacokinetic 
characteristics of minocycline. 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 30 of 65 
 
 CONFIDENTIAL   7.6.  Blinding 
The first part of this study is double-blind with limited access to the random ization code.  The 
randomization code will be held in confidence until after the study database is locked and a 
memo documenting the database lock has been issued.  Every effort will be made to retain the 
integrity of the blind.  When issued to the sites, the study drug will be identical in appearance for 
all subjects, regardless of treatment assignment.  
The treatment each subject receives will not be disclosed to the Investigator, study site personnel, 
subjects, monitors, or the Sponsor staff except as req uired for the purposes of conducting this 
study. 
In the event that emergency identification of study drug is required (eg, if the Investigator 
believes that the information is necessary to properly treat a subject with an AE), the study drug 
identity can b e obtained by the Investigator through the IRT system.  
Before breaking the blind for a subject, the Investigator should determine that the information is 
necessary (ie, that it will alter the subject’s immediate course of treatment and will contribute to 
the management of the AE).  In many cases, particularly when the emergency is clearly not 
related to study drug, the problem may be effectively managed by assuming that the subject is 
receiving active study drug without the need for unblinding.  Every effor t should be made to alert 
the Medical Monitor before requesting that the blind be broken.  If this is not possible, the 
Medical Monitor should be immediately notified of the breaking of the blind.  The Investigator 
will record the unblinding procedures in the subject’s source documents.  
If unblinding is necessary, the subject will be withdrawn from the study and Week 12 Visit 
assessments will be completed.  
7.7.  Prior and Concomitant Therapy    
Subjects should use the cleanser,  (provided by the Sponsor).  An 
alternative, non -medicated, cleanser may be used if agreed to by the Sponsor.  
The use of or change in the dose of any and all concomitant medication, either prescription or 
over-the-counter, during the study will be recorded. The r eason for use or change of dose of a 
concomitant therapy may need to be reported as an AE.  Therapies (medication and non -
medication therapies) not restricted by the protocol may be used.  Non -prohibited chronic 
therapies being used at Baseline may be cont inued. If a subject is using an oral contraceptive 
product, she should have been on the same product for at least 3 months and she should continue 
using the same or equivalent product for the duration of the double -blind portion of the study.  
If a subject is taking anticoagulant therapy, the subject should be advised that they may require a 
downward adjustment of their anticoagulant dosage.  
All topical or systemic medications listed in the exclusion criteria are prohibited  during the 
double-blind part of th is study (through Week 12) .  Similarly, no other topical medications are 
permitted to be used on the face  during this period .  Subjects requiring systemic antibiotics not 
known to affect acne will be considered on a case -by-case basis.  During the open -label part of 
the study, concomitant acne medications are permitted; their use should be properly recorded.  
CCI
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 31 of 65 
 
 CONFIDENTIAL   See the Investigators’ Brochure for information about tetracyclines and possible drug -drug 
interactions 
7.8.  Use of Contraception  
Tetracycline-class antibiotics can cause fetal harm when administered to a pregnant woman.  
Tetracycline-class antibiotics used during tooth development (last half of pregnancy, infancy, 
and childhood to the age of 8 years) may cause permanent discoloration of teeth (yellow -gray-
brown). 
Prior to study enrollment, females of childbearing potential must be advised of the importance of 
avoiding pregnancy during study participation and the potential risk factors for an unintentional 
pregnancy. Females of childbearing potential include a ny female who has experienced menarche 
and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal 
ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea > 12 
consecutive months).  Females of chil dbearing potential must have a negative urine pregnancy 
test and, if they are sexually active or become sexually active during the study, must use an 
effective method of birth control such as those listed below during the course of the study.  The 
following is not an all-inclusive list; the subject must discuss with the Investigator the most 
appropriate form of birth control:  
  Hormonal methods  
o  Oral contraceptives – (Topical antibiotics may lessen the effectiveness of oral 
contraceptives. Therefore, a second form of birth control must be utilized in 
subjects using oral contraceptives)  
o  Implant 
o  Injection 
o  Transdermal patch  
o  Intravaginal Ring  
  Intrauterine Device (hormonal or non -hormonal) 
  Barrier methods  
o  Condom (male or female) with spermicide  
o  Diaphragm with spermi cide 
  Abstinence 
7.9.  Treatment Compliance  
Each subject is to be instructed on the importance of following the dosing schedule and returning 
all kits (empty/used/unused) at the appropriate visits.  The study personnel will question the 
subject on the history of study drug use since the last visit. A subject who deviates significantly 
from the prescribed dosage will be counseled.   
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 32 of 65 
 
 CONFIDENTIAL   8.  EFFICACY ASSESSMENTS  
8.1.  Primary Efficacy Assessments 
The primary efficacy assessments will be the IGA and lesion counts.  
8.1.1.  Investigator Glob al Assessment Score (IGA)  
Table 3 displays the IGA scale for acne vulgaris , which will be used by the investigators to 
assess the severity of a subject’s acne vulgaris.  The Case Report Forms (CRFs) will allow for 
Investigators to report lesions worsening beyond Grade 4 with treatment.    The IGA must be 
performed prior to the lesion count.  
The same evaluator should perform all evaluations for a subject; when this is not possible, 
another approved evaluator may perfo rm the evaluations.  
Table 3: IGA Scale for Acne Vulgaris  
Score Grade   Description 
0 Clear Normal, clear skin with no evidence of acne vulgaris 
 
1  
Almost clear Rare noninflammatory  lesions may be present, with rare non-inflamed papules 
(papules must be resolving and may be hyperpigmented,  though not pink- red) 
2 Mild Some noninflammatory  lesions are present, with few inflammatory  lesions 
(papules/pustules  only; no nodulocystic lesions) 
 
3   
Moderate Many noninflam matory lesions.  Multiple  inflammatory  lesions evident with several  
to many papules/pustules,  and there may be one small nodulocystic lesion 
4 Severe Inflammatory  lesions are more apparent,  many comedones and papules/pustules,  there 
may be a few nodulocystic lesions 
5  Very Severe Highly inflammatory  lesions predominate,  variable number of comedones, many 
papules/pustules  and many nodulocystic lesions 
8.1.2.  Lesion Counts  
Subjects are eligible for enrollment if they have:  
  20 to 50 inflammatory lesions (papules, pustules, and nodules)  
  25 to 100 noninflammatory lesions (open and closed comedones)  
  No more than 2 nodules can be present on the face at Screening  
Lesions will be characterized as inflammatory or non -inflammatory using the following criteria:  
  Inflammatory  lesions: 
Papule – a solid, elevated lesion less than 0.5 cm in diameter  
Pustule – an elevated lesion containing pus less than 0.5 cm in diameter  
Nodule – palpable solid lesion greater than 0.5 cm in diameter; has depth, not 
necessarily elevated  
 
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 33 of 65 
 
 CONFIDENTIAL     Noninflammatory lesions: 
Open comedones  (blackhead) – non-infected plugged hair follicle with 
dilated/open orifice; black in color  
Closed comedones  (whitehead) – non-infected plugged hair follicle: small 
(microscopic) opening at skin surface  
Facial lesion counts w ill be made for the forehead, left and right cheeks, nose and chin  at each 
visit.  Total inflammatory lesions (pustules, papules, and nodular lesions)  and noninflammatory 
lesions (open and closed comedones) will be counted  and recorded separately.  Lesion counts 
will be repeated at Weeks 3, 6, 9 and 12 . 
8.2.  Photography  
Photography of the face will be performed at Baseline and at Weeks 6  and 12 using recognized 
methods.  The equipment and techniques for this photography and for archiving the images are  
described in the Study Manual.  Photographs will be reviewed at the site and by the sponsor for 
quality.  Photographs will not be used to assess the lesion counts or the Investigator’s assessment 
of global severity but will be archived to be available for subsequen t review, if required, by the 
sponsor, auditors or the FDA.  
8.3.  Subject Satisfaction Questionnaire  
A satisfaction questionnaire will be administered at Visit 6, Week 12  and Visit 13, Week 52  (see 
Section 16.1, Appendix 1). 
9.  SAFETY ASSESSMENTS  
The safety assessments in this study are standard safety measures in clinical studies, including 
physical examinations,  the monitoring of vital signs, AEs (volunteered, observed, and elicited by 
general questioning in a non -suggestive manner), and clinical laboratory test results .  In addition, 
skin assessments at the drug application site(s) will be performed.  
9.1.  Medical/Surgical History  
A complete medical and surgical history will be obtained at Screening, which will include 
diseases of the head, ears, eyes, nose and throat; respiratory diseases; cardiovascular diseases; 
gastrointestinal diseases, hepatic diseases, genitourinary diseases, musculoskeletal diseases, 
endocrine diseases, neurological diseases, psychiatric diseases, skin  diseases, allergies, 
hematological diseases, and other abnormalities.  
9.2.  Medication History  
A history of medication usage (including previous use of acne medications  and non-medication 
therapies) will be recorded at Screening.  The start and stop dates of pr evious use of medications 
in the last 3 months will be recorded.  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 34 of 65 
 
 CONFIDENTIAL   9.3.  Concomitant Medications  
All medication that the subject is currently taking or any change in medication or dos age since 
the last visit will be documented throughout the study.  
9.4.  Vital Signs 
Heart rate and blood pressure will be measured at all post-Baseline visits.  All blood pressure 
measurements will be made using a sphygmomanometer with an appropriate cuff size for the 
individual subject.  Measurements will be administered while the subject i s seated after at least 
5 minutes at rest.  
9.5.  Physical Examination  
A complete physical examination will include an evaluation of general appearance, skin, 
HEENT, neck, lymph nodes, lungs, heart, abdomen, musculoskeletal system , and neurologic 
system. A standard 12-lead EKG (after at least 5 minutes rest) will be performed at Baseline  in 
subjects over 39 years of age . 
Weight will be recorded at the Baseline Visit , Visit 6 (Week 12) and Final Visit (Week 52).  
Height will be measured at Baseline, only . 
9.6.  Clinical Laboratory Tests  
Serum chemistry, hematology and urinalysis will be evaluated at Baseline, Week 12/ Final Visit 
of the double-blind phase of the Study, and at Week 28 and Week 52/Final Visit of the open -
label phase of the Study. Serum chemistry , hematology, and urinalysis  tests will be performed at 
a central laboratory.  
Refer to the manual from the central laboratory for detailed instructions on collecting, 
processing, and shipping of samples .  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 35 of 65 
 
 CONFIDENTIAL   Hematology  Urinalysis Serum chemistry  
Hematocrit 
Hemoglobin 
MCH 
MCHC 
MCV 
MPV 
Platelet count  
RBC 
RDW 
WBC 
Reticulocyte count  
WBC differential  (% & 
absolute) : 
Basophils 
Eosinophils 
Lymphocytes  
Monocytes 
Neutrophils 
 
 Bilirubin 
Blood 
Glucose 
Ketones 
Leukocytes esterase  
pH 
Protein 
Specific gravity  
 
Urine pregnancy perf ormed at the site  
 
 
 Alanine aminotransferase (ALT)  
Albumin 
Alkaline phosphatase  
Aspartic acid transaminase (AST)  
Blood urea nitrogen (BUN)  
Calcium 
Chloride 
Cholesterol 
Creatinine 
Creatinine kinase 
Gamma glutamyl transferase (GGT)  
Globulin 
Glucose 
Phosphorus 
Potassium 
Sodium 
Total bilirubin (if elevated obtain 
direct bilirubin)  
Total protein 
Triglycerides 
Uric acid 
9.6.1.  Urine Pregnancy Test  
A urine pregnancy test will be performed on all females of childbearing potential at Baseline, 
Week 3, Week 6, Week 9 and Week 12 of the double -blind phase of the Study and Final Visit or 
when a subject prematurely withdraws from the study.  
Home pregnancy kits will be provided at each visit to all female subjects  of childbearing 
potential in the open-label phase of the Study and are to be used at least monthly and if a 
pregnancy is suspected between visits (e.g., if a subject misses a period). A urine pregnancy test 
will be performed at  Week 52/ Final Visit. 
 
9.6.2.  Sample Collection, Storage, and Shipping  
Sample collection kits, req uisition slips, and shipping boxes will be supplied by the central 
laboratory. Sample collection procedures and shipping instructions will be detailed in the 
laboratory manual. Study centers must be equipped to store the samples according to the 
laboratory manual procedures before shipping samples to the central laboratory.  
9.7.  Other Safety Measurements  
9.7.1.  Tolerability  
Erythema, dryness, hyperpigmentation and skin peeling at the sites of study drug application will 
be assessed by the investigator at each study vis it on a scale of 0 to 3 (0=none; 1=mild; 
2=moderate; 3=severe). Itching will be assessed using the same scale based on the subjects’ 
subjective assessment.  The intensity and location of each finding will be recorded.   These signs 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 36 of 65 
 
 CONFIDENTIAL   and symptoms should not b e recorded as AEs unless they require concomitant treatment or lead 
to the subject’s discontinuation from the study.  
9.8.  Adverse Events  
9.8.1.  Method of Determining Adverse Events  
Safety assessments will include recording AEs reported spontaneously by the subject or observed 
by the Investigator.   AEs will be recorded at each visit throughout the study on the  appropriate 
CRF. Every attempt should be made to describe the AE in terms of a diagnosis.   If a clear 
diagnosis has been made, individual signs and symptoms will not be recorded unless they 
represent atypical or extreme manifestations of the diagnosis, in which case they should be 
reported as separate events.  If a clear diagnosis cannot be established, each sign and symptom 
must be recorded individually.  
Subjects should be asked whether, since the time of the last observation or visit, they had any of 
the following:  
  Experienced any changes in well -being 
  Used any new medications  
  Changed medication regimens (both prescription and over -the-counter) 
  Were admitted to a hospital or had any accidents  
  Developed unusual headaches or changes in vision  
All questions should be of a general nature and should not suggest symptoms.  
When an AE is suspected, all relevant evaluations will be carried out and appropriate treatment 
provided.  Additional follow -up will be done as necessary (Section 9.8.4) and recorded in the 
subject ’s source documents, and the results will be provided to the Sponsor.  
For AE definitions and reporting requirements , refer to Section 9.8.2 and Section 9.8.3, 
respectively. 
9.8.2.  Adverse Event Definitions  
9.8.2.1.  Adverse Events  
An adverse event (AE) is any unfavorable or unintended sign, symptom,  or disease that appears 
or worsens in a subject after the subject signs the ICF  (and/or Assent Form)  for a clinical study . 
Examples of what may be considered an AE include any of the following:  
  A new illness  
  An exacerbation of a sign or symptom of an unde rlying condition or of a concomitant 
illness unrelated to participation in the clinical study or an effect of the study drug or 
comparator drug  
No causal relationship with the study drug is implied by the use of the term “adverse event.”  An 
exacerbation o f a pre-existing condition/illness is defined as a more frequent occurrence or as an 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 37 of 65 
 
 CONFIDENTIAL   increase in the severity of the pre -existing condition/illness during the study.   Planned or elective 
surgical procedures for pre -existing conditions that have not worsene d are not AEs.  However, 
any complication that occurs during a planned or elective surgery is an AE.   (If the event meets 
the criteria for a serious adverse event [S AE], such as an extended hospitalization, it will be 
considered an SAE).  Conditions leadin g to unplanned surgical procedures may also be AEs. 
9.8.2.2.  Serious Adverse Events  
A “serious adverse event” (SAE) is any AE that:  
  Results in death  
  Is life-threatening 
(Note: The term “life -threatening” refers to any AE that, as it occurs, puts the subject 
at immediate risk of death.  It does not refer to an AE that hypothetically might have 
caused death if it were more severe.)  
  Results in hospitalization or prolongation of current hospitalization (not including 
hospitalization for a pre -existing condition that has  not increased in severity or 
frequency from the subject’s underlying medical condition  prior to entry into the 
study) 
  Results in persistent or significant disability/incapacity  
  Is a congenital anomaly/birth defect in the offspring of a subject  
  Is another serious (important medical events)  events 
 
(Note: Important medical events may not be immediately life -threatening or result in 
death or hospitalization but may be considered serious when, based upon appropriate 
medical judgment, they may jeopardize the su bject or require medical or surgical 
intervention to prevent one of the outcomes listed above.   Examples of such medical 
events include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home; blood dyscrasias or convulsions tha t do not result in inpatient 
hospitalization; or development of drug dependency or drug abuse. ) 
SAEs will be reported by the Sponsor to the regulatory authorities as required.  
9.8.2.3.  Severity of Adverse Events  
“Severity” of the AE refers to the extent to which an  AE affects the subject’s daily activities and 
differs from “Serious ,” which is a regulatory classification.  Severity will be categorized 
according to the following criteria:  
  Mild:  The symptom has a negligible effect or no impairing effect on the subject ’s 
normal function.  
  Moderate:  The symptom impairs the subject ’s normal function to some extent.  
  Severe:  The symptom has an obvious, significantly impairing effect on the subject ’s 
normal function.  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 38 of 65 
 
 CONFIDENTIAL   9.8.2.4.  Relationship of Adverse Events to Study Treatments  
“Causa lity” refers to the relationship of the AE to study drug and will be categorized according 
to the following criteria:  
  Unlikely:  There is no medical evidence to suggest that the AE may be related to 
study drug usage, or there is another more probable medic al explanation.  
  Possible:  There is medical evidence to suggest that there is a reasonable possibility 
that the AE may be related to study drug usage. However, other medical explanations 
cannot be excluded as a possible cause.  
  Probable:  There is strong me dical evidence to suggest that the AE is related to study 
drug usage. 
9.8.2.5.  Adverse Events Expectedness  
Expected AEs are defined as those described in the Investigator’s Brochure.   If an event 
increases in intensity or severity from that described in the IB, it will be considered unexpected.  
9.8.3.  Reporting Adverse Events  
AEs that occur from the time of informed consent /assent through completion of the last study 
visit should be reported.  Any AE that the Investigator becomes aware of that occurs within 30 
days of study completion or withdrawal should also be reported.  
Every attempt should be made to describe the AE in terms of a diagnosis.  If a clear diagnosis 
has been made, individual signs and symptoms will not be recorded unless they represent 
atypical or extreme m anifestations of the diagnosis, in which case they should be reported as 
separate events.  If a clear diagnosis cannot be established, each sign and symptom must be 
recorded individually.  
Any serious AEs occurring in a subject receiving study drug must be reported to the Sponsor or 
designee within 24 hours of the site being informed of the event, even if the event does not 
appear to be drug -related.  The report must be made by sending a completed Serious Adverse 
Event (SAE) Report form to the Sponsor  or designee.  Any pertinent follow -up information 
should be provided in a similar manner.  Contact information is provided below:  
TKL Clinical Pharmacovigilance  
 
9.8.4.  Adverse Event Follow -up 
Adverse events , and tolerability signs and symptoms greater than zero (0),  that are ongoing when  
a subject withdraws from or completes the study will be followed until resolution or stabilization 
(in the opinion of the Investigator), or for 30 days, whichever is shorter.   Investigators and the 
Sponsor will decide if longer follow -up is appropriate on a case -by-case basis.  Subjects who 
experience any clinically significant AE will remain under medical supervision until the 
Investigator or the Sponsor’s Medical Monitor deems the AE to be resolved, stabilized,  or no 
longer serious enough to warrant follow -up. 
CCI
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 39 of 65 
 
 CONFIDENTIAL   Laboratory values that are abnormal and not assessed as AEs may be followed at the discretion 
of the Investigator or the Sponsor’s Medical Monitor until resolved or stabilized.  
9.8.4.1.  Pregnancy reporting  
Prior to study enrollment, females of childbearing potential must be advised of the importance of 
avoiding pregnancy during study participation and the potential risk factors for an unintentional 
pregnancy.  The Informed Consent or Assent Form that the subject sig ns must document this 
discussion.  
If a subject or Investigator suspects that the subject may be pregnant prior to study drug 
administration, the study drug must be withheld until the results of laboratory pregnancy testing 
are available.  If pregnancy is confirmed, the subject must not receive study drug and must not be 
enrolled in the study.  
A urine pregnancy test will be performed on all females of childbearing potential at Baseline, 
Week 3, Week 6, Week 9 and Week  12 of the double -blind phase of the Stu dy and Final Visit or 
when a subject prematurely withdraws from the study.  
Home pregnancy kits will be provided at each visit to all female subjects of childbearing 
potential in the open-label phase of the Study and are to be used at least monthly and if a 
pregnancy is suspected between visits (e.g., if a subject misses a period). A urine pregnancy test 
will be performed at Week 52/Final Visit. 
During the study, all females of childbearing potential should be instructed to contact the  
Investigator immediate ly if they suspect they might be pregnant (eg, missed or late menstrual 
period).  If a subject or Investigator suspects that the subject may be pregnant at any time before 
or during the study , the study drug must be withheld until the results of laboratory  pregnancy 
testing are available.  The Sponsor and Site Monitor must be notified and available information 
captured on a “Suspected Pregnancy” form.   If pregnancy is confirmed, the subject must be 
withdrawn from  the study and the Sponsor and Site Monitor n otified.  Additional relevant 
information about the confirmed pregnancy will be recorded on the appropriate form(s) but the 
pregnancy will not be captured as an AE . 
The subject should be followed until the outcome of the pregnancy is known.  
9.8.5.  Clinically Sign ificantly Abnormal Laboratory Results  
All laboratory values that are outside of the normal range for that parameter will be so flagged 
when reported to the site.  The Investigator will determine which out -of-range laboratory test 
results should be charact erized as clinically significant and will so annotate the laboratory report.  
If a clinically significant laboratory abnormality requires treatment or is the reason for a subject 
being discontinued from the study, the abnormal result must also be classifie d as an AE. 
9.9.  Appropriateness of Safety Measurement  
The safety assessments in this study are standard safety measures in clinical trials.  
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 40 of 65 
 
 CONFIDENTIAL   10.  STATISTICAL DESIGN A ND ANALYSIS  
10.1.  Statistical Analysis Plan  
A detailed statistical analysis plan will be finalized prior to breaking of the study blind.  
Descriptive statistics for qualitative variables (eg, race) will include the number and percentage 
of subjects with the qualitative response.  Missing responses will be enumerated, but the 
calculation of percentages will exc lude missing responses.  For quantitative variables (eg, age), 
descriptive statistics will include the number of subjects with non -missing data, mean, standard 
deviation, median, minimum value and maximum value.  All hypothesis testing will be 
conducted using two-sided tests with  α=0.05 level of significance  unless otherwise specified . 
All study data will be presented in listings.  
10.2.  Determination of Sample Size  
In a phase 2 study, the proportion of subjects with an IGA score of 0 or 1 after 12 weeks of  
treatment was 20% in the minocycline 4% foam group compared to 2% in the vehicle group. The 
following table provides a few alternate assumptions and corresponding sample sizes. Power was 
set to 90% and type -1 error to two -sided 0.05. Sample size was calculated based on Fisher’s 
Exact test. 
Vehicle IGA (0,1) Minocycline 4% 
foam IGA (0,1) Sample sizes 
(vehicle, active)  
   
   
   
Assuming 12% dropout rate,  subjects on active, and  subjects on vehicle will provide at 
least 90% power for a statistic ally significant difference on IGA 0 or 1. In the same phase 2 
study, the change from baseline in inflammatory lesions was  in the minocycline 4% foam 
versus  in the vehicle group. The standard deviation in change from baseline was 
approximately 9. 2. The following table shows alternate assumptions and corresponding sample 
sizes, for 90% power and a two -sided type 1 error of 0.05. The sample sizes were calculated 
using a t-test. 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 41 of 65 
 
 CONFIDENTIAL   Vehicle mean 
inflammatory 
lesion reduction  Minocycline 4% foam 
mean inflammatory 
lesion reduction  Sample sizes 
(vehicle, active)  
   
   
   
To summarize, using some conservative estimates of the effect on minocycline 4% foam versus 
the vehicle for both IGA and change in inflammatory les ions at week  subjects on active, 
and  on vehicle will provide > 90% power for s statistically significant difference.  
Another consideration for the sample size must be given to the secondary endpoint of 
noninflammatory lesions which will be comp ared to the vehicle for non -inferiority. The margin 
for non-inferiority will be 30% of the change from baseline to week 12. In a phase 2 study, 
change from baseline in noninflammatory lesions at week 9 was  for the vehicle group with 
a standard deviati on of 18. Assuming approximately the same reduction at week 12, a 30% non -
inferiority margin is about  lesions. The following table provides approximate sample sizes 
for alternate assumptions for 90% power to show non -inferiority. 
Vehicle mean 
noninflammatory 
lesion reduction  Minocycline 4% foam 
mean noninflammatory 
lesion reduction  Sample sizes 
(vehicle, active)  
   
   
   
 
If Minocyclin e 4% foam has the same effect on noninflammatory lesions as vehicle,  subjects 
on vehicle and  on 4% foam will be needed for 90% power to show non -inferiority. If 
Minocycline 4% foam has a slightly less effect on noninflammatory lesions (  lesion 
reduction versus  in vehicle), there will be about 90% power to show  non-inferiority. 
10.3.   Analysis Populations  
The Intent-to-Treat (ITT) population will include all randomized subjects. The ITT population 
will be the primary population for all efficacy analyses.  
The Safety population will include all randomized subjects who t ook at least one dose of study 
drug.  Subjects who have no post -Baseline assessments will be included in the Safety population 
unless all dispensed study drug is returned unused.  
The Per Protocol (PP) population i s defined as the subset of the ITT population without any 
protocol deviations that may have an impact on the efficacy assessments.  The subjects to be 
CCI
CCI
C
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CC
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 42 of 65 
 
 CONFIDENTIAL   included in the PP population will be determined by the Sponsor/CRO prior to the unblinding of 
the study.  The PP population will be secondary for t he co-primary endpoints only.  
Subjects may be excluded from the PP population if any of the following are met:  
  Did not meet inclusion/exclusion criteria  
  Have administered any interfering concomitant medications  
  Have not, in the opinion of the investigator , been compliant with the treatment 
regimen (e.g. reported frequent missed doses)  
Prior to breaking the blind, additional criteria for exclusion from the PP population may be  
included to accommodate for unforeseen events that occurred during the conduct of  the study.  
10.4.  Efficacy Endpoints  
The primary population for all efficacy analyses will be the ITT population.  Subjects will be 
analyzed according to their randomized treatment.  The primary method of handling missing data 
will be the last observation carri ed forward (LOCF) approach.   Sensitivity analyses using 
multiple imputations and baseline observation carried forward (BOCF) will be performed on the 
co-primary endpoints only.  
Supportive efficacy analyses will also be performed on the PP population.  All  analyses using the 
PP population will use the Observed -Cases (OC) approach .  i.e., there will be no imputation for 
missing data at any time point.  
Changes from Baseline lesion count will be calculated as the Baseline value minus the post -
Baseline value.  Thus, a positive change will reflect a reduction in lesion count.  The percent 
change from Baseline lesion count will be calculated as the Baseline value minus the post -
Baseline value divided by the Baseline value, expressed as a percentage.  Thus, a posit ive 
percent change will reflect a reduction in lesion count.  
10.4.1.  Primary Efficacy Endpoints  
The co-primary efficacy endpoints are:  
  The absolute change from Baseline in the inflammatory lesion count at Week 12  
  Treatment Success (dichotomized as Yes/No) at Week 12, where success is defined 
as an IGA score of 0 or 1, and at least a 2 -grade improvement (decrease) from 
Baseline 
The null hypotheses of the equality of the FMX-101 4% and vehicle means for absolute change 
from Baseline to Week 12 in the inflammatory les ion count and the equality of IGA success rates 
at Week 12 will each be tested at a two-sided 0.05 level of significance.  Change from baseline in 
inflammatory lesion count will be analyzed using an Analysis of Covariance (ANCOVA), with 
Treatment as a main effect, baseline inflammatory lesion count as a covariate, and 
investigational site a blocking factor. Investigational site by Treatment interaction will be tested 
at 0.1 level, and if significant, it will further be explored. The dichotomized IGA will be 
analyzed using a Cochran -Mantel-Haenszel (CMH) test, stratified by investigational site.  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 43 of 65 
 
 CONFIDENTIAL   10.4.2.  Secondary Efficacy Endpoints  
  The absolute change from Baseline in the noninflammatory lesion count at Week 12  
  The absolute change from Baseline in the inflammatory le sion count and IGA 
Treatment Success at the interim visit at Week 9  
  The absolute change from Baseline in the inflammatory lesion count and IGA 
Treatment Success at the interim visit at Week 6  
10.4.3.  Tertiary efficacy endpoints  
  The percent change from Baseline in the inflammatory lesion count at Weeks 3, 6, 9 
and 12 
  The absolute change from Baseline in the inflammatory and noninflammatory lesions, 
and the IGA Treatment Success at Week 3 
  The absolute change from Baseline in the noninflammatory lesion count at Weeks 3, 
6, 9 and 12 
  The percent change from Baseline in the noninflammatory lesion count at Weeks 3, 6, 
9 and 12 
Secondary efficacy endpoint will be tested sequentially in the order listed above, at 0.05 level of 
significance, only if the co -primary efficacy en dpoints are significant.  
10.5.  Safety endpoints   
Treatment-emergent adverse events (TEAEs), vital signs , physical examinations, and clinical 
laboratory measurements  will be reported on the Safety population.  Subjects will be reported 
according to the treatment  they actually received.  No statistical tests will be performed for any 
of the safety assessments.  
Baseline for vital signs, physical examinations, and clinical laboratory measurements is defined 
as the last non -missing value prior to the first dose of st udy drug. 
10.5.1.  Adverse Events  
The Medical Dictionary for Regulatory Activities (MedDRA) terminology will be used to 
classify all AEs with respect to system organ class (SOC) and preferred term.  
TEAEs will be defined as events that emerge during treatment having  been absent pre -treatment, 
or worsen relative to the pre -treatment state.  Summaries of AEs will be limited to TEAEs.  The 
number and percentage of subjects reporting each SOC and preferred term will be summarized 
for each treatment group  and by the Study  Period.  At each level of summarization, a subject will  
be counted once if he/she reported one or more events.  The severity of TEAEs and relationship 
to study drug will be summarized in a similar manner.  For summaries of relationship to study 
drug, a subject will be classified according to the closest relationship.  For summaries of TEAE 
severity, a subject will be classified according to the highest severity.  
Summaries of SAEs and subjects who prematurely withdraw from the study due to AEs will be 
presented. 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 44 of 65 
 
 CONFIDENTIAL   10.5.2.  Vital Signs  
Vital sign parameters will be summarized using descriptive statistics at Baseline and at each 
post-baseline time point.  Changes from Baseline will also be summarized.  Baseline is defined 
as the last non -missing value prior to the first  dose of study drug.  
10.5.3.  Physical Examinations  
Physical examinations will be summarized using descriptive statistics at Baseline and at each 
post-baseline time point .  Shifts from Baseline will also be summarized.  Baseline is defined as 
the last non-missing value prior to the first dose of study drug.  
10.5.4.  Clinical Laboratory Results   
Baseline is defined as the last non -missing value prior to the first dose of study drug.  
Shift tables for each clinical laboratory test will cross -tabulate the number of subjects with  values 
below the laboratory reference range (low), values within the laboratory reference range 
(normal) or above the laboratory range (high) at baseline with the number of subjects with low, 
normal or high values at each post-baseline time point .  
A listing of subjects with pre -treatment and treatment -emergent clinically significant abnormal 
laboratory values will be presented for each treatment group. Clinical significance is based on 
the Investigator’s judgment.   
10.6.  Statistical Analysis 
10.6.1.  Interim Analysis   
No interim analysis is planned.  
10.6.2.  Subject Accounting, Demographic, and Baseline Characteristics  
Demographic, baseline characteristics, and prior and concomitant medications will be 
summarized by treatment.  Study completion status and reasons for discontinuat ion will also be 
displayed by treatment.   
Medical and surgical history will only be presented in the listings.  
10.6.3.  Efficacy Analysis  
The co-primary endpoint of absolute change from Baseline in inflammatory lesions at Week 12 
will be analyzed using an Analysis  of Covariance (ANCOVA) model with main effect treatment 
and investigational site as a covariate.  The treatment by investigational site interaction will be 
tested separately at 0.1 level of significance, and if significant, will be further be explored.  A  
95% confidence interval will be calculated on the difference in mean changes from baseline  
between FMX -101 4% and vehicle. 
The co-primary endpoint of IGA Treatment Success rat e at Week 12 will be analyzed using a 
Cochran –Mantel –Haenszel (CMH) test with in vestigational site as the stratification factor.  If the 
overall IGA Treatment Success  rate is less than 10%, a Fisher’s Exact test will be used to 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 45 of 65 
 
 CONFIDENTIAL   corroborate the CMH test.  A 95% confidence interval will be constructed on the difference in 
IGA Treatment Success rates between FMX -101 4% and vehicle.  
If FMX-101, 4% is found superior to vehicle (one -sided p<=0.025) for both co -primary 
endpoints, the secondary endpoints will be tested sequentially. The first secondary endpoint of 
noninflammatory lesions at Week 12 will be tested initially as a non -inferiority comparison of 
FMX-101, 4% to vehicle. Non -inferiority margin is defined as 30% of the noninflam matory 
lesion reduction in the vehicle group at Week 12. A lower 97.5% confidence limit will be 
calculated for µa-0.6×µv, where µa and µv are the mean reduction of no ninflamatory lesions of 
FMX-101, 4% and vehicle respectively. If the confidence limit is above 0, non -inferiority will be 
concluded. If non -inferiority is concluded, the superiority of FMX -101, 4% to vehicle for 
noninflammatory lesions at Week 12 will be tested. The sequential testing will proceed 
according to the order in Section 10.4.2.1.  Testing of secondary efficacy endpoints at an earlier 
timepoint for each type of lesion and IGA  Treatment Success  will be performed only if 
superiority (one -sided p<=0.025) is seen at the later timepoint.   
Secondary efficacy parameters will be analyzed similar to the appropriate co -primary efficacy 
parameter. 
Absolute change from baseline in inflammatory lesion count and the IGA assessments in the 
open-label phase of the study will be summarized. No statistical testing will be performed for the 
open label efficacy data.  
10.6.4.  Safety Analysis  
The Medical Dictionary for Regulator y Activities (MedDRA) terminology will be used to 
classify all AEs with respect to system organ class (SOC) and preferred term.  
TEAEs will be defined as events that emerge during treatment having been absent pre -treatment, 
or worsen relative to the pre -treatment state.  Summaries of AEs will be limited to TEAEs.  The 
number and percentage of subjects reporting each SOC and preferred term will be summarized 
for each treatment group.  At each level of summarization, a subject will be counted once if 
he/she reported one or more events.  The severity of TEAEs and relationship to study drug will 
be summarized in a similar manner.  For summaries of relationship to study drug, a subject will 
be classified according to the closest relationship.  For summaries of TEA E severity, a subject 
will be classified according to the highest severity.  
Summaries of SAEs and subjects who prematurely withdraw from the study due to AEs will be 
presented. 
Vital sign parameters will be summarized using descriptive statistics at Baseli ne and at each 
post-baseline time point.  Changes from Baseline will also be summarized.  
Physical examinations will be summarized using descriptive statistics at Baseline and for the 
final visit.  Shifts from Baseline will also be summarized.  
Shift tables for each clinical laboratory test will cross -tabulate the number of subjects with values 
below the laboratory reference range (low), values within the laboratory reference range 
(normal) or above the laboratory range (high) at baseline with the number of s ubjects with low, 
normal or high values at the Final Visit.  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 46 of 65 
 
 CONFIDENTIAL   A listing of subjects with pre -treatment and treatment -emergent clinically significant abnormal 
laboratory values will be presented for each treatment group. Clinical significance is based on 
the Investigator’s judgment.  
11.  STUDY MANAGEMENT  
11.1.  Monitoring 
The Investigator will be responsible for preparing and maintaining adequate and accurate source 
documents (medical records, raw data collection forms, etc.) designed to record all observations 
and other pertinent data for each subje ct treated with the study drug.  The Investigator will allow 
representatives of the Sponsor, contract designees, authorized regulatory authority inspectors, 
and the IRB to have direct access to all documents pertaining to the s tudy.  The Investigator is to 
immediately notify the Sponsor or the Sponsor’s representative  of any regulatory authority  
inspections.  The Investigator will be informed about the outcome of any Sponsor audit.  
This study will be monitored regularly, by or u nder supervision of a monitor from the Sponsor.  
The frequency of monitoring visits will be agreed upon by the Sponsor’s representative and the 
study site.  
Monitoring visits will take place on a regular basis according to the enrollment rate and number 
of subjects enrolled at each investigational site.  During these visits, the monitor will check the 
completion of the CRF entries, compliance with the study protocol and with GCP -ICH, and the 
agreement of key entries with the source data.  The monitor will a lso verify the corre ct use of the 
study drug.  At the Final Visit  or at an agreed to time prior to the Final Visit , the monitor will 
check all remaining material including the remaining quantities of the study drug and will 
organize their return to the Spo nsor or designee.  At each visit, the Investigator and staff will be 
expected to cooperate with the Sponsor’s representative(s) for the purposes of review and 
verification of protocol compliance, AE reporting, CRFs, source documents, clinical supplies 
and inventory records, and any additional records as may have been previously arranged between 
the Investigator and the Sponsor’s representative(s).  
The Investigator and/or other designated study personnel are expected to contact the Sponsor’s 
or the Sponsor’s  representative’s  clinical research associate, as needed, regarding study concerns 
and/or questions.  Contact information is provided in the Study Binder for the site. 
11.2.  Protocol Amendments  
The Sponsor may propose to amend this protocol at any time.  
No change to the protocol will be implemented until the Sponsor and the IRB have reviewed and 
approved the amendment.  
In the event of an emergency, the Investigator shall implement any medical procedures deemed 
appropriate for subject safety.   All such procedures must have written documentation and be 
promptly reported to the Sponsor.  
Amendments to the protocol, if any, are included in  Section 16.2, page 53.  This protocol version 
includes Amendment 1 , effective February 26, 2016  and Amendment 2, effective April 6, 2016.   
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 47 of 65 
 
 CONFIDENTIAL   11.3.  Protocol Deviations  
A protocol deviation is any change, diver gence or departure from the IRB -approved protocol by 
the study staff (intentional or unintentional).  All deviations are to be documented at the site and 
reported to the IRB according to the IRB’s guidelines.  
In the event of an emergency, the Investigator shall implement any medical procedures deemed 
appropriate for subject  safety.  All such procedures must have written documentation and be 
promptly reported to the Sponsor.  
11.4.  Withdrawal of Subjects  
Withdrawn subjects are those who do not complete all evaluations and procedures outlined in the 
protocol.  Subjects who discontinu e taking study drug for any reason must also be withdrawn 
from the study.  Subjects may be withdrawn from the study because of one of the following:  
  Adverse Event:   An AE that, in the opinion of the Investigator or Sponsor, suggests 
that continued particip ation in the study is not in the subject’s best interest for safety 
reasons.  All AEs that are present when the subject withdraws from the study will be 
followed as described in Section 9.8.4. 
  Abnormal Laboratory  Result:  Any clinically significant laboratory abnormality 
that requires withdrawal of the subj ect from the study should be considered an AE 
leading to withdrawal.  If possible, laboratory tests will be repeated for any results 
that were clinically signif icantly abnormal until the abnormality is resolved or 
stabilized to the satisfaction of the Investigator in consultation with the Medical 
Monitor. 
  Lost to Follow -up:  Confirmed at minimum by 2 phone calls and a traceable letter 
without response. 
  Subject Request:  Subject requests , for any reason (eg, AE) , to be withdrawn or 
withdraws his/her consent . 
  Poor protocol adherence :  A subject may be withdrawn from the study at the 
discretion of the Investigator or Sponsor due to poor compliance with protocol 
requirements that may compromise the study results or subject safety.  
  Other:  Other reasons include but are not limited to: Investigator decision that it is in 
the subject’s best interest to be withdrawn, administrative reasons, relocation of 
subject, etc.  If a subject becomes pregnant during the study, the subject will be 
withdrawn from the study and followed through conclusion of the pregnancy.  
If a subject is withdrawn from the study following the start of study drug during Period 1 of the 
study, all Week 12 assessments should be completed.   If a subject is withdrawn from the study 
following the start of study drug  during Period 2 of the study , all Final Visit assessments should 
be completed.  Subjects withdrawn from the study will not be replaced.  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 48 of 65 
 
 CONFIDENTIAL   11.5.  Termination of the Study  
The study may be terminated at any time at the request of the Sponsor or a regulatory authority, 
with proper and timely notification of all parties concerned.   The IRB will be informed promptly 
and the Sponsor or the Investigator will supply  reason(s) for the termination or suspension, as 
specified by the applicable regulatory requirements.  Otherwise, the study is considered 
terminated upon completion of all subject treatments and evaluations.  
11.6.  Publication Policy  
The data obtained in this  study are the property of the Sponsor, which will make reasonable 
efforts to assure that the results are published in a peer -reviewed journal.  As some of the 
information concerning the investigational product and development activities at the Sponsor 
may be of strictly confidential nature, any manuscript or other presentation of data must first be 
reviewed by the Sponsor before its submission.  
12.  ETHICS 
12.1.  Conduct of the Study  
This study will be conducted in accordance with the ICH Harmonized Tripartite Guideline f or 
GCP, 1997; the US Title 21 CFR parts 50, 56, and 312; and the ethical principles that have their 
origin in the Declaration of Helsinki.  The study will not begin until all of the requirements of the 
appropriate regulatory authorities have been fulfilled . 
12.2.  Institutional Review Boards (IRB)  
This protocol (and any changes), all consent /assent forms, and subject consent procedures must 
be reviewed and approve d by a properly constituted IRB .  The information presented to the IRB  
at the time initial approval is  sought must include any plans for subject recruitment that involve 
advertising or other direct contact with potential subjects outside of the doctor -subject 
relationship.  A letter of approval issued by the IRB must be sent to the Sponsor prior to 
initiation of the study.   Any changes made to the protocol must be approved by the IRB prior to 
implementation, except where needed to eliminate a potential imminent safety hazard to the 
subjects.  In this case, immediate implementation may apply place followed b y IRB approval. 
Review and approval by the IRB  for continuation of the study must apply place at least once a 
year. 
12.3.  Written Informed Consent  
The Investigator or designee will explain the nature of the study, its purpose and associated 
procedures, the expec ted duration and the potential benefits and risks of participation to each 
subject prior to his/her entry into the study (ie, before examinations and procedures associated 
with selection for the study are initiated).  Each subject will have ample opportuni ty to ask 
questions and will be informed about the right to withdraw from the study at any time without 
any disadvantage and without having to provide reasons for this decision.  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 49 of 65 
 
 CONFIDENTIAL   Following this informative discussion, the subject will be asked if he/she is willing to sign a 
statement of informed consent.   Only subjects who voluntarily sign the Informed Consent Forms 
(ICF) may enter the study.  Subjects less than 18 years of age  (or as required by state law)  must 
sign an Assent Form for the study and a parent or legal guardian must sign the ICF.  
The ICF and Assent Form must be reviewed and approved by the Sponsor and the IRB prior to 
their use. 
The original signed ICF and Assent Form will remain in the Investigator ’s files.  The 
Investigator or designee will in dicate in each subject’s source documents that he / she has 
informed the subject about the study and its procedures, the subject has signed and dated the 
ICF/Assent Form , and the subject has been given a copy of the documents.  The Investigator or 
designee will inform subjects of any new information that may be relevant to the subjects’ 
willingness to continue in the study.  
12.4.  Subject Confidentiality  
The Sponsor ensures that the following have permission to review all study -related documents: 
monitor, auditor,  IRB and regulatory authorities.  The subject’s identity and study -related records 
will remain confidential throughout the duration of the study data collection and reporting 
process. 
A unique subject identification code is assigned to each potential study  subject.  The 
identification code protects the subject’s identity and is used in lieu of the subject’s name when 
reporting subject data.  The data will always maintain the confidentiality of the subject.  
The investigator or designee will review the subjec t data, which will be referenced using the 
subject identifier.  At the conclusion of the study, the data obtained may be presented to regional 
regulatory authorities but the subject’s identity will not be revealed.   In addition, if any clinical 
data obtained from the study is published in scientific journals or presented at scientific meetings 
the subject’s identity will not be revealed.  
12.5.  Records Retention  
The Investigator must maintain essential study documents (protocol and amendments, source 
documentation  corresponding to all information contained in the CRFs, signed informed consent  
and assent forms, relevant correspondence, and all other supporting documentation) until at least 
2 years after the last approval of a marketing application in an ICH region a nd until there are no 
pending or contemplated marketing applications in an ICH region, or at least 2 years after the 
formal discontinuation of clinical development of the investigational product.  These documents 
should be retained for a longer period if r equired by the applicable regulatory requirements or the 
hospital, institution, or private practice in which the study is being conducted.   Subject 
identification codes (subject names and corresponding study numbers) will be retained for this 
same time per iod. Custody of the records may be transferred to another responsible party, 
acceptable to the Sponsor, who agrees to abide by the retention policies.  Written notice of 
transfer must be submitted to the Sponsor.   The Investigator must contact the Sponsor prior to 
disposing of any study records.  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 50 of 65 
 
 CONFIDENTIAL   12.6.  Financing 
Funding for this study will be agreed between the Investigator and the Sponsor and will be 
confirmed in writing before the study starts.  
Completion of Financial Disclosure Forms will be required before the  study starts.  Any 
additions to the primary site personnel will necessitate the completion of new Financial 
Disclosure Forms.  This information will also be collected at site closure and one year after the 
completion of the study.  
Disclosure Forms.  Inves tigators will be informed that they must report any new information to 
the sponsor or designate at site closure and one year after the completion of the study.  
13.  QUALITY CONTROL AND QUALITY ASSURANCE  
The Sponsor and Investigator will apply all steps possible  to ensure the accuracy, consistency, 
completeness, and reliability of the data, including participating in an Investigator meeting 
and/or site initiation visit, routine site monitoring, review of CRFs against source documents, and 
quality control checks.  
In addition, a representative from the Sponsor’s Clinical Quality Assurance (CQA) Department 
or designee may conduct periodic audits of the study processes, including, but not limited to, 
auditing the clinical site, laboratories, vendors and CROs, the cli nical database, and the final 
study report. 
14.  DATA HANDLING AND RE CORD KEEPING  
This study will use web -based, electronic case report forms (eCRFs) developed through a 
validated, Electronic Records / Electronic Signatures -compliant platfo rm (US Title 21  CFR Part 
11).  Foamix Clinical Data Management  department or designee will create the electronic CRFs 
and corresponding clinical database based on the final protocol.  
All site personnel who will be using this system will receive formal training on the system, a fter 
which each person will be issued a unique user name and password.   Only the person who owns 
the user name and password will enter the system using that user name and password.  For data 
security reasons and to be in compliance with regulatory guidelin es, usernames and passwords 
are not transferable.  
The Investigator is responsible for all data entered via the eCRFs and must confirm the accuracy 
of the data by electronically approving (signing) the eCRFs.  This responsibility includes the 
timely complet ion and accuracy of the data entered into the eCRFs by their site personnel as well 
as the review of some  data entered directly into the database (eg, clinical laboratory results) by 
an external vendor.  The Sponsor will review the database to identify dat a errors or 
inconsistencies, which will be posted in the RDC system as queries for resolution. In addition, 
the Sponsor may make obvious corrections to the data in the database (eg, obvious errors in 
dates) and so inform the Investigator without issuing a query to the site.  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 51 of 65 
 
 CONFIDENTIAL   15.  REFERENCE LIST  
1.  Brown SK, Shalita A R; Acne Vulgaris, Follicutitis, and Acne Rosacea. Lancet 
351:1871-76, 1998 
2.  Guidance for Industry: “Acne Vulgaris: developing Drugs for Treatment ” Se ptember 
2005 FDA Draft Guidance  
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 52 of 65 
 
 CONFIDENTIAL   16.  APPENDICES  
16.1.  Appendix 1 – Subjects Satisfaction Questionnaire  
 
The following 8  questions will be asked of the subject at Visit 6, Week12  and Visit 13, Week 52 : 
1.  How satisfied are you with this product  in treating your acne? 
2.  How satisfied are you with how easy this product is to use? 
3.  How satisfied  are you with this product compared to other products you have previously 
used for acne, such as gels and creams ? 
4.  How satisfied are you with how this product feels on your skin after treatment?  
5.  How satisfied are you with  the odor of this  product after treatment ? 
6.  How satisfied are you with  the color of this product after treatment ? 
7.  Overall, how satisfied  are you with this product? 
8.  Overall, how likely are you to recommend this product to a friend? 
 
Answers to Questions 1 -7 will be selected f rom the following:  
1=Very Satisfied  
2=Satisfied 
3=Somewhat Satisfied  
4=Dissatisfied  
5=Very Dissatisfied  
 
Answer to Question 8 will be selected from the following:  
1=Very Likely 
2=Likely 
3=Somewhat Likely 
4=Unlikely 
5=Very Unlikely 
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 53 of 65 
 
 CONFIDENTIAL    
16.2.  Appendix 2 – Protocol Amendments  
This appendix describes the amendment (s) that have been made to the protocol for Study 
FX2014-0. 
Section 16.2.1 describes the changes made to Protocol FX2014-05  Version 1 issued January 19, 
2016, via Amendment 1 effective February 26, 2016 . 
Section 16.2.2 describes the changes made to Protocol FX2014-05  Version 2 issued February 
26, 2016, via Amendment 2 effective April  6, 2016.   
16.2.1.  Amendment 1 , effective February 26, 2016  
The following is the summary of the changes that were made to Protocol FX2014-05  Version 1 
issued 19-JAN-2016. 
Administrative changes: 
Section  Revision 
    Title Page Added:  
    Signature Page  Added 
    Study Administrative 
Structure Added:  
 
    SAE Reporting Information  Added: TKL Clinical Pharmacovigilance  
 
 
Content changes:   
New or changed test is  bolded. 
Section Revision Rationale 
Old Text New Text  
1.10.1. Efficacy  . . Weeks 1, 3, 6, 9 and 12  . Weeks 3, 6, 9 and 12.  Correction 
1.11  Statistical 
Methods IGA score at Week 12 
(where success is defined as 
at least a 2-grade decrease 
from Baseline) . IGA Treatment Success 
(dichotomized as Yes/No) 
at Week 12, where success 
is defined as an IGA score 
of 0 or 1, and at least a 2 -
grade decrease from 
Baseline.   Modified as per FDA 
suggestion 
At least a 2-grade 
improvement (decrease) 
from Baseline in the IGA 
score will be analyzed 
using . . . The IGA Treatment 
Success rates will be 
compared between the 
treatment groups using . . .  
PPD
PPD
CCI
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 54 of 65 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
6.  Study 
Procedures Inserted Procedures at the 
Screening Visit will include 
obtaining blood and urine 
samples for clinical 
laboratory tests.  These 
results must be no more 
than 30 days old at the 
time of Baseline Visit  
randomization.  Clarification of ti ming of 
laboratory tests during 
Screening 
6.  Study 
Procedures – 
Table 1 Inserted “X” for Tolerability 
Assessment at all post -
Baseline visits  Added at request of FDA  
“X” for Blood and urine 
samples at Baseline  “X” for Blood and urine 
samples at Screeni ng Sampling moved to earlier 
timepoint 
Inserted “X” for Blood and urine 
samples at Week 3  Added at request of FDA  
Inserted  “X” for Dispense study drug 
at Week 1 Correction  
Inserted “X” to Confirm next visit  Correction 
Footnote inserted  Footnote 6  -  Home 
pregnancy tests will be 
dispensed to all female 
subjects at risk of 
becoming pregnant and 
will be performed 
whenever there is a 
suspicion of pregnancy 
(e.g., a missed period)  Added at request of FDA  
6.  Study 
Procedures – 
Table 1 
Footnote 2 If a subject prematurely 
withdraws from the study, 
all evaluations described 
under Visit 6/Week 12 must 
be performed.   Subject may continue into 
open-label phase of study. 
If a subject is not 
continuing into open -label 
phase for any reason (see 
Section 4.1.2), all 
evaluations described under 
Visit 6/Week 12 must be 
performed.   Clarification of process at 
Visit 6 
6.1 – 6.2   Study 
Procedures 
at Visits 3 – 14 Record AEs  Record AEs and 
Tolerability Assessments  Changed at all post -Baseline 
Visits at request of FDA  
6.1.1  Screening 
Visit Using the Interactive Web 
Response system (IWRS),  
assign the subject a . . .  Assign the subject a  . . .  Screening number will not 
be assigned by IWRS  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 55 of 65 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
Inserted  •   Collect blood and urine 
samples for clinical 
laboratory t ests . . . Lab tests moved from 
Baseline to Screening Visit 
6.1.2  Baseline 
Visit, Visit 1 • Confirm eligibility  none Deleted repetition  
• Collect blood and urine 
samples for clinical 
laboratory tests . . . deleted Lab tests moved from 
Baseline to Scree ning Visit 
6.1.3    Visit 2, 
Week 1  Inserted  • Dispense 1 kit (2 
canisters) of study drug  Correction 
6.1.4. Visit 3, 
Week 3 inserted • Collect blood and urine 
samples for clinical . . .  Added per FDA request  
• Confirm that subject 
continues to use th e drug 
product and only provided 
cleanser correctly  Deleted Redundant 
6.1.7. Visit 6, 
Week 12  End of Double -Blind or 
Early Termination   End of Double -Blind or 
Continuation in Open 
Label / Early Termination   Title changed for clarity  
6.2   Part 2 – 
Open-label  Table 
2 Footnote inserted  Footnote 3  -  Home 
pregnancy tests will be 
dispensed to all female 
subjects at risk of 
becoming pregnant and 
will be performed 
whenever there is a 
suspicion of pregnancy 
(e.g., a missed period)  Added at request of FDA  
Inserted “X” for Tolerability 
Assessment at all post -
Baseline visits  Added at request of FDA  
Inserted “X” for Blood and urine 
samples at Week 28  Added at request of FDA  
6.2.1   Visit 7 – 
Week 16 Dispense 1 kits (2 canisters) 
of FMX-101, 4% 
minocycline foam if required  Dispense 2 kits (4 canisters) 
of FMX-101, 4% 
minocycline foam if required  Correction 
6.2.2  Visit 9, 
Week 28 inserted • At Visit 9 (Week 28) only 
– Collect blood and urine . 
. . Added per FDA request  
7.1.3.1  Part 1 – 
Double-blind none After shaking the canister 
well . . . Added text to include 
instruction to shake  
 . . .supplies will be 
dispensed at Baseline and 
Weeks 3, 6 and 9 . . . . . . supplies will be 
dispensed at Baseline and 
Weeks 1, 3, 6 and 9 . . . Correction 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 56 of 65 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
7.1.5  Labeling of 
Study Drug none “Shake well before using”  Added text to label about 
shaking  
7.1.6  Storage of 
Drug FMX-101, 4% and vehicle 
canisters must be stored at 
20°C – 25°C  . . . FMX-101, 4% and vehicle 
canisters must be stored at 
2°C – 8°C until being 
dispensed to the subjects.  
Subsequently, they must be 
stored at 20°C – 25°C . . . Inclusion of instruction that 
site must keep drug 
refrigerated until it is 
dispensed 
7.2   Study Drug 
Accountability  Inserted 
 In addition, the weight of 
each canister will be 
determined prior to being 
dispensed to the subjects 
and each canister that has 
been retrieved from the 
subject will be returned to 
the vendor to be weighed  Added per FDA request  
7.7  Prior and 
Concomitant 
Therapy  Inserted 
 If a subject is taking 
anticoagulant therapy, the 
subject should be advised 
that they may require a 
downward adjustment of 
their anticoagulant dosage.  Tetracyclines may decrease 
plasma prothrombin activity  
7.8  Use of 
Contraception  • Hormonal methods  
o Oral contraceptives   
. . . birth control must be 
utilized in subjects using 
topical contraceptives)  • Hormonal methods  
o Oral contraceptives   
. . . birth control must be 
utilized in subjects using 
oral contraceptives)  Correction 
8.1.1  IGA 
Table 3 See a) below See b) below Removal of quan titative 
description of non -
inflammatory lesions  
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 57 of 65 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
8.1.2  Lesion 
counts Facial lesion counts . . . 
Inflammatory lesions 
(pustules, papules, and 
nodular lesions) and 
noninflammatory lesions 
(open and closed 
comedones) will be counted 
for each area  and recorded 
separately.  The totals of 
inflammatory and non -
inflammatory lesions will 
be calculated from t hese 
regional lesion counts .   
Lesion counts will be 
repeated at Weeks 3, 6, 9 
and 12. Totals do not need 
to be calculated at these 
visits. Facial lesion count s  . . .  
Total inflammatory lesions 
(pustules, papules, and 
nodular lesions) and 
noninflammatory lesions 
(open and closed 
comedones) will be counted 
and recorded separately.    
Lesion counts will be 
repeated at Weeks 3, 6, 9 
and 12.  Counting method modified 
and addressed in Data 
Management Plan  
9.2  Medication 
History A history of medication 
usage . . . medications in the 
last 3 months (6 months for 
acne medications)  will be 
recorded. A history of medication 
usage . . . medications in the 
last 3 months will be 
recorded. Consistency with Section 
6.1.1. 
9.4  Vital Signs  Heart rate and blood 
pressure will be measured at 
all visits.   Heart rate and blood 
pressure will be measured at 
all post-Baseline visits.   Correction 
9.8.1   Method of 
Determining 
Adverse Events inserted •  Developed unusual 
headaches or changes in 
vision Queried at each visit as per 
FDA request 
9.8.3.  Reporting 
Adverse Events  Any serious AEs . . . must be 
reported to the Sponsor 
within . . . Any serious AEs . . . must be 
reported to the Sponsor or 
designee within . . . Correction of omission  
10.2  
Determination of 
Sample Size  None See text at c) below  Modified as per FDA 
suggestion 
10.4.1  Primary 
Efficacy 
Endpoints  IGA score at Week 12 
(where success is defined as 
at least a 2-grade decrease 
from Baseline) . Treatment Success 
(dichotomized as Yes/No) 
at Week 12, where success 
is defined as an IGA score 
of 0 or 1, and at least a 2 -
grade improvement 
(decrease) from Baseline.    Modified as per FDA 
suggestion 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 58 of 65 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
10.4.2. Secondary 
Efficacy 
Endpoints 
 • The absolute change 
from Baseline in the 
noninflammatory lesion 
count at Week 12  
• The absolute change 
from Baseline in the 
inflammatory lesion count 
and IGA at the interim visit 
at Week 9 
• The absolute change 
from Baseline in the 
noninflamm atory lesion 
count at Week 9  
• The absolute change 
from Baseline in the 
inflammatory lesion count 
and IGA Treatment Success 
at the interim visit at Week 6  
• The absolute change 
from Baseline in the 
noninflammatory lesion 
count at Week 6  • The absolute chan ge 
from Baseline in the 
noninflammatory lesion 
count at Week 12  
• The absolute change 
from Baseline in the 
inflammatory lesion count 
and IGA Treatment 
Success at the interim visit 
at Week 9 
• The absolute change 
from Baseline in the 
inflammatory lesion cou nt 
and IGA Treatment 
Success at the interim visit 
at Week 6 Modified as per FDA 
suggestion 
10.4.3. Tertiary 
Efficacy 
Endpoints 
 • The percent change from 
Baseline in the inflammatory 
lesion count at Weeks 3, 6, 9 
and 12 
• The percent change 
from Baseline in the 
noninflammatory lesion 
count at Weeks 3, 6, 9 and 
12 
• The absolute change 
from Baseline in the 
inflammatory and 
noninflammatory lesions, 
and the dichotomized IGA 
score, (where success is 
defined as at least a 2 -
grade decrease from 
Baseline), at Week 3 
• The percent change from 
Baseline in the 
noninflammatory lesion 
count at Weeks 3, 6, 9 and 
12 • The percent change from 
Baseline in the inflammatory 
lesion count at Weeks 3, 6, 9 
and 12 
• The absolute change 
from Baseline in the 
inflammatory and 
noninflammatory lesions, 
and the IGA Treatment 
Success at Week 3 
• The absolute change 
from Baseline in the 
noninflammatory lesion 
count at Weeks 3, 6, and 9  
• The percent change from 
Baseline in the 
noninflammatory lesion 
count at Weeks 3, 6, 9 and 
12 Modified as per FDA 
suggestion 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 59 of 65 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
10.6.3 Efficacy 
Analysis The co-primary endpoint of 
at least a 2-grade 
improvement (decrease) 
from Baseline in the IGA 
score at Week 12 will be 
analyzed . . . overall IGA 
response rates  are less than 
10% . . . on the difference in 
IGA success rates between 
FMX-101 4% and vehicle.  The co-primary endpoint of 
IGA Treatment Success 
rate at Week 12 will be 
analyzed . . . overall IGA 
Treatment Success rate  is 
less than 10%  . . . on the 
difference in IGA 
Treatment Success  rates 
between FMX -101 4% and 
vehicle. Modified as per FDA 
suggestion 
. . .Testing of secondary 
efficacy endpoints at an 
earlier timepoint for each 
type of lesion and IGA will 
be performed only if 
superiority (one -sided 
p<=0.025) is seen at the later 
timepoint. .  Testing of secondary 
efficacy endpoints at an 
earlier timepoint for each 
type of lesion and IGA 
Treatment Success  will be 
performed only if superiority 
(one-sided p<=0.025) is seen 
at the later timepoint.  Modified as per FDA 
suggestion 
11.1  Monitoring  Monitoring visits will apply 
place . . . Monitoring visits will take 
place Correction  
 . . . Sponsor . . .  . . . Sponsor or Sponsor’s 
representative . . . Multiple corrections  
 
 
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 60 of 65 
 
 CONFIDENTIAL   a)  Old Table 3 – IGA Scale 
 
Table 3: IGA Scale for Acne Vulgaris  
Score Grade Description 
0 Clear Normal, clear skin with no evidence of acne vulgaris 
 
1  
Almost clear Rare noninflammatory  lesions present; rare (eg, <5) non-inflamed papules 
(papules must be resolving and may be hyperpigmented,  though not pink-
red) 
2 Mild Some noninflamma tory lesions are present; few (eg, <10) inflammatory  
lesions (papules/pustules  only; no nodulocystic  lesions) 
 
3  
Moderate Many noninflammatory  lesions; multiple (eg, between 25 and 40) 
inflammatory  lesions present; many papules/pustules;  there may or may not 
be a few nodulocystic lesions 
4  Severe Inflammatory  lesions predominate,  many papules/pustules  (eg, between 40 and 75); 
there may be a few nodulocystic lesions 
5 Very Severe Highly inflammatory  lesions predominate,  variable number of comedones, many 
papules/pustules  and many nodulocystic lesions 
 
b)  New Table 3 – IGA Scale 
 
Table 3: IGA Scale for Acne Vulgaris  
Score Grade   Description 
0 Clear Normal, clear skin with no evidence of acne vulgaris 
 
1  
Almost clear Rare noninflammatory  lesions may be present, with rare non-inflamed papules 
(papules must be resolving and may be hyperpigmented,  though not pink- red) 
2 Mild Some noninflammatory  lesions are present, with few inflammatory  lesions 
(papules/pustules  only; no nodulocystic lesions) 
 
3   
Moderate Many noninflammatory  lesions.  Multiple inflammatory  lesions evident with 
several to many papules/pustules,  and there may be one small nodulocystic lesion 
4 Severe Inflammatory  lesions are more apparent,  many comedones and papules/pustules,  
there may be a few nodulocystic lesions 
5  Very Severe Highly inflammatory  lesions predominate,  variable number of comedones, many 
papules/pustules  and many nodulocystic lesions 
 
 
c)  Inserted in Section 10.2  
Another consideration for the sample size must be given to the  secondary endpoint of 
noninflammatory lesions which will be compared to the vehicle for non -inferiority. The margin 
for non-inferiority will be 30% of the change from baseline to week 12. In a phase 2 study, 
change from baseline in noninflammatory lesions  at week 9 was 22.8 for the vehicle group with 
a standard deviation of 18. Assuming approximately the same reduction at week 12, a 30% non -
inferiority margin is about 6.8 lesions. The following table provides approximate sample sizes 
for alternate assumpti ons for 90% power to show non -inferiority. 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 61 of 65 
 
 CONFIDENTIAL   Vehicle mean 
noninflammatory 
lesion reduction  Minocycline 4% foam 
mean noninflammatory 
lesion reduction  Sample sizes 
(vehicle, active)  
   
   
   
 
If Minocyclin e 4% foam has the same effect on noninflammatory lesions as vehicle,  subjects 
on vehicle and  on 4% foam will be needed for 90% power to show non -inferiority. If 
Minocycline 4% foam has a slightly less effect on noninflammatory lesions (  lesion 
reduction versus  in vehicle), there will be about 90% power to show non -inferiority. 
16.2.2.  Amendment 2 , effective April  6, 2016 
The following is the summary of the changes that were made to Protocol FX2014-05  Version 2 
issued February 26, 2016 . 
 
Section Revision Rationale 
Old Text New Text  
5.2 Exclusion Criteria  2. Dermatological condition 
of the face or facial hair 
(eg, beard, sideburns, 
mustache) that could 
interfere with the clinical 
evaluations  2. Acne conglobata, acne 
fulminans, secondary 
acne (chloracne, drug 
induced acne) or any 
dermatological condition .  Specific exclusions added 
for clarity 
6. Study Procedures  
Table 1: Schedule of 
Procedures 
 
 
 
 
 
 
 
 
Footnote 3 
 
 Urine pregnancy test 
(females, only)  Urine pregnancy test 
(females of childbearing 
potential only) Clarification  
Inserted “X” for pregnancy tests to 
be performed at Week 3, 6 
and 9 Modified per FDA  
Inserted New line and “X” for 
Subject Satisfaction 
Questionnaire for Week 12  Procedure added  
. . . This visit and  the 
procedures required at this 
visit can be co mbined with 
Screening. . . . . . The procedures required 
at these visits can be 
combined . . .  Clarification  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 62 of 65 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
 
Footnote 6 Home pregnancy tests will 
be dispensed to all female 
subjects at risk of becoming 
pregnant and will be 
performed whenever there 
is a suspicion o f pregnancy 
(e.g., a missed period)  Perform urine pregnancy 
test at indicated visits.  
Also dispense home urine 
pregnancy test at Week 12 
if subject is continuing 
into open-label treatment  Modified per FDA  
6.1.2. Baseline Visit, 
Visit 1 
 . . . This visit and the 
procedures required at this 
visit can be combined with 
Screening. . . . . . The procedures required 
at this visit can be 
combined with Screening . . 
. Clarification 
Perform urine pregnancy 
test Perform urine pregnancy 
test in females of 
childbearing potential Clarification 
6.1.4. Visit 3, Week 3;  
6.1.5. Visit 4, Week 6;  
6.1.6. Visit 5, Week 9  Inserted 
 Perform urine pregnancy 
test in females of 
childbearing potential  Modified per FDA  
6.1.7. Visit 6, Week 12  Collect a urine sample from 
female subjects for a urine 
pregnancy test  Perform urine pregnancy 
test in females of 
childbearing potential  Clarification 
Inserted • Administer Subject 
Satisfaction 
Questionnaire  Procedure added  
• If subject is continuing  
. . . dispense 1 kit (2 
canisters) of FMX-101 . . . • If subject is continuing 
. . . dispense 2 kits (4 
canisters) of FMX-101 . Correction 
6.2 Part 2 – Open-label 
Table 4: Schedule of 
Procedures 
 
 
 
 
Footnote 3  
 
 
 Inserted “X” for pregnancy tests to 
be dispensed at Wee ks 16, 
22, 28, 34, 40 and 46.  Modified per FDA  
Inserted New line and “X” for 
Subject Satisfaction 
Questionnaire  for Week 52 Procedure added  
Home pregnancy tests will 
be dispensed to all female 
subjects at risk of becoming 
pregnant whenever . . .  Home pregnancy tests will 
be dispensed at each visit 
to all female subjects of 
childbearing potential  and 
will be performed at least 
monthly and whenever . . . 
Perform urine pregnancy 
test at Final Visit.  Modified per FDA  
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 63 of 65 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
6.2.1. Visit 7, Week 16  Inserted 
 Dispense Home 
pregnancy kit to all 
female subjects of 
childbearing potential  Modified per FDA  
 
6.2.2. Visits 8 – 12, 
Weeks 22 - 46 Inserted 
 Dispense Home 
pregnancy kit to all 
female subjects of 
childbearing potential  Modified per FDA  
 
6.2.3. Visit 13, Final  
Visit – Week 52 Collect a urine sample from 
female subjects for a urine 
pregnancy test  Perform urine pregnancy 
test in females of 
childbearing potential  Clarification 
Inserted • Administer Subject 
Satisfaction 
Questionnaire  Procedure added  
7.1.3.1. Part 1 – 
Double-blind 
 After shaking . . . , a small 
amount of foam should be 
expressed . . . . additional 
amounts of foam should 
also be applied . . 
.approximately the same 
time each day preferably in 
the evening. After shaking . . .a small 
amount of foam  (about 1/2 
gram or a cherry -sized 
amount) should be 
expressed . . .   additional 
amounts (up to a total of 
4g) of foam should also be 
applied . . .the same time 
each day preferably in the 
evening at bedtime. Clarification of amounts 
and timing 
8.3. Subject 
Satisfaction 
Questionnaire  
 Inserted A satisfaction 
questionnaire will be 
administered at Visit 6, 
Week 12 and Visit 13, 
Week 52 (see Section 16.1, 
Appendix 1).  Procedure added  
9.6. Clinical 
Laboratory Tests  Serum chemistry, 
hematology and 
urinalysis will be 
evaluated at Baseline , 
Week 12 and Final Visit. Serum chemistry, 
hematology and 
urinalysis will be 
evaluated at Baseline, 
Week 12/ Final Visit of 
the double-blind phase 
of the Study, and at 
Week 28 and Week 
52/Final Visit of the 
open-label phase of the 
Study. Modified per FDA  
 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 64 of 65 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
9.6.1. Urine Pregnancy 
Test A urine sample will be 
collected from all female 
subjects for a urine 
pregnancy test at 
Baseline, Week 12  and 
Final Visit or when a 
subject prematurely 
withdraws from the 
study. A urine pregnancy test 
will be performed on all 
females of childbearing 
potential at Baseline, 
Week 3, Week 6, Week 
9 and Week  12 of the 
double-blind phase of 
the Study and Final Visit 
or when a subject  
prematurely withdraws 
from the study.  
Home pregnancy kits 
will be provided at  each 
visit to all female 
subjects of childbearing 
potential in the open-
label phase of the Study 
and are to be used at 
least monthly and if a 
pregnancy is suspected 
between visits (e.g., if a 
subject misses a 
period). A urine 
pregnancy test will be 
performed at Week 52/ 
Final Visit. Modified per FDA  
 
9.7.1. Tolerability  . . pigmentation . . .  . . .hyperpigmentation . . .  Correction 
9.8.4. Adverse Event 
Follow-up Adverse events  that are 
ongoing when a subject 
withdraws from or 
completes the study will 
be followed until 
resolution or stabilization 
(in the opinion of the 
Investigator), or for 30 
days, whichever is 
shorter.   Adverse events, and 
tolerability signs and 
symptoms greater than 
zero (0), that are ongoing 
when a subject 
withdraws from or 
completes the study will 
be followed until 
resolution or stabilization 
(in the opinion of the 
Investigator), or for 30 
days, whichever is 
shorter.   Modified as per FDA 
suggestion 
F OA M I X          FMX-101, 4%     Protocol FX2014-05 Version 3   Page 65 of 65 
 
 CONFIDENTIAL   Section Revision Rationale 
Old Text New Text  
9.8.4.1. Pregnancy 
reporting A urine pregnancy test will 
be performed . . . at 
Baseline and 
Week 12/Final Visit of the 
double-blind phase of the 
Study or when a subject 
prematurely withdraws . . .  A urine pregnancy test will 
be performed . . .at 
Baseline, Week 3, Week 6,  
Week 9 and Week 12/Final 
Visit of the double -blind 
phase of the Stu dy or when 
a subject prematurely 
withdraws . . .  Modified as per FDA 
suggestion 
Home pregnancy kits will 
be provided to all female 
subjects at risk of becoming 
pregnant and are to be used 
if a pregnancy is suspected 
between visits (e.g., if a 
subject misses a period). 
 Home pregnancy kits will 
be provided to all female 
subjects of childbearing 
potential in the open-label 
phase of the Study and are 
to be used at least monthly 
and if a pregnancy is 
suspected between visits 
(e.g., if a subject misses a 
period). A urine pregn ancy 
test will be performed at 
Final Visit. 
10.3 Analysis 
Populations • Have not been 
compliant with the dosing 
regimen (ie, subjects 
missed more than 5 
consecutive days of dosing 
and took less than 80% of 
expected doses)  • Have not, in the 
opinion of the 
investigator, been 
compliant with the 
treatment regimen (e.g. 
reported frequent missed 
doses) Modify definition of Per 
Protocol Population  
10.6.3  Efficacy 
Analysis Non-inferiority margin is 
defined as 40% of the 
noninflammatory lesion 
reduction in the vehicle 
group at Week 12  Non-inferiority margin is 
defined as 30% of the 
noninflammatory lesion 
reduction in the vehicle 
group at Week 12  Correction 
16.1.  Appendix 1 – 
Subjects Satisfaction 
Questionnaire  Inserted See Appendix 1 (p.52) Procedure added  
 